id	sid	tid	token	lemma	pos
dpc-5430	1	1	dermatology	dermatology	NOUN
dpc-5430	1	2	:	:	PUNCT
dpc-5430	1	3	practical	practical	ADJ
dpc-5430	1	4	and	and	CCONJ
dpc-5430	1	5	conceptual	conceptual	ADJ
dpc-5430	1	6	review	review	NOUN
dpc-5430	1	7	|	|	ADV
dpc-5430	1	8	dermatol	dermatol	ADJ
dpc-5430	1	9	pract	pract	NOUN
dpc-5430	1	10	concept	concept	NOUN
dpc-5430	1	11	.	.	PUNCT
dpc-5430	2	1	2025;15(4):5430	2025;15(4):5430	NUM
dpc-5430	2	2	1	1	NUM
dpc-5430	2	3	clinical	clinical	ADJ
dpc-5430	2	4	efficacy	efficacy	NOUN
dpc-5430	2	5	and	and	CCONJ
dpc-5430	2	6	safety	safety	NOUN
dpc-5430	2	7	of	of	ADP
dpc-5430	2	8	intralesional	intralesional	ADJ
dpc-5430	2	9	bevacizumab	bevacizumab	NOUN
dpc-5430	2	10	in	in	ADP
dpc-5430	2	11	dermatology	dermatology	NOUN
dpc-5430	2	12	:	:	PUNCT
dpc-5430	2	13	insights	insight	NOUN
dpc-5430	2	14	from	from	ADP
dpc-5430	2	15	a	a	DET
dpc-5430	2	16	systematic	systematic	ADJ
dpc-5430	2	17	review	review	NOUN
dpc-5430	2	18	fereshte	fereshte	VERB
dpc-5430	2	19	rastegarnasab1	rastegarnasab1	PROPN
dpc-5430	2	20	,	,	PUNCT
dpc-5430	2	21	najmeh	najmeh	PROPN
dpc-5430	2	22	tavousi2	tavousi2	PROPN
dpc-5430	2	23	,	,	PUNCT
dpc-5430	2	24	mahsa	mahsa	NOUN
dpc-5430	2	25	pourmahdi	pourmahdi	NOUN
dpc-5430	2	26	-	-	PUNCT
dpc-5430	2	27	boroujeni2	boroujeni2	NOUN
dpc-5430	2	28	,	,	PUNCT
dpc-5430	2	29	kimia	kimia	NOUN
dpc-5430	2	30	afshar2	afshar2	NOUN
dpc-5430	2	31	,	,	PUNCT
dpc-5430	2	32	shadi	shadi	PROPN
dpc-5430	2	33	behfar3	behfar3	PROPN
dpc-5430	2	34	,	,	PUNCT
dpc-5430	2	35	bahareh	bahareh	NOUN
dpc-5430	2	36	abtahi	abtahi	PROPN
dpc-5430	2	37	-	-	PUNCT
dpc-5430	2	38	naeini4,5	naeini4,5	PROPN
dpc-5430	2	39	1	1	NUM
dpc-5430	2	40	hypertension	hypertension	NOUN
dpc-5430	2	41	research	research	NOUN
dpc-5430	2	42	center	center	NOUN
dpc-5430	2	43	,	,	PUNCT
dpc-5430	2	44	cardiovascular	cardiovascular	ADJ
dpc-5430	2	45	research	research	NOUN
dpc-5430	2	46	institute	institute	PROPN
dpc-5430	2	47	,	,	PUNCT
dpc-5430	2	48	isfahan	isfahan	PROPN
dpc-5430	2	49	university	university	PROPN
dpc-5430	2	50	of	of	ADP
dpc-5430	2	51	medical	medical	ADJ
dpc-5430	2	52	sciences	sciences	PROPN
dpc-5430	2	53	,	,	PUNCT
dpc-5430	2	54	isfahan	isfahan	NOUN
dpc-5430	2	55	,	,	PUNCT
dpc-5430	2	56	iran	iran	PROPN
dpc-5430	2	57	2	2	NUM
dpc-5430	2	58	student	student	NOUN
dpc-5430	2	59	research	research	NOUN
dpc-5430	2	60	committee	committee	NOUN
dpc-5430	2	61	,	,	PUNCT
dpc-5430	2	62	isfahan	isfahan	PROPN
dpc-5430	2	63	university	university	PROPN
dpc-5430	2	64	of	of	ADP
dpc-5430	2	65	medical	medical	ADJ
dpc-5430	2	66	sciences	sciences	PROPN
dpc-5430	2	67	,	,	PUNCT
dpc-5430	2	68	isfahan	isfahan	NOUN
dpc-5430	2	69	,	,	PUNCT
dpc-5430	2	70	iran	iran	PROPN
dpc-5430	2	71	3	3	NUM
dpc-5430	2	72	rafsanjan	rafsanjan	PROPN
dpc-5430	2	73	university	university	NOUN
dpc-5430	2	74	of	of	ADP
dpc-5430	2	75	medical	medical	ADJ
dpc-5430	2	76	sciences	science	NOUN
dpc-5430	2	77	,	,	PUNCT
dpc-5430	2	78	rafsanjan	rafsanjan	ADJ
dpc-5430	2	79	,	,	PUNCT
dpc-5430	2	80	iran	iran	PROPN
dpc-5430	2	81	4	4	NUM
dpc-5430	2	82	pediatric	pediatric	ADJ
dpc-5430	2	83	dermatology	dermatology	NOUN
dpc-5430	2	84	division	division	NOUN
dpc-5430	2	85	of	of	ADP
dpc-5430	2	86	department	department	NOUN
dpc-5430	2	87	of	of	ADP
dpc-5430	2	88	pediatrics	pediatric	NOUN
dpc-5430	2	89	,	,	PUNCT
dpc-5430	2	90	imam	imam	PROPN
dpc-5430	2	91	hossein	hossein	PROPN
dpc-5430	2	92	children	children	PROPN
dpc-5430	2	93	’s	’s	PART
dpc-5430	2	94	hospital	hospital	NOUN
dpc-5430	2	95	,	,	PUNCT
dpc-5430	2	96	isfahan	isfahan	PROPN
dpc-5430	2	97	university	university	PROPN
dpc-5430	2	98	of	of	ADP
dpc-5430	2	99	medical	medical	ADJ
dpc-5430	2	100	sciences	sciences	PROPN
dpc-5430	2	101	,	,	PUNCT
dpc-5430	2	102	isfahan	isfahan	NOUN
dpc-5430	2	103	,	,	PUNCT
dpc-5430	2	104	iran	iran	PROPN
dpc-5430	2	105	5	5	NUM
dpc-5430	2	106	skin	skin	NOUN
dpc-5430	2	107	diseases	disease	NOUN
dpc-5430	2	108	and	and	CCONJ
dpc-5430	2	109	leishmaniasis	leishmaniasis	NOUN
dpc-5430	2	110	research	research	NOUN
dpc-5430	2	111	center	center	NOUN
dpc-5430	2	112	,	,	PUNCT
dpc-5430	2	113	isfahan	isfahan	PROPN
dpc-5430	2	114	university	university	PROPN
dpc-5430	2	115	of	of	ADP
dpc-5430	2	116	medical	medical	ADJ
dpc-5430	2	117	sciences	sciences	PROPN
dpc-5430	2	118	,	,	PUNCT
dpc-5430	2	119	isfahan	isfahan	NOUN
dpc-5430	2	120	,	,	PUNCT
dpc-5430	2	121	iran	iran	PROPN
dpc-5430	2	122	key	key	ADJ
dpc-5430	2	123	words	word	NOUN
dpc-5430	2	124	:	:	PUNCT
dpc-5430	2	125	bevacizumab	bevacizumab	PROPN
dpc-5430	2	126	,	,	PUNCT
dpc-5430	2	127	avastin	avastin	PROPN
dpc-5430	2	128	,	,	PUNCT
dpc-5430	2	129	anti	anti	ADJ
dpc-5430	2	130	-	-	ADJ
dpc-5430	2	131	vegf	vegf	ADJ
dpc-5430	2	132	,	,	PUNCT
dpc-5430	2	133	intralesional	intralesional	ADJ
dpc-5430	2	134	,	,	PUNCT
dpc-5430	2	135	dermatology	dermatology	NOUN
dpc-5430	2	136	citation	citation	NOUN
dpc-5430	2	137	:	:	PUNCT
dpc-5430	2	138	rastegarnasab	rastegarnasab	VERB
dpc-5430	2	139	f	f	PROPN
dpc-5430	2	140	,	,	PUNCT
dpc-5430	2	141	tavousi	tavousi	ADP
dpc-5430	2	142	n	n	CCONJ
dpc-5430	2	143	,	,	PUNCT
dpc-5430	2	144	pourmahdi	pourmahdi	ADJ
dpc-5430	2	145	-	-	PUNCT
dpc-5430	2	146	boroujeni	boroujeni	NOUN
dpc-5430	2	147	m	m	PROPN
dpc-5430	2	148	,	,	PUNCT
dpc-5430	2	149	afshar	afshar	ADJ
dpc-5430	2	150	k	k	X
dpc-5430	2	151	,	,	PUNCT
dpc-5430	2	152	behfar	behfar	PROPN
dpc-5430	2	153	s	s	SYM
dpc-5430	2	154	,	,	PUNCT
dpc-5430	2	155	abtahi	abtahi	PROPN
dpc-5430	2	156	-	-	PUNCT
dpc-5430	2	157	naeini	naeini	PROPN
dpc-5430	2	158	b.	b.	PROPN
dpc-5430	2	159	clinical	clinical	PROPN
dpc-5430	2	160	efficacy	efficacy	NOUN
dpc-5430	2	161	and	and	CCONJ
dpc-5430	2	162	safety	safety	NOUN
dpc-5430	2	163	of	of	ADP
dpc-5430	2	164	intralesional	intralesional	ADJ
dpc-5430	2	165	bevacizumab	bevacizumab	NOUN
dpc-5430	2	166	in	in	ADP
dpc-5430	2	167	dermatology	dermatology	NOUN
dpc-5430	2	168	:	:	PUNCT
dpc-5430	2	169	insights	insight	NOUN
dpc-5430	2	170	from	from	ADP
dpc-5430	2	171	a	a	DET
dpc-5430	2	172	systematic	systematic	ADJ
dpc-5430	2	173	review	review	NOUN
dpc-5430	2	174	.	.	PUNCT
dpc-5430	3	1	dermatol	dermatol	NOUN
dpc-5430	3	2	pract	pract	PROPN
dpc-5430	3	3	concept	concept	NOUN
dpc-5430	3	4	.	.	PUNCT
dpc-5430	4	1	2025;15(4):5430	2025;15(4):5430	NUM
dpc-5430	4	2	.	.	PUNCT
dpc-5430	5	1	doi	doi	NOUN
dpc-5430	5	2	:	:	PUNCT
dpc-5430	5	3	https://doi.org/10.5826/dpc.1504a5430	https://doi.org/10.5826/dpc.1504a5430	X
dpc-5430	5	4	accepted	accept	VERB
dpc-5430	5	5	:	:	PUNCT
dpc-5430	5	6	may	may	AUX
dpc-5430	5	7	27	27	NUM
dpc-5430	5	8	,	,	PUNCT
dpc-5430	5	9	2025	2025	NUM
dpc-5430	5	10	;	;	PUNCT
dpc-5430	5	11	published	publish	VERB
dpc-5430	5	12	:	:	PUNCT
dpc-5430	6	1	october	october	PROPN
dpc-5430	6	2	2025	2025	NUM
dpc-5430	6	3	copyright	copyright	NOUN
dpc-5430	6	4	:	:	PUNCT
dpc-5430	6	5	©	©	PROPN
dpc-5430	6	6	2025	2025	NUM
dpc-5430	6	7	rastegarnasab	rastegarnasab	VERB
dpc-5430	6	8	et	et	PROPN
dpc-5430	6	9	al	al	PROPN
dpc-5430	6	10	.	.	PUNCT
dpc-5430	7	1	this	this	PRON
dpc-5430	7	2	is	be	AUX
dpc-5430	7	3	an	an	DET
dpc-5430	7	4	open	open	ADJ
dpc-5430	7	5	-	-	PUNCT
dpc-5430	7	6	access	access	NOUN
dpc-5430	7	7	article	article	NOUN
dpc-5430	7	8	distributed	distribute	VERB
dpc-5430	7	9	under	under	ADP
dpc-5430	7	10	the	the	DET
dpc-5430	7	11	terms	term	NOUN
dpc-5430	7	12	of	of	ADP
dpc-5430	7	13	the	the	DET
dpc-5430	7	14	creative	creative	ADJ
dpc-5430	7	15	commons	common	NOUN
dpc-5430	7	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-5430	7	17	license	license	NOUN
dpc-5430	7	18	(	(	PUNCT
dpc-5430	7	19	by	by	ADP
dpc-5430	7	20	-	-	PUNCT
dpc-5430	7	21	nc-4.0	nc-4.0	NOUN
dpc-5430	7	22	)	)	PUNCT
dpc-5430	7	23	,	,	PUNCT
dpc-5430	7	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-5430	7	25	,	,	PUNCT
dpc-5430	7	26	which	which	PRON
dpc-5430	7	27	permits	permit	VERB
dpc-5430	7	28	unrestricted	unrestricted	ADJ
dpc-5430	7	29	noncommercial	noncommercial	ADJ
dpc-5430	7	30	use	use	NOUN
dpc-5430	7	31	,	,	PUNCT
dpc-5430	7	32	distribution	distribution	NOUN
dpc-5430	7	33	,	,	PUNCT
dpc-5430	7	34	and	and	CCONJ
dpc-5430	7	35	reproduction	reproduction	NOUN
dpc-5430	7	36	in	in	ADP
dpc-5430	7	37	any	any	DET
dpc-5430	7	38	medium	medium	NOUN
dpc-5430	7	39	,	,	PUNCT
dpc-5430	7	40	provided	provide	VERB
dpc-5430	7	41	the	the	DET
dpc-5430	7	42	original	original	ADJ
dpc-5430	7	43	authors	author	NOUN
dpc-5430	7	44	and	and	CCONJ
dpc-5430	7	45	source	source	NOUN
dpc-5430	7	46	are	be	AUX
dpc-5430	7	47	credited	credit	VERB
dpc-5430	7	48	.	.	PUNCT
dpc-5430	8	1	funding	funding	NOUN
dpc-5430	8	2	:	:	PUNCT
dpc-5430	8	3	none	none	NOUN
dpc-5430	8	4	.	.	PUNCT
dpc-5430	9	1	competing	compete	VERB
dpc-5430	9	2	interests	interest	NOUN
dpc-5430	9	3	:	:	PUNCT
dpc-5430	9	4	none	none	NOUN
dpc-5430	9	5	.	.	PUNCT
dpc-5430	10	1	authorship	authorship	NOUN
dpc-5430	10	2	:	:	PUNCT
dpc-5430	10	3	all	all	DET
dpc-5430	10	4	authors	author	NOUN
dpc-5430	10	5	have	have	AUX
dpc-5430	10	6	contributed	contribute	VERB
dpc-5430	10	7	significantly	significantly	ADV
dpc-5430	10	8	to	to	ADP
dpc-5430	10	9	this	this	DET
dpc-5430	10	10	publication	publication	NOUN
dpc-5430	10	11	.	.	PUNCT
dpc-5430	11	1	corresponding	correspond	VERB
dpc-5430	11	2	author	author	NOUN
dpc-5430	11	3	:	:	PUNCT
dpc-5430	11	4	bahareh	bahareh	PROPN
dpc-5430	11	5	abtahi	abtahi	PROPN
dpc-5430	11	6	-	-	PUNCT
dpc-5430	11	7	naeini	naeini	NOUN
dpc-5430	11	8	,	,	PUNCT
dpc-5430	11	9	1	1	NUM
dpc-5430	11	10	pediatric	pediatric	ADJ
dpc-5430	11	11	dermatology	dermatology	NOUN
dpc-5430	11	12	division	division	NOUN
dpc-5430	11	13	of	of	ADP
dpc-5430	11	14	department	department	NOUN
dpc-5430	11	15	of	of	ADP
dpc-5430	11	16	pediatrics	pediatric	NOUN
dpc-5430	11	17	,	,	PUNCT
dpc-5430	11	18	imam	imam	PROPN
dpc-5430	11	19	hossein	hossein	PROPN
dpc-5430	11	20	children	children	PROPN
dpc-5430	11	21	’s	’s	PART
dpc-5430	11	22	hospital	hospital	NOUN
dpc-5430	11	23	,	,	PUNCT
dpc-5430	11	24	isfahan	isfahan	PROPN
dpc-5430	11	25	university	university	PROPN
dpc-5430	11	26	of	of	ADP
dpc-5430	11	27	medical	medical	ADJ
dpc-5430	11	28	sciences	sciences	PROPN
dpc-5430	11	29	,	,	PUNCT
dpc-5430	11	30	isfahan	isfahan	NOUN
dpc-5430	11	31	,	,	PUNCT
dpc-5430	11	32	iran	iran	PROPN
dpc-5430	11	33	;	;	PUNCT
dpc-5430	11	34	2	2	NUM
dpc-5430	11	35	skin	skin	NOUN
dpc-5430	11	36	diseases	disease	NOUN
dpc-5430	11	37	and	and	CCONJ
dpc-5430	11	38	leishmaniasis	leishmaniasis	NOUN
dpc-5430	11	39	research	research	NOUN
dpc-5430	11	40	center	center	NOUN
dpc-5430	11	41	,	,	PUNCT
dpc-5430	11	42	isfahan	isfahan	PROPN
dpc-5430	11	43	university	university	PROPN
dpc-5430	11	44	of	of	ADP
dpc-5430	11	45	medical	medical	ADJ
dpc-5430	11	46	sciences	sciences	PROPN
dpc-5430	11	47	,	,	PUNCT
dpc-5430	11	48	isfahan	isfahan	NOUN
dpc-5430	11	49	,	,	PUNCT
dpc-5430	11	50	iran	iran	PROPN
dpc-5430	11	51	.	.	PUNCT
dpc-5430	12	1	orcid	orcid	NOUN
dpc-5430	13	1	i	i	PRON
dpc-5430	13	2	d	d	NOUN
dpc-5430	13	3	:	:	PUNCT
dpc-5430	13	4	0000	0000	NUM
dpc-5430	13	5	-	-	PUNCT
dpc-5430	13	6	0003	0003	NUM
dpc-5430	13	7	-	-	PUNCT
dpc-5430	13	8	1081	1081	NUM
dpc-5430	13	9	-	-	PUNCT
dpc-5430	13	10	9477	9477	NUM
dpc-5430	13	11	.	.	PUNCT
dpc-5430	14	1	e	e	X
dpc-5430	14	2	-	-	NOUN
dpc-5430	14	3	mail	mail	NOUN
dpc-5430	14	4	:	:	PUNCT
dpc-5430	14	5	abtahi.bahareh@yahoo.com	abtahi.bahareh@yahoo.com	X
dpc-5430	15	1	introduction	introduction	NOUN
dpc-5430	15	2	:	:	PUNCT
dpc-5430	15	3	bevacizumab	bevacizumab	PROPN
dpc-5430	15	4	is	be	AUX
dpc-5430	15	5	a	a	DET
dpc-5430	15	6	humanized	humanize	VERB
dpc-5430	15	7	monoclonal	monoclonal	NOUN
dpc-5430	15	8	antibody	antibody	NOUN
dpc-5430	15	9	specifically	specifically	ADV
dpc-5430	15	10	targeting	target	VERB
dpc-5430	15	11	the	the	DET
dpc-5430	15	12	vascular	vascular	ADJ
dpc-5430	15	13	endothelial	endothelial	ADJ
dpc-5430	15	14	growth	growth	NOUN
dpc-5430	15	15	factor	factor	NOUN
dpc-5430	15	16	(	(	PUNCT
dpc-5430	15	17	vegf	vegf	PROPN
dpc-5430	15	18	)	)	PUNCT
dpc-5430	15	19	.	.	PUNCT
dpc-5430	16	1	in	in	ADP
dpc-5430	16	2	addition	addition	NOUN
dpc-5430	16	3	to	to	ADP
dpc-5430	16	4	cancer	cancer	NOUN
dpc-5430	16	5	and	and	CCONJ
dpc-5430	16	6	ophthalmology	ophthalmology	NOUN
dpc-5430	16	7	,	,	PUNCT
dpc-5430	16	8	bevacizumab	bevacizumab	NOUN
dpc-5430	16	9	has	have	VERB
dpc-5430	16	10	other	other	ADJ
dpc-5430	16	11	off	off	ADP
dpc-5430	16	12	-	-	PUNCT
dpc-5430	16	13	label	label	NOUN
dpc-5430	16	14	uses	use	NOUN
dpc-5430	16	15	.	.	PUNCT
dpc-5430	17	1	among	among	ADP
dpc-5430	17	2	these	these	PRON
dpc-5430	17	3	,	,	PUNCT
dpc-5430	17	4	the	the	DET
dpc-5430	17	5	treatment	treatment	NOUN
dpc-5430	17	6	of	of	ADP
dpc-5430	17	7	hereditary	hereditary	ADJ
dpc-5430	17	8	hemorrhagic	hemorrhagic	NOUN
dpc-5430	17	9	telangiectasia	telangiectasia	NOUN
dpc-5430	17	10	and	and	CCONJ
dpc-5430	17	11	hemangioma	hemangioma	NOUN
dpc-5430	17	12	can	can	AUX
dpc-5430	17	13	be	be	AUX
dpc-5430	17	14	mentioned	mention	VERB
dpc-5430	17	15	.	.	PUNCT
dpc-5430	18	1	objectives	objective	NOUN
dpc-5430	18	2	:	:	PUNCT
dpc-5430	18	3	although	although	SCONJ
dpc-5430	18	4	there	there	PRON
dpc-5430	18	5	are	be	VERB
dpc-5430	18	6	reports	report	NOUN
dpc-5430	18	7	of	of	ADP
dpc-5430	18	8	successful	successful	ADJ
dpc-5430	18	9	treatments	treatment	NOUN
dpc-5430	18	10	by	by	ADP
dpc-5430	18	11	bevacizumab	bevacizumab	NOUN
dpc-5430	18	12	,	,	PUNCT
dpc-5430	18	13	there	there	PRON
dpc-5430	18	14	is	be	VERB
dpc-5430	18	15	no	no	DET
dpc-5430	18	16	systematic	systematic	ADJ
dpc-5430	18	17	review	review	NOUN
dpc-5430	18	18	on	on	ADP
dpc-5430	18	19	the	the	DET
dpc-5430	18	20	topical	topical	ADJ
dpc-5430	18	21	use	use	NOUN
dpc-5430	18	22	of	of	ADP
dpc-5430	18	23	this	this	DET
dpc-5430	18	24	medication	medication	NOUN
dpc-5430	18	25	in	in	ADP
dpc-5430	18	26	dermatology	dermatology	NOUN
dpc-5430	18	27	.	.	PUNCT
dpc-5430	19	1	therefore	therefore	ADV
dpc-5430	19	2	,	,	PUNCT
dpc-5430	19	3	this	this	DET
dpc-5430	19	4	study	study	NOUN
dpc-5430	19	5	aimed	aim	VERB
dpc-5430	19	6	to	to	PART
dpc-5430	19	7	investigate	investigate	VERB
dpc-5430	19	8	this	this	DET
dpc-5430	19	9	topic	topic	NOUN
dpc-5430	19	10	.	.	PUNCT
dpc-5430	20	1	methods	method	NOUN
dpc-5430	20	2	:	:	PUNCT
dpc-5430	20	3	a	a	DET
dpc-5430	20	4	systematic	systematic	ADJ
dpc-5430	20	5	search	search	NOUN
dpc-5430	20	6	on	on	ADP
dpc-5430	20	7	topical	topical	ADJ
dpc-5430	20	8	bevacizumab	bevacizumab	NOUN
dpc-5430	20	9	was	be	AUX
dpc-5430	20	10	done	do	VERB
dpc-5430	20	11	with	with	ADP
dpc-5430	20	12	mesh	mesh	NOUN
dpc-5430	20	13	-	-	PUNCT
dpc-5430	20	14	based	base	VERB
dpc-5430	20	15	keywords	keyword	NOUN
dpc-5430	20	16	on	on	ADP
dpc-5430	20	17	online	online	ADJ
dpc-5430	20	18	databases	database	NOUN
dpc-5430	20	19	of	of	ADP
dpc-5430	20	20	pubmed	pubmed	PROPN
dpc-5430	20	21	,	,	PUNCT
dpc-5430	20	22	scopus	scopus	PROPN
dpc-5430	20	23	,	,	PUNCT
dpc-5430	20	24	and	and	CCONJ
dpc-5430	20	25	web	web	NOUN
dpc-5430	20	26	of	of	ADP
dpc-5430	20	27	science	science	NOUN
dpc-5430	20	28	in	in	ADP
dpc-5430	20	29	december	december	PROPN
dpc-5430	20	30	2022	2022	NUM
dpc-5430	20	31	.	.	PUNCT
dpc-5430	21	1	the	the	DET
dpc-5430	21	2	records	record	NOUN
dpc-5430	21	3	were	be	AUX
dpc-5430	21	4	evaluated	evaluate	VERB
dpc-5430	21	5	,	,	PUNCT
dpc-5430	21	6	and	and	CCONJ
dpc-5430	21	7	the	the	DET
dpc-5430	21	8	eligible	eligible	ADJ
dpc-5430	21	9	articles	article	NOUN
dpc-5430	21	10	were	be	AUX
dpc-5430	21	11	selected	select	VERB
dpc-5430	21	12	.	.	PUNCT
dpc-5430	22	1	results	result	NOUN
dpc-5430	22	2	:	:	PUNCT
dpc-5430	22	3	we	we	PRON
dpc-5430	22	4	reviewed	review	VERB
dpc-5430	22	5	related	related	ADJ
dpc-5430	22	6	studies	study	NOUN
dpc-5430	22	7	,	,	PUNCT
dpc-5430	22	8	and	and	CCONJ
dpc-5430	22	9	the	the	DET
dpc-5430	22	10	disease	disease	NOUN
dpc-5430	22	11	name	name	NOUN
dpc-5430	22	12	,	,	PUNCT
dpc-5430	22	13	treatment	treatment	NOUN
dpc-5430	22	14	protocol	protocol	NOUN
dpc-5430	22	15	(	(	PUNCT
dpc-5430	22	16	injection	injection	NOUN
dpc-5430	22	17	dosage	dosage	NOUN
dpc-5430	22	18	and	and	CCONJ
dpc-5430	22	19	intervals	interval	NOUN
dpc-5430	22	20	)	)	PUNCT
dpc-5430	22	21	,	,	PUNCT
dpc-5430	22	22	outcomes	outcome	NOUN
dpc-5430	22	23	,	,	PUNCT
dpc-5430	22	24	and	and	CCONJ
dpc-5430	22	25	complications	complication	NOUN
dpc-5430	22	26	were	be	AUX
dpc-5430	22	27	summarized	summarize	VERB
dpc-5430	22	28	for	for	ADP
dpc-5430	22	29	conclusions	conclusion	NOUN
dpc-5430	22	30	.	.	PUNCT
dpc-5430	23	1	abstract	abstract	ADJ
dpc-5430	23	2	2	2	NUM
dpc-5430	23	3	review	review	NOUN
dpc-5430	23	4	|	|	ADV
dpc-5430	23	5	dermatol	dermatol	ADJ
dpc-5430	23	6	pract	pract	NOUN
dpc-5430	23	7	concept	concept	NOUN
dpc-5430	23	8	.	.	PUNCT
dpc-5430	24	1	2025;15(4):5430	2025;15(4):5430	NUM
dpc-5430	24	2	introduction	introduction	NOUN
dpc-5430	24	3	bevacizumab	bevacizumab	NOUN
dpc-5430	24	4	,	,	PUNCT
dpc-5430	24	5	an	an	DET
dpc-5430	24	6	anti	anti	ADJ
dpc-5430	24	7	-	-	ADJ
dpc-5430	24	8	vegf	vegf	NOUN
dpc-5430	24	9	-	-	PUNCT
dpc-5430	24	10	a	a	DET
dpc-5430	24	11	medication	medication	NOUN
dpc-5430	24	12	,	,	PUNCT
dpc-5430	24	13	is	be	AUX
dpc-5430	24	14	a	a	DET
dpc-5430	24	15	humanized	humanize	VERB
dpc-5430	24	16	monoclonal	monoclonal	NOUN
dpc-5430	24	17	antibody	antibody	NOUN
dpc-5430	24	18	specifically	specifically	ADV
dpc-5430	24	19	targeting	target	VERB
dpc-5430	24	20	the	the	DET
dpc-5430	24	21	vascular	vascular	ADJ
dpc-5430	24	22	endothelial	endothelial	ADJ
dpc-5430	24	23	growth	growth	NOUN
dpc-5430	24	24	factor	factor	NOUN
dpc-5430	24	25	(	(	PUNCT
dpc-5430	24	26	vegf	vegf	PROPN
dpc-5430	24	27	)	)	PUNCT
dpc-5430	24	28	.	.	PUNCT
dpc-5430	25	1	bevacizumab	bevacizumab	PROPN
dpc-5430	25	2	binds	bind	VERB
dpc-5430	25	3	to	to	ADP
dpc-5430	25	4	vegf	vegf	NOUN
dpc-5430	25	5	-	-	PUNCT
dpc-5430	25	6	a	a	PROPN
dpc-5430	25	7	and	and	CCONJ
dpc-5430	25	8	inhibits	inhibit	VERB
dpc-5430	25	9	vegf	vegf	PROPN
dpc-5430	25	10	-	-	PUNCT
dpc-5430	25	11	a	a	NOUN
dpc-5430	25	12	from	from	ADP
dpc-5430	25	13	connecting	connect	VERB
dpc-5430	25	14	to	to	ADP
dpc-5430	25	15	its	its	PRON
dpc-5430	25	16	receptor	receptor	NOUN
dpc-5430	25	17	.	.	PUNCT
dpc-5430	26	1	this	this	DET
dpc-5430	26	2	process	process	NOUN
dpc-5430	26	3	stops	stop	VERB
dpc-5430	26	4	vascular	vascular	ADJ
dpc-5430	26	5	endothelial	endothelial	ADJ
dpc-5430	26	6	growth	growth	NOUN
dpc-5430	26	7	,	,	PUNCT
dpc-5430	26	8	endothelial	endothelial	ADJ
dpc-5430	26	9	cell	cell	NOUN
dpc-5430	26	10	proliferation	proliferation	NOUN
dpc-5430	26	11	,	,	PUNCT
dpc-5430	26	12	and	and	CCONJ
dpc-5430	26	13	angiogenesis	angiogenesis	NOUN
dpc-5430	27	1	[	[	X
dpc-5430	27	2	1	1	NUM
dpc-5430	27	3	-	-	SYM
dpc-5430	27	4	3	3	NUM
dpc-5430	27	5	]	]	PUNCT
dpc-5430	27	6	.	.	PUNCT
dpc-5430	28	1	neovascularization	neovascularization	NOUN
dpc-5430	28	2	and	and	CCONJ
dpc-5430	28	3	angiogenesis	angiogenesis	NOUN
dpc-5430	28	4	are	be	AUX
dpc-5430	28	5	involved	involve	VERB
dpc-5430	28	6	in	in	ADP
dpc-5430	28	7	the	the	DET
dpc-5430	28	8	pathogenesis	pathogenesis	NOUN
dpc-5430	28	9	of	of	ADP
dpc-5430	28	10	several	several	ADJ
dpc-5430	28	11	conditions	condition	NOUN
dpc-5430	28	12	,	,	PUNCT
dpc-5430	28	13	such	such	ADJ
dpc-5430	28	14	as	as	ADP
dpc-5430	28	15	inflammatory	inflammatory	ADJ
dpc-5430	28	16	and	and	CCONJ
dpc-5430	28	17	malignant	malignant	ADJ
dpc-5430	28	18	processes	process	NOUN
dpc-5430	28	19	.	.	PUNCT
dpc-5430	29	1	theoretically	theoretically	ADV
dpc-5430	29	2	,	,	PUNCT
dpc-5430	29	3	anti	anti	ADJ
dpc-5430	29	4	-	-	ADJ
dpc-5430	29	5	vegf	vegf	ADJ
dpc-5430	29	6	medication	medication	NOUN
dpc-5430	29	7	can	can	AUX
dpc-5430	29	8	improve	improve	VERB
dpc-5430	29	9	these	these	DET
dpc-5430	29	10	conditions	condition	NOUN
dpc-5430	29	11	by	by	ADP
dpc-5430	29	12	inhibiting	inhibit	VERB
dpc-5430	29	13	angiogenesis	angiogenesis	NOUN
dpc-5430	29	14	[	[	X
dpc-5430	29	15	4	4	NUM
dpc-5430	29	16	]	]	PUNCT
dpc-5430	29	17	.	.	PUNCT
dpc-5430	30	1	bevacizumab	bevacizumab	PROPN
dpc-5430	30	2	prevents	prevent	VERB
dpc-5430	30	3	the	the	DET
dpc-5430	30	4	growth	growth	NOUN
dpc-5430	30	5	of	of	ADP
dpc-5430	30	6	blood	blood	NOUN
dpc-5430	30	7	vessels	vessel	NOUN
dpc-5430	30	8	that	that	PRON
dpc-5430	30	9	supply	supply	VERB
dpc-5430	30	10	nutrients	nutrient	NOUN
dpc-5430	30	11	and	and	CCONJ
dpc-5430	30	12	oxygen	oxygen	NOUN
dpc-5430	30	13	to	to	ADP
dpc-5430	30	14	tumors	tumor	NOUN
dpc-5430	30	15	,	,	PUNCT
dpc-5430	30	16	which	which	PRON
dpc-5430	30	17	results	result	VERB
dpc-5430	30	18	in	in	ADP
dpc-5430	30	19	slowing	slow	VERB
dpc-5430	30	20	down	down	ADP
dpc-5430	30	21	their	their	PRON
dpc-5430	30	22	growth	growth	NOUN
dpc-5430	30	23	and	and	CCONJ
dpc-5430	30	24	spread	spread	VERB
dpc-5430	30	25	[	[	X
dpc-5430	30	26	2,5	2,5	NUM
dpc-5430	30	27	]	]	PUNCT
dpc-5430	30	28	.	.	PUNCT
dpc-5430	31	1	in	in	ADP
dpc-5430	31	2	2004	2004	NUM
dpc-5430	31	3	,	,	PUNCT
dpc-5430	31	4	the	the	DET
dpc-5430	31	5	us	us	PROPN
dpc-5430	31	6	food	food	NOUN
dpc-5430	31	7	and	and	CCONJ
dpc-5430	31	8	drug	drug	PROPN
dpc-5430	31	9	administration	administration	PROPN
dpc-5430	31	10	(	(	PUNCT
dpc-5430	31	11	fda	fda	PROPN
dpc-5430	31	12	)	)	PUNCT
dpc-5430	31	13	approved	approve	VERB
dpc-5430	31	14	the	the	DET
dpc-5430	31	15	use	use	NOUN
dpc-5430	31	16	of	of	ADP
dpc-5430	31	17	bevacizumab	bevacizumab	NOUN
dpc-5430	31	18	(	(	PUNCT
dpc-5430	31	19	avastin	avastin	PROPN
dpc-5430	31	20	)	)	PUNCT
dpc-5430	31	21	for	for	ADP
dpc-5430	31	22	the	the	DET
dpc-5430	31	23	treatment	treatment	NOUN
dpc-5430	31	24	of	of	ADP
dpc-5430	31	25	metastatic	metastatic	ADJ
dpc-5430	31	26	colorectal	colorectal	ADJ
dpc-5430	31	27	cancer	cancer	NOUN
dpc-5430	31	28	,	,	PUNCT
dpc-5430	31	29	and	and	CCONJ
dpc-5430	31	30	in	in	ADP
dpc-5430	31	31	2009	2009	NUM
dpc-5430	31	32	,	,	PUNCT
dpc-5430	31	33	for	for	ADP
dpc-5430	31	34	glioblastoma	glioblastoma	NOUN
dpc-5430	31	35	;	;	PUNCT
dpc-5430	31	36	since	since	SCONJ
dpc-5430	31	37	then	then	ADV
dpc-5430	31	38	,	,	PUNCT
dpc-5430	31	39	it	it	PRON
dpc-5430	31	40	has	have	AUX
dpc-5430	31	41	been	be	AUX
dpc-5430	31	42	authorized	authorize	VERB
dpc-5430	31	43	for	for	ADP
dpc-5430	31	44	use	use	NOUN
dpc-5430	31	45	in	in	ADP
dpc-5430	31	46	many	many	ADJ
dpc-5430	31	47	other	other	ADJ
dpc-5430	31	48	types	type	NOUN
dpc-5430	31	49	of	of	ADP
dpc-5430	31	50	cancer	cancer	NOUN
dpc-5430	31	51	,	,	PUNCT
dpc-5430	31	52	including	include	VERB
dpc-5430	31	53	non	non	ADJ
dpc-5430	31	54	-	-	ADJ
dpc-5430	31	55	squamous	squamous	ADJ
dpc-5430	31	56	cell	cell	NOUN
dpc-5430	31	57	lung	lung	NOUN
dpc-5430	31	58	carcinoma	carcinoma	NOUN
dpc-5430	31	59	,	,	PUNCT
dpc-5430	31	60	prostate	prostate	NOUN
dpc-5430	31	61	cancer	cancer	NOUN
dpc-5430	31	62	,	,	PUNCT
dpc-5430	31	63	metastatic	metastatic	ADJ
dpc-5430	31	64	breast	breast	NOUN
dpc-5430	31	65	cancer	cancer	NOUN
dpc-5430	31	66	,	,	PUNCT
dpc-5430	31	67	and	and	CCONJ
dpc-5430	31	68	metastatic	metastatic	ADJ
dpc-5430	31	69	renal	renal	ADJ
dpc-5430	31	70	cell	cell	NOUN
dpc-5430	31	71	carcinoma	carcinoma	NOUN
dpc-5430	32	1	[	[	X
dpc-5430	32	2	2,6	2,6	NUM
dpc-5430	32	3	]	]	PUNCT
dpc-5430	32	4	.	.	PUNCT
dpc-5430	33	1	it	it	PRON
dpc-5430	33	2	is	be	AUX
dpc-5430	33	3	also	also	ADV
dpc-5430	33	4	one	one	NUM
dpc-5430	33	5	of	of	ADP
dpc-5430	33	6	the	the	DET
dpc-5430	33	7	first	first	ADJ
dpc-5430	33	8	choices	choice	NOUN
dpc-5430	33	9	for	for	ADP
dpc-5430	33	10	inhibiting	inhibit	VERB
dpc-5430	33	11	angiogenesis	angiogenesis	NOUN
dpc-5430	33	12	approved	approve	VERB
dpc-5430	33	13	by	by	ADP
dpc-5430	33	14	the	the	DET
dpc-5430	33	15	fda	fda	PROPN
dpc-5430	34	1	[	[	X
dpc-5430	34	2	2	2	NUM
dpc-5430	34	3	]	]	PUNCT
dpc-5430	34	4	.	.	PUNCT
dpc-5430	35	1	avastin	avastin	PROPN
dpc-5430	35	2	is	be	AUX
dpc-5430	35	3	widely	widely	ADV
dpc-5430	35	4	used	use	VERB
dpc-5430	35	5	in	in	ADP
dpc-5430	35	6	ophthalmology	ophthalmology	NOUN
dpc-5430	35	7	to	to	PART
dpc-5430	35	8	treat	treat	VERB
dpc-5430	35	9	neovascular	neovascular	NOUN
dpc-5430	35	10	glaucoma	glaucoma	NOUN
dpc-5430	35	11	,	,	PUNCT
dpc-5430	35	12	retinal	retinal	ADJ
dpc-5430	35	13	vein	vein	ADJ
dpc-5430	35	14	occlusion	occlusion	NOUN
dpc-5430	35	15	,	,	PUNCT
dpc-5430	35	16	and	and	CCONJ
dpc-5430	35	17	diabetic	diabetic	ADJ
dpc-5430	35	18	retinopathy	retinopathy	NOUN
dpc-5430	35	19	and	and	CCONJ
dpc-5430	35	20	as	as	ADP
dpc-5430	35	21	an	an	DET
dpc-5430	35	22	intravitreal	intravitreal	ADJ
dpc-5430	35	23	injection	injection	NOUN
dpc-5430	35	24	to	to	PART
dpc-5430	35	25	treat	treat	VERB
dpc-5430	35	26	macular	macular	ADJ
dpc-5430	35	27	edema	edema	NOUN
dpc-5430	36	1	[	[	X
dpc-5430	36	2	7	7	NUM
dpc-5430	36	3	-	-	SYM
dpc-5430	36	4	9	9	NUM
dpc-5430	36	5	]	]	PUNCT
dpc-5430	36	6	.	.	PUNCT
dpc-5430	37	1	it	it	PRON
dpc-5430	37	2	has	have	AUX
dpc-5430	37	3	also	also	ADV
dpc-5430	37	4	been	be	AUX
dpc-5430	37	5	increasingly	increasingly	ADV
dpc-5430	37	6	used	use	VERB
dpc-5430	37	7	in	in	ADP
dpc-5430	37	8	the	the	DET
dpc-5430	37	9	treatment	treatment	NOUN
dpc-5430	37	10	of	of	ADP
dpc-5430	37	11	retinopathy	retinopathy	NOUN
dpc-5430	37	12	of	of	ADP
dpc-5430	37	13	prematurity	prematurity	NOUN
dpc-5430	37	14	,	,	PUNCT
dpc-5430	37	15	alone	alone	ADJ
dpc-5430	37	16	or	or	CCONJ
dpc-5430	37	17	in	in	ADP
dpc-5430	37	18	combination	combination	NOUN
dpc-5430	37	19	with	with	ADP
dpc-5430	37	20	standard	standard	ADJ
dpc-5430	37	21	laser	laser	NOUN
dpc-5430	37	22	therapy	therapy	NOUN
dpc-5430	37	23	[	[	X
dpc-5430	37	24	10,11	10,11	NOUN
dpc-5430	37	25	]	]	PUNCT
dpc-5430	37	26	.	.	PUNCT
dpc-5430	38	1	in	in	ADP
dpc-5430	38	2	addition	addition	NOUN
dpc-5430	38	3	to	to	ADP
dpc-5430	38	4	the	the	DET
dpc-5430	38	5	field	field	NOUN
dpc-5430	38	6	of	of	ADP
dpc-5430	38	7	cancer	cancer	NOUN
dpc-5430	38	8	and	and	CCONJ
dpc-5430	38	9	ophthalmology	ophthalmology	NOUN
dpc-5430	38	10	,	,	PUNCT
dpc-5430	38	11	bevacizumab	bevacizumab	NOUN
dpc-5430	38	12	has	have	VERB
dpc-5430	38	13	some	some	DET
dpc-5430	38	14	off	off	ADP
dpc-5430	38	15	-	-	PUNCT
dpc-5430	38	16	label	label	NOUN
dpc-5430	38	17	applications	application	NOUN
dpc-5430	38	18	in	in	ADP
dpc-5430	38	19	the	the	DET
dpc-5430	38	20	treatment	treatment	NOUN
dpc-5430	38	21	of	of	ADP
dpc-5430	38	22	mucocutaneous	mucocutaneous	ADJ
dpc-5430	38	23	conditions	condition	NOUN
dpc-5430	38	24	[	[	X
dpc-5430	38	25	12	12	NUM
dpc-5430	38	26	]	]	PUNCT
dpc-5430	38	27	,	,	PUNCT
dpc-5430	38	28	including	include	VERB
dpc-5430	38	29	hereditary	hereditary	ADJ
dpc-5430	38	30	hemorrhagic	hemorrhagic	NOUN
dpc-5430	38	31	telangiectasia	telangiectasia	PROPN
dpc-5430	38	32	(	(	PUNCT
dpc-5430	38	33	hht	hht	PROPN
dpc-5430	38	34	)	)	PUNCT
dpc-5430	39	1	[	[	X
dpc-5430	39	2	13,14	13,14	X
dpc-5430	39	3	]	]	PUNCT
dpc-5430	39	4	and	and	CCONJ
dpc-5430	39	5	hemangioma	hemangioma	NOUN
dpc-5430	40	1	[	[	X
dpc-5430	40	2	15	15	NUM
dpc-5430	40	3	]	]	PUNCT
dpc-5430	40	4	.	.	PUNCT
dpc-5430	41	1	although	although	SCONJ
dpc-5430	41	2	there	there	PRON
dpc-5430	41	3	are	be	VERB
dpc-5430	41	4	several	several	ADJ
dpc-5430	41	5	reports	report	NOUN
dpc-5430	41	6	of	of	ADP
dpc-5430	41	7	successful	successful	ADJ
dpc-5430	41	8	treatments	treatment	NOUN
dpc-5430	41	9	with	with	ADP
dpc-5430	41	10	bevacizumab	bevacizumab	NOUN
dpc-5430	41	11	in	in	ADP
dpc-5430	41	12	dermatological	dermatological	ADJ
dpc-5430	41	13	conditions	condition	NOUN
dpc-5430	41	14	,	,	PUNCT
dpc-5430	41	15	there	there	PRON
dpc-5430	41	16	is	be	VERB
dpc-5430	41	17	no	no	DET
dpc-5430	41	18	systematic	systematic	ADJ
dpc-5430	41	19	review	review	NOUN
dpc-5430	41	20	about	about	ADP
dpc-5430	41	21	the	the	DET
dpc-5430	41	22	use	use	NOUN
dpc-5430	41	23	of	of	ADP
dpc-5430	41	24	this	this	DET
dpc-5430	41	25	medication	medication	NOUN
dpc-5430	41	26	in	in	ADP
dpc-5430	41	27	dermatology	dermatology	NOUN
dpc-5430	41	28	.	.	PUNCT
dpc-5430	42	1	objectives	objective	NOUN
dpc-5430	42	2	in	in	ADP
dpc-5430	42	3	this	this	DET
dpc-5430	42	4	study	study	NOUN
dpc-5430	42	5	,	,	PUNCT
dpc-5430	42	6	we	we	PRON
dpc-5430	42	7	systematically	systematically	ADV
dpc-5430	42	8	reviewed	review	VERB
dpc-5430	42	9	related	related	ADJ
dpc-5430	42	10	papers	paper	NOUN
dpc-5430	42	11	and	and	CCONJ
dpc-5430	42	12	summarized	summarize	VERB
dpc-5430	42	13	the	the	DET
dpc-5430	42	14	use	use	NOUN
dpc-5430	42	15	of	of	ADP
dpc-5430	42	16	bevacizumab	bevacizumab	NOUN
dpc-5430	42	17	in	in	ADP
dpc-5430	42	18	dermatology	dermatology	NOUN
dpc-5430	42	19	in	in	ADP
dpc-5430	42	20	four	four	NUM
dpc-5430	42	21	categories	category	NOUN
dpc-5430	42	22	,	,	PUNCT
dpc-5430	42	23	including	include	VERB
dpc-5430	42	24	hht	hht	PROPN
dpc-5430	42	25	,	,	PUNCT
dpc-5430	42	26	vascular	vascular	ADJ
dpc-5430	42	27	malformation	malformation	NOUN
dpc-5430	42	28	,	,	PUNCT
dpc-5430	42	29	vascular	vascular	ADJ
dpc-5430	42	30	proliferation	proliferation	NOUN
dpc-5430	42	31	,	,	PUNCT
dpc-5430	42	32	and	and	CCONJ
dpc-5430	42	33	others	other	NOUN
dpc-5430	42	34	(	(	PUNCT
dpc-5430	42	35	lichen	lichen	NOUN
dpc-5430	42	36	planus	planus	NOUN
dpc-5430	42	37	,	,	PUNCT
dpc-5430	42	38	and	and	CCONJ
dpc-5430	42	39	basal	basal	ADJ
dpc-5430	42	40	cell	cell	NOUN
dpc-5430	42	41	carcinoma	carcinoma	NOUN
dpc-5430	42	42	)	)	PUNCT
dpc-5430	42	43	.	.	PUNCT
dpc-5430	43	1	methods	method	NOUN
dpc-5430	43	2	in	in	ADP
dpc-5430	43	3	this	this	DET
dpc-5430	43	4	study	study	NOUN
dpc-5430	43	5	,	,	PUNCT
dpc-5430	43	6	online	online	ADJ
dpc-5430	43	7	databases	database	NOUN
dpc-5430	43	8	were	be	AUX
dpc-5430	43	9	searched	search	VERB
dpc-5430	43	10	systematically	systematically	ADV
dpc-5430	43	11	in	in	ADP
dpc-5430	43	12	december	december	PROPN
dpc-5430	43	13	2022	2022	NUM
dpc-5430	43	14	.	.	PUNCT
dpc-5430	44	1	keywords	keyword	NOUN
dpc-5430	44	2	including	include	VERB
dpc-5430	44	3	“	"	PUNCT
dpc-5430	44	4	anti	anti	ADJ
dpc-5430	44	5	-	-	ADJ
dpc-5430	44	6	vascular	vascular	ADJ
dpc-5430	44	7	endothelial	endothelial	ADJ
dpc-5430	44	8	growth	growth	NOUN
dpc-5430	44	9	factor	factor	NOUN
dpc-5430	44	10	”	"	PUNCT
dpc-5430	44	11	,	,	PUNCT
dpc-5430	44	12	“	"	PUNCT
dpc-5430	44	13	anti	anti	ADJ
dpc-5430	44	14	-	-	NOUN
dpc-5430	44	15	vegf	vegf	NOUN
dpc-5430	44	16	”	"	PUNCT
dpc-5430	44	17	,	,	PUNCT
dpc-5430	44	18	“	"	PUNCT
dpc-5430	44	19	bevacizumab	bevacizumab	NOUN
dpc-5430	44	20	”	"	PUNCT
dpc-5430	44	21	,	,	PUNCT
dpc-5430	44	22	“	"	PUNCT
dpc-5430	44	23	avastin	avastin	PROPN
dpc-5430	44	24	”	"	PUNCT
dpc-5430	44	25	,	,	PUNCT
dpc-5430	44	26	“	"	PUNCT
dpc-5430	44	27	derma	derma	NOUN
dpc-5430	44	28	*	*	PUNCT
dpc-5430	44	29	”	"	PUNCT
dpc-5430	44	30	,	,	PUNCT
dpc-5430	44	31	“	"	PUNCT
dpc-5430	44	32	skin	skin	NOUN
dpc-5430	44	33	”	"	PUNCT
dpc-5430	44	34	,	,	PUNCT
dpc-5430	44	35	“	"	PUNCT
dpc-5430	44	36	cutaneous	cutaneous	ADJ
dpc-5430	44	37	”	"	PUNCT
dpc-5430	44	38	,	,	PUNCT
dpc-5430	44	39	“	"	PUNCT
dpc-5430	44	40	intralesional	intralesional	NOUN
dpc-5430	44	41	”	"	PUNCT
dpc-5430	44	42	,	,	PUNCT
dpc-5430	44	43	and	and	CCONJ
dpc-5430	44	44	“	"	PUNCT
dpc-5430	44	45	topical	topical	NOUN
dpc-5430	44	46	”	"	PUNCT
dpc-5430	44	47	were	be	AUX
dpc-5430	44	48	selected	select	VERB
dpc-5430	44	49	according	accord	VERB
dpc-5430	44	50	to	to	ADP
dpc-5430	44	51	the	the	DET
dpc-5430	44	52	mesh	mesh	NOUN
dpc-5430	44	53	terms	term	NOUN
dpc-5430	44	54	.	.	PUNCT
dpc-5430	45	1	all	all	DET
dpc-5430	45	2	keywords	keyword	NOUN
dpc-5430	45	3	were	be	AUX
dpc-5430	45	4	searched	search	VERB
dpc-5430	45	5	in	in	ADP
dpc-5430	45	6	pubmed	pubmed	PROPN
dpc-5430	45	7	,	,	PUNCT
dpc-5430	45	8	scopus	scopus	PROPN
dpc-5430	45	9	,	,	PUNCT
dpc-5430	45	10	and	and	CCONJ
dpc-5430	45	11	web	web	NOUN
dpc-5430	45	12	of	of	ADP
dpc-5430	45	13	science	science	NOUN
dpc-5430	45	14	with	with	ADP
dpc-5430	45	15	the	the	DET
dpc-5430	45	16	following	follow	VERB
dpc-5430	45	17	query	query	NOUN
dpc-5430	45	18	:	:	PUNCT
dpc-5430	45	19	(	(	PUNCT
dpc-5430	45	20	(	(	PUNCT
dpc-5430	45	21	anti	anti	ADJ
dpc-5430	45	22	-	-	ADJ
dpc-5430	45	23	vascular	vascular	ADJ
dpc-5430	45	24	endothelial	endothelial	ADJ
dpc-5430	45	25	growth	growth	NOUN
dpc-5430	45	26	factor[title	factor[title	NOUN
dpc-5430	45	27	/	/	SYM
dpc-5430	45	28	abstract	abstract	NOUN
dpc-5430	45	29	]	]	X
dpc-5430	45	30	)	)	PUNCT
dpc-5430	45	31	or	or	CCONJ
dpc-5430	45	32	(	(	PUNCT
dpc-5430	45	33	anti	anti	ADJ
dpc-5430	45	34	-	-	ADJ
dpc-5430	45	35	vegf	vegf	ADJ
dpc-5430	45	36	[	[	X
dpc-5430	45	37	title	title	NOUN
dpc-5430	45	38	/	/	SYM
dpc-5430	45	39	abstract	abstract	NOUN
dpc-5430	45	40	]	]	X
dpc-5430	45	41	)	)	PUNCT
dpc-5430	45	42	or	or	CCONJ
dpc-5430	45	43	(	(	PUNCT
dpc-5430	45	44	bevacizumab[title	bevacizumab[title	NOUN
dpc-5430	45	45	/	/	SYM
dpc-5430	45	46	abstract	abstract	NOUN
dpc-5430	45	47	]	]	X
dpc-5430	45	48	)	)	PUNCT
dpc-5430	45	49	or	or	CCONJ
dpc-5430	45	50	(	(	PUNCT
dpc-5430	45	51	avastin[title	avastin[title	NOUN
dpc-5430	45	52	/	/	SYM
dpc-5430	45	53	abstract	abstract	ADJ
dpc-5430	45	54	]	]	X
dpc-5430	45	55	)	)	PUNCT
dpc-5430	45	56	)	)	PUNCT
dpc-5430	45	57	and	and	CCONJ
dpc-5430	45	58	(	(	PUNCT
dpc-5430	45	59	(	(	PUNCT
dpc-5430	45	60	derma*[title	derma*[title	NOUN
dpc-5430	45	61	/	/	SYM
dpc-5430	45	62	abstract	abstract	ADJ
dpc-5430	45	63	]	]	X
dpc-5430	45	64	)	)	PUNCT
dpc-5430	45	65	or	or	CCONJ
dpc-5430	45	66	(	(	PUNCT
dpc-5430	45	67	skin[title	skin[title	NOUN
dpc-5430	45	68	/	/	SYM
dpc-5430	45	69	abstract	abstract	NOUN
dpc-5430	45	70	]	]	X
dpc-5430	45	71	)	)	PUNCT
dpc-5430	45	72	or	or	CCONJ
dpc-5430	45	73	(	(	PUNCT
dpc-5430	45	74	cutaneous[title	cutaneous[title	ADJ
dpc-5430	45	75	/	/	SYM
dpc-5430	45	76	abstract	abstract	ADJ
dpc-5430	45	77	]	]	X
dpc-5430	45	78	)	)	PUNCT
dpc-5430	45	79	or	or	CCONJ
dpc-5430	45	80	(	(	PUNCT
dpc-5430	45	81	intralesional[title	intralesional[title	ADJ
dpc-5430	45	82	/	/	NOUN
dpc-5430	45	83	abstract	abstract	ADJ
dpc-5430	45	84	]	]	X
dpc-5430	45	85	)	)	PUNCT
dpc-5430	45	86	or	or	CCONJ
dpc-5430	45	87	(	(	PUNCT
dpc-5430	45	88	topical[title	topical[title	PRON
dpc-5430	45	89	/	/	SYM
dpc-5430	45	90	abstract	abstract	NOUN
dpc-5430	45	91	]	]	X
dpc-5430	45	92	)	)	PUNCT
dpc-5430	45	93	)	)	PUNCT
dpc-5430	45	94	.	.	PUNCT
dpc-5430	46	1	all	all	DET
dpc-5430	46	2	articles	article	NOUN
dpc-5430	46	3	consisting	consist	VERB
dpc-5430	46	4	of	of	ADP
dpc-5430	46	5	these	these	DET
dpc-5430	46	6	keywords	keyword	NOUN
dpc-5430	46	7	were	be	AUX
dpc-5430	46	8	included	include	VERB
dpc-5430	46	9	.	.	PUNCT
dpc-5430	47	1	duplicated	duplicate	VERB
dpc-5430	47	2	articles	article	NOUN
dpc-5430	47	3	were	be	AUX
dpc-5430	47	4	removed	remove	VERB
dpc-5430	47	5	by	by	ADP
dpc-5430	47	6	endnote	endnote	PROPN
dpc-5430	47	7	version	version	NOUN
dpc-5430	47	8	20	20	NUM
dpc-5430	47	9	software	software	NOUN
dpc-5430	47	10	.	.	PUNCT
dpc-5430	48	1	first	first	ADV
dpc-5430	48	2	,	,	PUNCT
dpc-5430	48	3	titles	title	NOUN
dpc-5430	48	4	of	of	ADP
dpc-5430	48	5	articles	article	NOUN
dpc-5430	48	6	were	be	AUX
dpc-5430	48	7	screened	screen	VERB
dpc-5430	48	8	,	,	PUNCT
dpc-5430	48	9	and	and	CCONJ
dpc-5430	48	10	any	any	DET
dpc-5430	48	11	irrelevant	irrelevant	ADJ
dpc-5430	48	12	record	record	NOUN
dpc-5430	48	13	such	such	ADJ
dpc-5430	48	14	as	as	ADP
dpc-5430	48	15	cancer	cancer	NOUN
dpc-5430	48	16	or	or	CCONJ
dpc-5430	48	17	ophthalmological	ophthalmological	ADJ
dpc-5430	48	18	use	use	NOUN
dpc-5430	48	19	was	be	AUX
dpc-5430	48	20	excluded	exclude	VERB
dpc-5430	48	21	.	.	PUNCT
dpc-5430	49	1	also	also	ADV
dpc-5430	49	2	,	,	PUNCT
dpc-5430	49	3	reviews	review	NOUN
dpc-5430	49	4	of	of	ADP
dpc-5430	49	5	any	any	DET
dpc-5430	49	6	type	type	NOUN
dpc-5430	49	7	were	be	AUX
dpc-5430	49	8	excluded	exclude	VERB
dpc-5430	49	9	.	.	PUNCT
dpc-5430	50	1	in	in	ADP
dpc-5430	50	2	the	the	DET
dpc-5430	50	3	next	next	ADJ
dpc-5430	50	4	step	step	NOUN
dpc-5430	50	5	,	,	PUNCT
dpc-5430	50	6	the	the	DET
dpc-5430	50	7	abstracts	abstract	NOUN
dpc-5430	50	8	were	be	AUX
dpc-5430	50	9	screened	screen	VERB
dpc-5430	50	10	,	,	PUNCT
dpc-5430	50	11	and	and	CCONJ
dpc-5430	50	12	reviews	review	NOUN
dpc-5430	50	13	,	,	PUNCT
dpc-5430	50	14	experimental	experimental	ADJ
dpc-5430	50	15	studies	study	NOUN
dpc-5430	50	16	,	,	PUNCT
dpc-5430	50	17	and	and	CCONJ
dpc-5430	50	18	intravenous	intravenous	ADJ
dpc-5430	50	19	injections	injection	NOUN
dpc-5430	50	20	were	be	AUX
dpc-5430	50	21	omitted	omit	VERB
dpc-5430	50	22	.	.	PUNCT
dpc-5430	51	1	in	in	ADP
dpc-5430	51	2	the	the	DET
dpc-5430	51	3	final	final	ADJ
dpc-5430	51	4	step	step	NOUN
dpc-5430	51	5	,	,	PUNCT
dpc-5430	51	6	efforts	effort	NOUN
dpc-5430	51	7	aimed	aim	VERB
dpc-5430	51	8	to	to	PART
dpc-5430	51	9	screen	screen	VERB
dpc-5430	51	10	the	the	DET
dpc-5430	51	11	full	full	ADJ
dpc-5430	51	12	texts	text	NOUN
dpc-5430	51	13	of	of	ADP
dpc-5430	51	14	articles	article	NOUN
dpc-5430	51	15	based	base	VERB
dpc-5430	51	16	on	on	ADP
dpc-5430	51	17	the	the	DET
dpc-5430	51	18	same	same	ADJ
dpc-5430	51	19	criteria	criterion	NOUN
dpc-5430	51	20	.	.	PUNCT
dpc-5430	52	1	then	then	ADV
dpc-5430	52	2	the	the	DET
dpc-5430	52	3	remaining	remain	VERB
dpc-5430	52	4	full	full	ADJ
dpc-5430	52	5	texts	text	NOUN
dpc-5430	52	6	were	be	AUX
dpc-5430	52	7	evaluated	evaluate	VERB
dpc-5430	52	8	,	,	PUNCT
dpc-5430	52	9	and	and	CCONJ
dpc-5430	52	10	the	the	DET
dpc-5430	52	11	data	datum	NOUN
dpc-5430	52	12	were	be	AUX
dpc-5430	52	13	excluded	exclude	VERB
dpc-5430	52	14	.	.	PUNCT
dpc-5430	53	1	finally	finally	ADV
dpc-5430	53	2	,	,	PUNCT
dpc-5430	53	3	the	the	DET
dpc-5430	53	4	disease	disease	NOUN
dpc-5430	53	5	name	name	NOUN
dpc-5430	53	6	,	,	PUNCT
dpc-5430	53	7	treatment	treatment	NOUN
dpc-5430	53	8	protocol	protocol	NOUN
dpc-5430	53	9	(	(	PUNCT
dpc-5430	53	10	injection	injection	NOUN
dpc-5430	53	11	dosage	dosage	NOUN
dpc-5430	53	12	and	and	CCONJ
dpc-5430	53	13	intervals	interval	NOUN
dpc-5430	53	14	)	)	PUNCT
dpc-5430	53	15	,	,	PUNCT
dpc-5430	53	16	outcomes	outcome	NOUN
dpc-5430	53	17	,	,	PUNCT
dpc-5430	53	18	and	and	CCONJ
dpc-5430	53	19	complications	complication	NOUN
dpc-5430	53	20	were	be	AUX
dpc-5430	53	21	summarized	summarize	VERB
dpc-5430	53	22	for	for	ADP
dpc-5430	53	23	conclusions	conclusion	NOUN
dpc-5430	53	24	.	.	PUNCT
dpc-5430	54	1	results	result	NOUN
dpc-5430	54	2	after	after	ADP
dpc-5430	54	3	conducting	conduct	VERB
dpc-5430	54	4	the	the	DET
dpc-5430	54	5	systematic	systematic	ADJ
dpc-5430	54	6	search	search	NOUN
dpc-5430	54	7	,	,	PUNCT
dpc-5430	54	8	3014	3014	NUM
dpc-5430	54	9	articles	article	NOUN
dpc-5430	54	10	were	be	AUX
dpc-5430	54	11	found	find	VERB
dpc-5430	54	12	and	and	CCONJ
dpc-5430	54	13	inserted	insert	VERB
dpc-5430	54	14	into	into	ADP
dpc-5430	54	15	endnote	endnote	PROPN
dpc-5430	54	16	software	software	NOUN
dpc-5430	54	17	.	.	PUNCT
dpc-5430	55	1	by	by	ADP
dpc-5430	55	2	removing	remove	VERB
dpc-5430	55	3	the	the	DET
dpc-5430	55	4	duplicated	duplicate	VERB
dpc-5430	55	5	records	record	NOUN
dpc-5430	55	6	,	,	PUNCT
dpc-5430	55	7	1229	1229	NUM
dpc-5430	55	8	articles	article	NOUN
dpc-5430	55	9	remained	remain	VERB
dpc-5430	55	10	,	,	PUNCT
dpc-5430	55	11	and	and	CCONJ
dpc-5430	55	12	1199	1199	NUM
dpc-5430	55	13	articles	article	NOUN
dpc-5430	55	14	were	be	AUX
dpc-5430	55	15	excluded	exclude	VERB
dpc-5430	55	16	due	due	ADP
dpc-5430	55	17	to	to	ADP
dpc-5430	55	18	their	their	PRON
dpc-5430	55	19	irrelevant	irrelevant	ADJ
dpc-5430	55	20	title	title	NOUN
dpc-5430	55	21	or	or	CCONJ
dpc-5430	55	22	abstract	abstract	ADJ
dpc-5430	55	23	.	.	PUNCT
dpc-5430	56	1	the	the	DET
dpc-5430	56	2	full	full	ADJ
dpc-5430	56	3	text	text	NOUN
dpc-5430	56	4	of	of	ADP
dpc-5430	56	5	30	30	NUM
dpc-5430	56	6	articles	article	NOUN
dpc-5430	56	7	was	be	AUX
dpc-5430	56	8	screened	screen	VERB
dpc-5430	56	9	and	and	CCONJ
dpc-5430	56	10	14	14	NUM
dpc-5430	56	11	of	of	ADP
dpc-5430	56	12	them	they	PRON
dpc-5430	56	13	were	be	AUX
dpc-5430	56	14	selected	select	VERB
dpc-5430	56	15	.	.	PUNCT
dpc-5430	57	1	an	an	DET
dpc-5430	57	2	explorer	explorer	NOUN
dpc-5430	57	3	search	search	NOUN
dpc-5430	57	4	was	be	AUX
dpc-5430	57	5	also	also	ADV
dpc-5430	57	6	conducted	conduct	VERB
dpc-5430	57	7	,	,	PUNCT
dpc-5430	57	8	and	and	CCONJ
dpc-5430	57	9	seven	seven	NUM
dpc-5430	57	10	new	new	ADJ
dpc-5430	57	11	article	article	NOUN
dpc-5430	57	12	was	be	AUX
dpc-5430	57	13	added	add	VERB
dpc-5430	57	14	.	.	PUNCT
dpc-5430	58	1	figure	figure	NOUN
dpc-5430	58	2	1	1	NUM
dpc-5430	58	3	shows	show	VERB
dpc-5430	58	4	the	the	DET
dpc-5430	58	5	prisma	prisma	PROPN
dpc-5430	58	6	flow	flow	NOUN
dpc-5430	58	7	diagram	diagram	NOUN
dpc-5430	58	8	of	of	ADP
dpc-5430	58	9	the	the	DET
dpc-5430	58	10	current	current	ADJ
dpc-5430	58	11	review	review	NOUN
dpc-5430	58	12	.	.	PUNCT
dpc-5430	59	1	this	this	DET
dpc-5430	59	2	study	study	NOUN
dpc-5430	59	3	discusses	discuss	VERB
dpc-5430	59	4	the	the	DET
dpc-5430	59	5	use	use	NOUN
dpc-5430	59	6	of	of	ADP
dpc-5430	59	7	bevacizumab	bevacizumab	NOUN
dpc-5430	59	8	in	in	ADP
dpc-5430	59	9	dermatology	dermatology	NOUN
dpc-5430	59	10	in	in	ADP
dpc-5430	59	11	four	four	NUM
dpc-5430	59	12	categories	category	NOUN
dpc-5430	59	13	:	:	PUNCT
dpc-5430	59	14	hht	hht	PROPN
dpc-5430	59	15	,	,	PUNCT
dpc-5430	59	16	vascular	vascular	ADJ
dpc-5430	59	17	malformation	malformation	NOUN
dpc-5430	59	18	,	,	PUNCT
dpc-5430	59	19	vascular	vascular	ADJ
dpc-5430	59	20	proliferation	proliferation	NOUN
dpc-5430	59	21	,	,	PUNCT
dpc-5430	59	22	and	and	CCONJ
dpc-5430	59	23	others	other	NOUN
dpc-5430	59	24	(	(	PUNCT
dpc-5430	59	25	lichen	lichen	NOUN
dpc-5430	59	26	planus	planus	NOUN
dpc-5430	59	27	(	(	PUNCT
dpc-5430	59	28	lp	lp	NOUN
dpc-5430	59	29	)	)	PUNCT
dpc-5430	59	30	,	,	PUNCT
dpc-5430	59	31	and	and	CCONJ
dpc-5430	59	32	basal	basal	PROPN
dpc-5430	59	33	cell	cell	NOUN
dpc-5430	59	34	carcinoma	carcinoma	NOUN
dpc-5430	59	35	(	(	PUNCT
dpc-5430	59	36	bcc	bcc	PROPN
dpc-5430	59	37	)	)	PUNCT
dpc-5430	59	38	)	)	PUNCT
dpc-5430	60	1	(	(	PUNCT
dpc-5430	60	2	table	table	NOUN
dpc-5430	60	3	1	1	NUM
dpc-5430	60	4	)	)	PUNCT
dpc-5430	60	5	.	.	PUNCT
dpc-5430	61	1	conclusions	conclusion	NOUN
dpc-5430	61	2	:	:	PUNCT
dpc-5430	61	3	in	in	ADP
dpc-5430	61	4	this	this	DET
dpc-5430	61	5	study	study	NOUN
dpc-5430	61	6	,	,	PUNCT
dpc-5430	61	7	we	we	PRON
dpc-5430	61	8	systematically	systematically	ADV
dpc-5430	61	9	reviewed	review	VERB
dpc-5430	61	10	related	related	ADJ
dpc-5430	61	11	papers	paper	NOUN
dpc-5430	61	12	and	and	CCONJ
dpc-5430	61	13	summarized	summarize	VERB
dpc-5430	61	14	the	the	DET
dpc-5430	61	15	use	use	NOUN
dpc-5430	61	16	of	of	ADP
dpc-5430	61	17	bevacizumab	bevacizumab	NOUN
dpc-5430	61	18	in	in	ADP
dpc-5430	61	19	dermatology	dermatology	NOUN
dpc-5430	61	20	in	in	ADP
dpc-5430	61	21	four	four	NUM
dpc-5430	61	22	categories	category	NOUN
dpc-5430	61	23	,	,	PUNCT
dpc-5430	61	24	including	include	VERB
dpc-5430	61	25	hereditary	hereditary	ADJ
dpc-5430	61	26	hemorrhagic	hemorrhagic	NOUN
dpc-5430	61	27	telangiectasia	telangiectasia	NOUN
dpc-5430	61	28	,	,	PUNCT
dpc-5430	61	29	vascular	vascular	ADJ
dpc-5430	61	30	malformation	malformation	NOUN
dpc-5430	61	31	,	,	PUNCT
dpc-5430	61	32	vascular	vascular	ADJ
dpc-5430	61	33	proliferation	proliferation	NOUN
dpc-5430	61	34	,	,	PUNCT
dpc-5430	61	35	and	and	CCONJ
dpc-5430	61	36	others	other	NOUN
dpc-5430	61	37	(	(	PUNCT
dpc-5430	61	38	lichen	lichen	NOUN
dpc-5430	61	39	planus	planus	NOUN
dpc-5430	61	40	,	,	PUNCT
dpc-5430	61	41	and	and	CCONJ
dpc-5430	61	42	basal	basal	ADJ
dpc-5430	61	43	cell	cell	NOUN
dpc-5430	61	44	carcinoma	carcinoma	NOUN
dpc-5430	61	45	)	)	PUNCT
dpc-5430	61	46	.	.	PUNCT
dpc-5430	62	1	review	review	VERB
dpc-5430	62	2	|	|	ADV
dpc-5430	62	3	dermatol	dermatol	ADJ
dpc-5430	62	4	pract	pract	NOUN
dpc-5430	62	5	concept	concept	NOUN
dpc-5430	62	6	.	.	PUNCT
dpc-5430	63	1	2025;15(4):5430	2025;15(4):5430	NUM
dpc-5430	63	2	3	3	NUM
dpc-5430	63	3	hereditary	hereditary	ADJ
dpc-5430	63	4	hemorrhagic	hemorrhagic	NOUN
dpc-5430	63	5	telangiectasia	telangiectasia	PROPN
dpc-5430	63	6	(	(	PUNCT
dpc-5430	63	7	hht	hht	PROPN
dpc-5430	63	8	)	)	PUNCT
dpc-5430	63	9	the	the	DET
dpc-5430	63	10	use	use	NOUN
dpc-5430	63	11	of	of	ADP
dpc-5430	63	12	bevacizumab	bevacizumab	NOUN
dpc-5430	63	13	for	for	ADP
dpc-5430	63	14	hht	hht	PROPN
dpc-5430	63	15	,	,	PUNCT
dpc-5430	63	16	also	also	ADV
dpc-5430	63	17	known	know	VERB
dpc-5430	63	18	as	as	ADP
dpc-5430	63	19	osler	osler	NOUN
dpc-5430	63	20	-	-	PUNCT
dpc-5430	63	21	weber	weber	PROPN
dpc-5430	63	22	-	-	PUNCT
dpc-5430	63	23	rendu	rendu	NOUN
dpc-5430	63	24	syndrome	syndrome	NOUN
dpc-5430	63	25	,	,	PUNCT
dpc-5430	63	26	has	have	AUX
dpc-5430	63	27	been	be	AUX
dpc-5430	63	28	reported	report	VERB
dpc-5430	63	29	in	in	ADP
dpc-5430	63	30	14	14	NUM
dpc-5430	63	31	studies	study	NOUN
dpc-5430	63	32	.	.	PUNCT
dpc-5430	64	1	affected	affect	VERB
dpc-5430	64	2	patients	patient	NOUN
dpc-5430	64	3	with	with	ADP
dpc-5430	64	4	hht	hht	PROPN
dpc-5430	64	5	often	often	ADV
dpc-5430	64	6	develop	develop	VERB
dpc-5430	64	7	arteriovenous	arteriovenous	ADJ
dpc-5430	64	8	malformations	malformation	NOUN
dpc-5430	64	9	and	and	CCONJ
dpc-5430	64	10	mucocutaneous	mucocutaneous	ADJ
dpc-5430	64	11	telangiectasias	telangiectasia	NOUN
dpc-5430	64	12	,	,	PUNCT
dpc-5430	64	13	including	include	VERB
dpc-5430	64	14	nasal	nasal	ADJ
dpc-5430	64	15	mucosa	mucosa	NOUN
dpc-5430	64	16	with	with	ADP
dpc-5430	64	17	a	a	DET
dpc-5430	64	18	susceptibility	susceptibility	NOUN
dpc-5430	64	19	to	to	ADP
dpc-5430	64	20	bleeding	bleed	VERB
dpc-5430	64	21	[	[	X
dpc-5430	64	22	16	16	NUM
dpc-5430	64	23	]	]	PUNCT
dpc-5430	64	24	.	.	PUNCT
dpc-5430	65	1	due	due	ADP
dpc-5430	65	2	to	to	ADP
dpc-5430	65	3	the	the	DET
dpc-5430	65	4	elevated	elevated	ADJ
dpc-5430	65	5	levels	level	NOUN
dpc-5430	65	6	of	of	ADP
dpc-5430	65	7	serum	serum	NOUN
dpc-5430	65	8	and	and	CCONJ
dpc-5430	65	9	mucosal	mucosal	NOUN
dpc-5430	65	10	vegf	vegf	NOUN
dpc-5430	65	11	and	and	CCONJ
dpc-5430	65	12	transforming	transform	VERB
dpc-5430	65	13	growth	growth	NOUN
dpc-5430	65	14	factor	factor	NOUN
dpc-5430	65	15	-	-	PUNCT
dpc-5430	65	16	β	β	X
dpc-5430	65	17	(	(	PUNCT
dpc-5430	65	18	tgfβ	tgfβ	ADJ
dpc-5430	65	19	)	)	PUNCT
dpc-5430	65	20	in	in	ADP
dpc-5430	65	21	the	the	DET
dpc-5430	65	22	affected	affected	ADJ
dpc-5430	65	23	patients	patient	NOUN
dpc-5430	65	24	,	,	PUNCT
dpc-5430	65	25	bevacizumab	bevacizumab	PROPN
dpc-5430	65	26	,	,	PUNCT
dpc-5430	65	27	as	as	ADP
dpc-5430	65	28	an	an	DET
dpc-5430	65	29	anti	anti	NOUN
dpc-5430	65	30	-	-	NOUN
dpc-5430	65	31	vegf	vegf	NOUN
dpc-5430	65	32	,	,	PUNCT
dpc-5430	65	33	inhibits	inhibit	VERB
dpc-5430	65	34	angiogenesis	angiogenesis	NOUN
dpc-5430	65	35	and	and	CCONJ
dpc-5430	65	36	can	can	AUX
dpc-5430	65	37	help	help	VERB
dpc-5430	65	38	improve	improve	VERB
dpc-5430	65	39	recurrent	recurrent	ADJ
dpc-5430	65	40	epistaxis	epistaxis	ADJ
dpc-5430	66	1	[	[	X
dpc-5430	66	2	16	16	NUM
dpc-5430	66	3	]	]	PUNCT
dpc-5430	66	4	.	.	PUNCT
dpc-5430	67	1	epistaxis	epistaxis	ADJ
dpc-5430	67	2	severity	severity	NOUN
dpc-5430	67	3	is	be	AUX
dpc-5430	67	4	judged	judge	VERB
dpc-5430	67	5	by	by	ADP
dpc-5430	67	6	epistaxis	epistaxis	ADJ
dpc-5430	67	7	severity	severity	NOUN
dpc-5430	67	8	score	score	NOUN
dpc-5430	67	9	(	(	PUNCT
dpc-5430	67	10	ess	ess	NOUN
dpc-5430	67	11	)	)	PUNCT
dpc-5430	67	12	,	,	PUNCT
dpc-5430	67	13	which	which	PRON
dpc-5430	67	14	was	be	AUX
dpc-5430	67	15	assessed	assess	VERB
dpc-5430	67	16	preand	preand	NOUN
dpc-5430	67	17	post	post	ADJ
dpc-5430	67	18	-	-	NOUN
dpc-5430	67	19	treatment	treatment	NOUN
dpc-5430	67	20	in	in	ADP
dpc-5430	67	21	most	most	ADJ
dpc-5430	67	22	of	of	ADP
dpc-5430	67	23	the	the	DET
dpc-5430	67	24	studies	study	NOUN
dpc-5430	67	25	[	[	X
dpc-5430	67	26	17	17	NUM
dpc-5430	67	27	]	]	PUNCT
dpc-5430	67	28	.	.	PUNCT
dpc-5430	68	1	a	a	DET
dpc-5430	68	2	proper	proper	ADJ
dpc-5430	68	3	evaluation	evaluation	NOUN
dpc-5430	68	4	of	of	ADP
dpc-5430	68	5	pre	pre	ADJ
dpc-5430	68	6	-	-	NOUN
dpc-5430	68	7	treatment	treatment	ADJ
dpc-5430	68	8	ess	ess	NOUN
dpc-5430	68	9	is	be	AUX
dpc-5430	68	10	required	require	VERB
dpc-5430	68	11	to	to	PART
dpc-5430	68	12	choose	choose	VERB
dpc-5430	68	13	the	the	DET
dpc-5430	68	14	best	good	ADJ
dpc-5430	68	15	treatment	treatment	NOUN
dpc-5430	68	16	protocol	protocol	NOUN
dpc-5430	68	17	[	[	X
dpc-5430	68	18	18	18	NUM
dpc-5430	68	19	]	]	PUNCT
dpc-5430	68	20	.	.	PUNCT
dpc-5430	69	1	intranasal	intranasal	ADJ
dpc-5430	69	2	spray	spray	NOUN
dpc-5430	69	3	,	,	PUNCT
dpc-5430	69	4	50–100	50–100	PROPN
dpc-5430	69	5	mg	mg	X
dpc-5430	69	6	,	,	PUNCT
dpc-5430	69	7	can	can	AUX
dpc-5430	69	8	treat	treat	VERB
dpc-5430	69	9	mild	mild	ADJ
dpc-5430	69	10	symptoms	symptom	NOUN
dpc-5430	69	11	,	,	PUNCT
dpc-5430	69	12	while	while	SCONJ
dpc-5430	69	13	a	a	DET
dpc-5430	69	14	100	100	NUM
dpc-5430	69	15	mg	mg	PROPN
dpc-5430	69	16	submucosal	submucosal	NOUN
dpc-5430	69	17	injection	injection	NOUN
dpc-5430	69	18	is	be	AUX
dpc-5430	69	19	indicated	indicate	VERB
dpc-5430	69	20	for	for	ADP
dpc-5430	69	21	moderate	moderate	ADJ
dpc-5430	69	22	-	-	PUNCT
dpc-5430	69	23	to	to	ADP
dpc-5430	69	24	-	-	PUNCT
dpc-5430	69	25	severe	severe	ADJ
dpc-5430	69	26	cases	case	NOUN
dpc-5430	69	27	[	[	X
dpc-5430	69	28	16	16	NUM
dpc-5430	69	29	]	]	PUNCT
dpc-5430	69	30	.	.	PUNCT
dpc-5430	70	1	a	a	DET
dpc-5430	70	2	randomized	randomized	ADJ
dpc-5430	70	3	clinical	clinical	ADJ
dpc-5430	70	4	trial	trial	NOUN
dpc-5430	70	5	(	(	PUNCT
dpc-5430	70	6	rct	rct	PROPN
dpc-5430	70	7	)	)	PUNCT
dpc-5430	70	8	concluded	conclude	VERB
dpc-5430	70	9	that	that	SCONJ
dpc-5430	70	10	a	a	DET
dpc-5430	70	11	single	single	ADJ
dpc-5430	70	12	dose	dose	NOUN
dpc-5430	70	13	nasal	nasal	PROPN
dpc-5430	70	14	spray	spray	NOUN
dpc-5430	70	15	had	have	VERB
dpc-5430	70	16	no	no	DET
dpc-5430	70	17	clinical	clinical	ADJ
dpc-5430	70	18	effect	effect	NOUN
dpc-5430	70	19	and	and	CCONJ
dpc-5430	70	20	that	that	SCONJ
dpc-5430	70	21	there	there	PRON
dpc-5430	70	22	should	should	AUX
dpc-5430	70	23	be	be	AUX
dpc-5430	70	24	repeated	repeat	VERB
dpc-5430	70	25	doses	dose	NOUN
dpc-5430	70	26	to	to	PART
dpc-5430	70	27	reach	reach	VERB
dpc-5430	70	28	sufficient	sufficient	ADJ
dpc-5430	70	29	epistaxis	epistaxis	ADJ
dpc-5430	70	30	improvement	improvement	NOUN
dpc-5430	70	31	[	[	X
dpc-5430	70	32	19	19	NUM
dpc-5430	70	33	]	]	PUNCT
dpc-5430	70	34	.	.	PUNCT
dpc-5430	71	1	another	another	DET
dpc-5430	71	2	rct	rct	PROPN
dpc-5430	71	3	revealed	reveal	VERB
dpc-5430	71	4	that	that	SCONJ
dpc-5430	71	5	4	4	NUM
dpc-5430	71	6	mg	mg	NOUN
dpc-5430	71	7	topical	topical	ADJ
dpc-5430	71	8	bevacizumab	bevacizumab	NOUN
dpc-5430	71	9	per	per	ADP
dpc-5430	71	10	day	day	NOUN
dpc-5430	71	11	for	for	ADP
dpc-5430	71	12	seven	seven	NUM
dpc-5430	71	13	days	day	NOUN
dpc-5430	71	14	had	have	VERB
dpc-5430	71	15	no	no	DET
dpc-5430	71	16	clinical	clinical	ADJ
dpc-5430	71	17	effect	effect	NOUN
dpc-5430	71	18	and	and	CCONJ
dpc-5430	71	19	concluded	conclude	VERB
dpc-5430	71	20	that	that	SCONJ
dpc-5430	71	21	the	the	DET
dpc-5430	71	22	dosage	dosage	NOUN
dpc-5430	71	23	may	may	AUX
dpc-5430	71	24	be	be	AUX
dpc-5430	71	25	inadequate	inadequate	ADJ
dpc-5430	71	26	[	[	X
dpc-5430	71	27	14	14	NUM
dpc-5430	71	28	]	]	PUNCT
dpc-5430	71	29	.	.	PUNCT
dpc-5430	72	1	this	this	DET
dpc-5430	72	2	study	study	NOUN
dpc-5430	72	3	aimed	aim	VERB
dpc-5430	72	4	to	to	PART
dpc-5430	72	5	compare	compare	VERB
dpc-5430	72	6	the	the	DET
dpc-5430	72	7	effect	effect	NOUN
dpc-5430	72	8	of	of	ADP
dpc-5430	72	9	bevacizumab	bevacizumab	PROPN
dpc-5430	72	10	,	,	PUNCT
dpc-5430	72	11	estriol	estriol	PROPN
dpc-5430	72	12	,	,	PUNCT
dpc-5430	72	13	tranexamic	tranexamic	ADJ
dpc-5430	72	14	acid	acid	NOUN
dpc-5430	72	15	,	,	PUNCT
dpc-5430	72	16	and	and	CCONJ
dpc-5430	72	17	placebo	placebo	NOUN
dpc-5430	72	18	,	,	PUNCT
dpc-5430	72	19	and	and	CCONJ
dpc-5430	72	20	there	there	PRON
dpc-5430	72	21	was	be	VERB
dpc-5430	72	22	no	no	DET
dpc-5430	72	23	difference	difference	NOUN
dpc-5430	72	24	between	between	ADP
dpc-5430	72	25	these	these	DET
dpc-5430	72	26	groups	group	NOUN
dpc-5430	72	27	[	[	X
dpc-5430	72	28	14	14	NUM
dpc-5430	72	29	]	]	PUNCT
dpc-5430	72	30	.	.	PUNCT
dpc-5430	73	1	a	a	DET
dpc-5430	73	2	retrospective	retrospective	ADJ
dpc-5430	73	3	study	study	NOUN
dpc-5430	73	4	was	be	AUX
dpc-5430	73	5	done	do	VERB
dpc-5430	73	6	on	on	ADP
dpc-5430	73	7	32	32	NUM
dpc-5430	73	8	patients	patient	NOUN
dpc-5430	73	9	with	with	ADP
dpc-5430	73	10	hht	hht	PROPN
dpc-5430	73	11	receiving	receive	VERB
dpc-5430	73	12	25–100	25–100	PROPN
dpc-5430	73	13	mg	mg	PROPN
dpc-5430	73	14	bevacizumab	bevacizumab	NOUN
dpc-5430	73	15	,	,	PUNCT
dpc-5430	73	16	administered	administer	VERB
dpc-5430	73	17	topically	topically	ADV
dpc-5430	73	18	,	,	PUNCT
dpc-5430	73	19	submucosally	submucosally	ADV
dpc-5430	73	20	,	,	PUNCT
dpc-5430	73	21	or	or	CCONJ
dpc-5430	73	22	both	both	PRON
dpc-5430	73	23	.	.	PUNCT
dpc-5430	74	1	patients	patient	NOUN
dpc-5430	74	2	were	be	AUX
dpc-5430	74	3	interviewed	interview	VERB
dpc-5430	74	4	about	about	ADP
dpc-5430	74	5	their	their	PRON
dpc-5430	74	6	post	post	ADJ
dpc-5430	74	7	-	-	ADJ
dpc-5430	74	8	treatment	treatment	ADJ
dpc-5430	74	9	epistaxis	epistaxis	ADJ
dpc-5430	74	10	severity	severity	NOUN
dpc-5430	74	11	and	and	CCONJ
dpc-5430	74	12	revealed	reveal	VERB
dpc-5430	74	13	a	a	DET
dpc-5430	74	14	significant	significant	ADJ
dpc-5430	74	15	improvement	improvement	NOUN
dpc-5430	74	16	[	[	X
dpc-5430	74	17	13	13	NUM
dpc-5430	74	18	]	]	PUNCT
dpc-5430	74	19	.	.	PUNCT
dpc-5430	75	1	also	also	ADV
dpc-5430	75	2	,	,	PUNCT
dpc-5430	75	3	a	a	DET
dpc-5430	75	4	prospective	prospective	ADJ
dpc-5430	75	5	study	study	NOUN
dpc-5430	75	6	was	be	AUX
dpc-5430	75	7	done	do	VERB
dpc-5430	75	8	on	on	ADP
dpc-5430	75	9	six	six	NUM
dpc-5430	75	10	patients	patient	NOUN
dpc-5430	75	11	receiving	receive	VERB
dpc-5430	75	12	10	10	NUM
dpc-5430	75	13	treatment	treatment	NOUN
dpc-5430	75	14	courses	course	NOUN
dpc-5430	75	15	of	of	ADP
dpc-5430	75	16	50	50	NUM
dpc-5430	75	17	mg	mg	PROPN
dpc-5430	75	18	topical	topical	ADJ
dpc-5430	75	19	bevacizumab	bevacizumab	NOUN
dpc-5430	75	20	;	;	PUNCT
dpc-5430	75	21	an	an	DET
dpc-5430	75	22	effective	effective	ADJ
dpc-5430	75	23	symptomatic	symptomatic	ADJ
dpc-5430	75	24	treatment	treatment	NOUN
dpc-5430	75	25	for	for	ADP
dpc-5430	75	26	patients	patient	NOUN
dpc-5430	75	27	with	with	ADP
dpc-5430	75	28	pre	pre	ADJ
dpc-5430	75	29	-	-	NOUN
dpc-5430	75	30	treatment	treatment	NOUN
dpc-5430	75	31	ess<7	ess<7	PRON
dpc-5430	75	32	was	be	AUX
dpc-5430	75	33	found	find	VERB
dpc-5430	75	34	[	[	X
dpc-5430	75	35	14	14	NUM
dpc-5430	75	36	]	]	PUNCT
dpc-5430	75	37	.	.	PUNCT
dpc-5430	76	1	bevacizumab	bevacizumab	PROPN
dpc-5430	76	2	can	can	AUX
dpc-5430	76	3	be	be	AUX
dpc-5430	76	4	injected	inject	VERB
dpc-5430	76	5	intralesionally	intralesionally	ADV
dpc-5430	76	6	(	(	PUNCT
dpc-5430	76	7	il	il	PROPN
dpc-5430	76	8	)	)	PUNCT
dpc-5430	76	9	or	or	CCONJ
dpc-5430	76	10	intravenously	intravenously	ADV
dpc-5430	76	11	(	(	PUNCT
dpc-5430	76	12	iv	iv	X
dpc-5430	76	13	)	)	PUNCT
dpc-5430	76	14	.	.	PUNCT
dpc-5430	77	1	in	in	ADP
dpc-5430	77	2	comparison	comparison	NOUN
dpc-5430	77	3	to	to	ADP
dpc-5430	77	4	iv	iv	NUM
dpc-5430	77	5	injection	injection	NOUN
dpc-5430	77	6	of	of	ADP
dpc-5430	77	7	bevacizumab	bevacizumab	NOUN
dpc-5430	77	8	,	,	PUNCT
dpc-5430	77	9	il	il	PROPN
dpc-5430	77	10	injection	injection	NOUN
dpc-5430	77	11	is	be	AUX
dpc-5430	77	12	a	a	DET
dpc-5430	77	13	much	much	ADV
dpc-5430	77	14	better	well	ADJ
dpc-5430	77	15	choice	choice	NOUN
dpc-5430	77	16	because	because	SCONJ
dpc-5430	77	17	of	of	ADP
dpc-5430	77	18	less	less	ADV
dpc-5430	77	19	systemic	systemic	ADJ
dpc-5430	77	20	adverse	adverse	ADJ
dpc-5430	77	21	effects	effect	NOUN
dpc-5430	77	22	;	;	PUNCT
dpc-5430	77	23	it	it	PRON
dpc-5430	77	24	is	be	AUX
dpc-5430	77	25	also	also	ADV
dpc-5430	77	26	more	more	ADV
dpc-5430	77	27	available	available	ADJ
dpc-5430	77	28	and	and	CCONJ
dpc-5430	77	29	the	the	DET
dpc-5430	77	30	more	more	ADV
dpc-5430	77	31	cost	cost	NOUN
dpc-5430	77	32	-	-	PUNCT
dpc-5430	77	33	effective	effective	ADJ
dpc-5430	77	34	.	.	PUNCT
dpc-5430	78	1	the	the	DET
dpc-5430	78	2	intranasal	intranasal	ADJ
dpc-5430	78	3	submucosal	submucosal	NOUN
dpc-5430	78	4	injection	injection	NOUN
dpc-5430	78	5	is	be	AUX
dpc-5430	78	6	frequently	frequently	ADV
dpc-5430	78	7	administered	administer	VERB
dpc-5430	78	8	to	to	ADP
dpc-5430	78	9	the	the	DET
dpc-5430	78	10	lateral	lateral	ADJ
dpc-5430	78	11	nasal	nasal	PROPN
dpc-5430	78	12	wall	wall	PROPN
dpc-5430	78	13	,	,	PUNCT
dpc-5430	78	14	middle	middle	ADJ
dpc-5430	78	15	/	/	SYM
dpc-5430	78	16	inferior	inferior	ADJ
dpc-5430	78	17	turbinate	turbinate	NOUN
dpc-5430	78	18	,	,	PUNCT
dpc-5430	78	19	nasal	nasal	ADJ
dpc-5430	78	20	floor	floor	NOUN
dpc-5430	78	21	,	,	PUNCT
dpc-5430	78	22	and	and	CCONJ
dpc-5430	78	23	bony	bony	NOUN
dpc-5430	78	24	septum	septum	NOUN
dpc-5430	79	1	[	[	X
dpc-5430	79	2	16	16	NUM
dpc-5430	79	3	]	]	PUNCT
dpc-5430	79	4	.	.	PUNCT
dpc-5430	80	1	nasal	nasal	PROPN
dpc-5430	80	2	cartilaginous	cartilaginous	ADJ
dpc-5430	80	3	septum	septum	NOUN
dpc-5430	80	4	should	should	AUX
dpc-5430	80	5	not	not	PART
dpc-5430	80	6	be	be	AUX
dpc-5430	80	7	injected	inject	VERB
dpc-5430	80	8	with	with	ADP
dpc-5430	80	9	and	and	CCONJ
dpc-5430	80	10	without	without	ADP
dpc-5430	80	11	laser	laser	NOUN
dpc-5430	80	12	surgery	surgery	NOUN
dpc-5430	80	13	due	due	ADP
dpc-5430	80	14	to	to	ADP
dpc-5430	80	15	the	the	DET
dpc-5430	80	16	possibility	possibility	NOUN
dpc-5430	80	17	of	of	ADP
dpc-5430	80	18	septal	septal	ADJ
dpc-5430	80	19	perforation	perforation	NOUN
dpc-5430	80	20	[	[	X
dpc-5430	80	21	20,21	20,21	NUM
dpc-5430	80	22	]	]	PUNCT
dpc-5430	80	23	.	.	PUNCT
dpc-5430	81	1	a	a	DET
dpc-5430	81	2	study	study	NOUN
dpc-5430	81	3	introduced	introduce	VERB
dpc-5430	81	4	a	a	DET
dpc-5430	81	5	4	4	NUM
dpc-5430	81	6	-	-	PUNCT
dpc-5430	81	7	injection	injection	NOUN
dpc-5430	81	8	site	site	NOUN
dpc-5430	81	9	technique	technique	NOUN
dpc-5430	81	10	as	as	ADP
dpc-5430	81	11	a	a	DET
dpc-5430	81	12	new	new	ADJ
dpc-5430	81	13	treatment	treatment	NOUN
dpc-5430	81	14	option	option	NOUN
dpc-5430	81	15	:	:	PUNCT
dpc-5430	81	16	the	the	DET
dpc-5430	81	17	sphenopalatine	sphenopalatine	NOUN
dpc-5430	81	18	area	area	NOUN
dpc-5430	81	19	,	,	PUNCT
dpc-5430	81	20	the	the	DET
dpc-5430	81	21	upper	upper	ADJ
dpc-5430	81	22	part	part	NOUN
dpc-5430	81	23	of	of	ADP
dpc-5430	81	24	the	the	DET
dpc-5430	81	25	bony	bony	NOUN
dpc-5430	81	26	septum	septum	NOUN
dpc-5430	81	27	,	,	PUNCT
dpc-5430	81	28	the	the	DET
dpc-5430	81	29	upper	upper	ADJ
dpc-5430	81	30	part	part	NOUN
dpc-5430	81	31	of	of	ADP
dpc-5430	81	32	the	the	DET
dpc-5430	81	33	lateral	lateral	ADJ
dpc-5430	81	34	nasal	nasal	PROPN
dpc-5430	81	35	wall	wall	PROPN
dpc-5430	81	36	,	,	PUNCT
dpc-5430	81	37	and	and	CCONJ
dpc-5430	81	38	the	the	DET
dpc-5430	81	39	anterior	anterior	ADJ
dpc-5430	81	40	floor	floor	NOUN
dpc-5430	81	41	of	of	ADP
dpc-5430	81	42	the	the	DET
dpc-5430	81	43	nose	nose	NOUN
dpc-5430	81	44	.	.	PUNCT
dpc-5430	82	1	these	these	DET
dpc-5430	82	2	sites	site	NOUN
dpc-5430	82	3	are	be	AUX
dpc-5430	82	4	near	near	ADP
dpc-5430	82	5	the	the	DET
dpc-5430	82	6	entrance	entrance	NOUN
dpc-5430	82	7	points	point	NOUN
dpc-5430	82	8	of	of	ADP
dpc-5430	82	9	vessels	vessel	NOUN
dpc-5430	82	10	,	,	PUNCT
dpc-5430	82	11	which	which	PRON
dpc-5430	82	12	may	may	AUX
dpc-5430	82	13	result	result	VERB
dpc-5430	82	14	in	in	ADP
dpc-5430	82	15	better	well	ADJ
dpc-5430	82	16	control	control	NOUN
dpc-5430	83	1	[	[	X
dpc-5430	83	2	22	22	NUM
dpc-5430	83	3	]	]	PUNCT
dpc-5430	83	4	.	.	PUNCT
dpc-5430	84	1	an	an	DET
dpc-5430	84	2	rct	rct	PROPN
dpc-5430	84	3	compared	compare	VERB
dpc-5430	84	4	the	the	DET
dpc-5430	84	5	effect	effect	NOUN
dpc-5430	84	6	of	of	ADP
dpc-5430	84	7	a	a	DET
dpc-5430	84	8	100	100	NUM
dpc-5430	84	9	mg	mg	NOUN
dpc-5430	84	10	single	single	ADJ
dpc-5430	84	11	-	-	PUNCT
dpc-5430	84	12	dose	dose	VERB
dpc-5430	84	13	submucosal	submucosal	NOUN
dpc-5430	84	14	injection	injection	NOUN
dpc-5430	84	15	of	of	ADP
dpc-5430	84	16	bevacizumab	bevacizumab	NOUN
dpc-5430	84	17	with	with	ADP
dpc-5430	84	18	placebo	placebo	NOUN
dpc-5430	84	19	in	in	ADP
dpc-5430	84	20	reducing	reduce	VERB
dpc-5430	84	21	hht	hht	PROPN
dpc-5430	84	22	-	-	PUNCT
dpc-5430	84	23	related	relate	VERB
dpc-5430	84	24	epistaxis	epistaxis	NOUN
dpc-5430	84	25	.	.	PUNCT
dpc-5430	85	1	reducing	reduce	VERB
dpc-5430	85	2	epistaxis	epistaxis	NOUN
dpc-5430	85	3	was	be	AUX
dpc-5430	85	4	much	much	ADV
dpc-5430	85	5	greater	great	ADJ
dpc-5430	85	6	in	in	ADP
dpc-5430	85	7	the	the	DET
dpc-5430	85	8	bevacizumab	bevacizumab	NOUN
dpc-5430	85	9	group	group	NOUN
dpc-5430	86	1	[	[	X
dpc-5430	86	2	23	23	NUM
dpc-5430	86	3	]	]	PUNCT
dpc-5430	86	4	.	.	PUNCT
dpc-5430	87	1	a	a	DET
dpc-5430	87	2	5	5	NUM
dpc-5430	87	3	-	-	PUNCT
dpc-5430	87	4	year	year	NOUN
dpc-5430	87	5	-	-	PUNCT
dpc-5430	87	6	old	old	ADJ
dpc-5430	87	7	female	female	NOUN
dpc-5430	87	8	was	be	AUX
dpc-5430	87	9	reported	report	VERB
dpc-5430	87	10	with	with	ADP
dpc-5430	87	11	epistaxis	epistaxis	ADJ
dpc-5430	87	12	since	since	SCONJ
dpc-5430	87	13	birth	birth	NOUN
dpc-5430	87	14	.	.	PUNCT
dpc-5430	88	1	many	many	ADJ
dpc-5430	88	2	treatment	treatment	NOUN
dpc-5430	88	3	methods	method	NOUN
dpc-5430	88	4	had	have	AUX
dpc-5430	88	5	been	be	AUX
dpc-5430	88	6	used	use	VERB
dpc-5430	88	7	,	,	PUNCT
dpc-5430	88	8	with	with	ADP
dpc-5430	88	9	no	no	DET
dpc-5430	88	10	clinical	clinical	ADJ
dpc-5430	88	11	improvement	improvement	NOUN
dpc-5430	88	12	,	,	PUNCT
dpc-5430	88	13	including	include	VERB
dpc-5430	88	14	moisturizing	moisturizing	NOUN
dpc-5430	88	15	therapy	therapy	NOUN
dpc-5430	88	16	,	,	PUNCT
dpc-5430	88	17	aminocaproic	aminocaproic	ADJ
dpc-5430	88	18	acid	acid	NOUN
dpc-5430	88	19	,	,	PUNCT
dpc-5430	88	20	tranexamic	tranexamic	ADJ
dpc-5430	88	21	acid	acid	NOUN
dpc-5430	88	22	,	,	PUNCT
dpc-5430	88	23	and	and	CCONJ
dpc-5430	88	24	cauterization	cauterization	NOUN
dpc-5430	88	25	.	.	PUNCT
dpc-5430	89	1	finally	finally	ADV
dpc-5430	89	2	,	,	PUNCT
dpc-5430	89	3	she	she	PRON
dpc-5430	89	4	was	be	AUX
dpc-5430	89	5	treated	treat	VERB
dpc-5430	89	6	successfully	successfully	ADV
dpc-5430	89	7	with	with	ADP
dpc-5430	89	8	two	two	NUM
dpc-5430	89	9	injections	injection	NOUN
dpc-5430	89	10	of	of	ADP
dpc-5430	89	11	intranasal	intranasal	NOUN
dpc-5430	89	12	bevacizumab	bevacizumab	NOUN
dpc-5430	90	1	[	[	X
dpc-5430	90	2	24	24	NUM
dpc-5430	90	3	]	]	PUNCT
dpc-5430	90	4	.	.	PUNCT
dpc-5430	91	1	there	there	PRON
dpc-5430	91	2	are	be	VERB
dpc-5430	91	3	limited	limited	ADJ
dpc-5430	91	4	complications	complication	NOUN
dpc-5430	91	5	reported	report	VERB
dpc-5430	91	6	for	for	ADP
dpc-5430	91	7	intranasal	intranasal	NOUN
dpc-5430	91	8	therapy	therapy	NOUN
dpc-5430	91	9	,	,	PUNCT
dpc-5430	91	10	including	include	VERB
dpc-5430	91	11	septal	septal	ADJ
dpc-5430	91	12	perforation	perforation	NOUN
dpc-5430	91	13	[	[	X
dpc-5430	91	14	20,21	20,21	NUM
dpc-5430	91	15	]	]	PUNCT
dpc-5430	91	16	,	,	PUNCT
dpc-5430	91	17	subfebrile	subfebrile	ADJ
dpc-5430	91	18	body	body	NOUN
dpc-5430	91	19	temperature	temperature	NOUN
dpc-5430	91	20	[	[	X
dpc-5430	91	21	24	24	NUM
dpc-5430	91	22	]	]	PUNCT
dpc-5430	91	23	,	,	PUNCT
dpc-5430	91	24	nasal	nasal	NOUN
dpc-5430	91	25	symptoms	symptom	NOUN
dpc-5430	91	26	,	,	PUNCT
dpc-5430	91	27	headache	headache	NOUN
dpc-5430	91	28	,	,	PUNCT
dpc-5430	91	29	abdominal	abdominal	ADJ
dpc-5430	91	30	pain	pain	NOUN
dpc-5430	92	1	[	[	X
dpc-5430	92	2	14	14	NUM
dpc-5430	92	3	]	]	PUNCT
dpc-5430	92	4	,	,	PUNCT
dpc-5430	92	5	elevated	elevated	ADJ
dpc-5430	92	6	blood	blood	NOUN
dpc-5430	92	7	pressure	pressure	NOUN
dpc-5430	92	8	,	,	PUNCT
dpc-5430	92	9	body	body	NOUN
dpc-5430	92	10	tingling	tingle	VERB
dpc-5430	92	11	[	[	X
dpc-5430	92	12	23	23	NUM
dpc-5430	92	13	]	]	PUNCT
dpc-5430	92	14	,	,	PUNCT
dpc-5430	92	15	ageusia	ageusia	NOUN
dpc-5430	92	16	,	,	PUNCT
dpc-5430	92	17	and	and	CCONJ
dpc-5430	92	18	anosmia	anosmia	NOUN
dpc-5430	92	19	[	[	X
dpc-5430	92	20	18	18	NUM
dpc-5430	92	21	]	]	PUNCT
dpc-5430	92	22	.	.	PUNCT
dpc-5430	93	1	figure	figure	NOUN
dpc-5430	93	2	1	1	NUM
dpc-5430	93	3	.	.	PUNCT
dpc-5430	94	1	the	the	DET
dpc-5430	94	2	prisma	prisma	PROPN
dpc-5430	94	3	flow	flow	NOUN
dpc-5430	94	4	diagram	diagram	NOUN
dpc-5430	94	5	of	of	ADP
dpc-5430	94	6	the	the	DET
dpc-5430	94	7	study	study	NOUN
dpc-5430	94	8	.	.	PUNCT
dpc-5430	95	1	4	4	NUM
dpc-5430	95	2	review	review	NOUN
dpc-5430	95	3	|	|	ADV
dpc-5430	95	4	dermatol	dermatol	ADJ
dpc-5430	95	5	pract	pract	NOUN
dpc-5430	95	6	concept	concept	NOUN
dpc-5430	95	7	.	.	PUNCT
dpc-5430	96	1	2025;15(4):5430	2025;15(4):5430	NUM
dpc-5430	96	2	t	t	PROPN
dpc-5430	96	3	ab	ab	PROPN
dpc-5430	96	4	le	le	PROPN
dpc-5430	96	5	1	1	NUM
dpc-5430	96	6	.	.	PUNCT
dpc-5430	97	1	o	o	INTJ
dpc-5430	97	2	ve	ve	VERB
dpc-5430	97	3	rv	rv	X
dpc-5430	97	4	ie	ie	ADV
dpc-5430	97	5	w	w	PROPN
dpc-5430	97	6	o	o	X
dpc-5430	97	7	f	f	X
dpc-5430	97	8	l	l	NOUN
dpc-5430	98	1	it	it	PRON
dpc-5430	98	2	er	er	INTJ
dpc-5430	98	3	at	at	ADP
dpc-5430	98	4	ur	ur	NOUN
dpc-5430	98	5	e	e	NOUN
dpc-5430	98	6	in	in	ADP
dpc-5430	98	7	cl	cl	NOUN
dpc-5430	98	8	ud	ud	INTJ
dpc-5430	98	9	ed	ed	NOUN
dpc-5430	98	10	in	in	ADP
dpc-5430	98	11	t	t	PROPN
dpc-5430	98	12	hi	hi	INTJ
dpc-5430	98	13	s	s	PROPN
dpc-5430	98	14	sy	sy	INTJ
dpc-5430	98	15	st	st	PROPN
dpc-5430	98	16	em	em	PRON
dpc-5430	98	17	at	at	ADP
dpc-5430	98	18	ic	ic	PROPN
dpc-5430	98	19	r	r	NOUN
dpc-5430	98	20	ev	ev	X
dpc-5430	98	21	ie	ie	X
dpc-5430	98	22	w	w	PROPN
dpc-5430	98	23	.	.	PUNCT
dpc-5430	99	1	n	n	CCONJ
dpc-5430	99	2	o.	o.	PROPN
dpc-5430	99	3	fi	fi	NOUN
dpc-5430	100	1	rs	rs	PROPN
dpc-5430	100	2	t	t	PROPN
dpc-5430	100	3	a	a	DET
dpc-5430	100	4	ut	ut	PROPN
dpc-5430	100	5	ho	ho	PROPN
dpc-5430	100	6	r	r	PROPN
dpc-5430	100	7	/	/	SYM
dpc-5430	100	8	y	y	PROPN
dpc-5430	100	9	ea	ea	PROPN
dpc-5430	101	1	r	r	PROPN
dpc-5430	101	2	st	st	PROPN
dpc-5430	101	3	ud	ud	INTJ
dpc-5430	102	1	y	y	PROPN
dpc-5430	102	2	d	d	PROPN
dpc-5430	102	3	es	es	VERB
dpc-5430	102	4	ig	ig	PROPN
dpc-5430	102	5	n	n	PROPN
dpc-5430	102	6	sa	sa	NOUN
dpc-5430	102	7	m	m	VERB
dpc-5430	102	8	pl	pl	PROPN
dpc-5430	102	9	e	e	X
dpc-5430	102	10	si	si	PROPN
dpc-5430	102	11	ze	ze	PROPN
dpc-5430	102	12	a	a	DET
dpc-5430	102	13	ge	ge	PROPN
dpc-5430	102	14	d	d	PROPN
dpc-5430	102	15	is	be	AUX
dpc-5430	102	16	ea	ea	X
dpc-5430	102	17	se	se	PROPN
dpc-5430	102	18	b	b	PROPN
dpc-5430	103	1	ev	ev	INTJ
dpc-5430	103	2	ac	ac	PROPN
dpc-5430	104	1	iz	iz	INTJ
dpc-5430	104	2	um	um	INTJ
dpc-5430	104	3	ab	ab	PROPN
dpc-5430	104	4	p	p	X
dpc-5430	104	5	ro	ro	X
dpc-5430	104	6	to	to	PART
dpc-5430	104	7	co	co	VERB
dpc-5430	104	8	l	l	PROPN
dpc-5430	104	9	o	o	X
dpc-5430	104	10	ut	ut	PROPN
dpc-5430	104	11	co	co	NOUN
dpc-5430	104	12	m	m	PROPN
dpc-5430	104	13	e	e	NOUN
dpc-5430	104	14	c	c	X
dpc-5430	104	15	om	om	PROPN
dpc-5430	104	16	pl	pl	PROPN
dpc-5430	104	17	ic	ic	PROPN
dpc-5430	104	18	at	at	ADP
dpc-5430	104	19	io	io	X
dpc-5430	104	20	ns	ns	NUM
dpc-5430	104	21	1	1	NUM
dpc-5430	104	22	si	si	NOUN
dpc-5430	104	23	m	m	NOUN
dpc-5430	104	24	on	on	ADP
dpc-5430	104	25	ds	ds	ADP
dpc-5430	104	26	e	e	PROPN
dpc-5430	104	27	t	t	PROPN
dpc-5430	104	28	al	al	PROPN
dpc-5430	104	29	.	.	PUNCT
dpc-5430	105	1	/	/	SYM
dpc-5430	105	2	2	2	NUM
dpc-5430	105	3	00	00	NUM
dpc-5430	105	4	9	9	NUM
dpc-5430	105	5	r	r	NOUN
dpc-5430	105	6	et	et	NOUN
dpc-5430	105	7	ro	ro	NOUN
dpc-5430	105	8	sp	sp	ADP
dpc-5430	105	9	ec	ec	PROPN
dpc-5430	105	10	ti	ti	PROPN
dpc-5430	105	11	ve	ve	PROPN
dpc-5430	105	12	10	10	NUM
dpc-5430	105	13	58	58	NUM
dpc-5430	105	14	.3	.3	NUM
dpc-5430	105	15	±8	±8	NOUN
dpc-5430	106	1	.2	.2	NUM
dpc-5430	106	2	h	h	PROPN
dpc-5430	106	3	h	h	NOUN
dpc-5430	106	4	t	t	PROPN
dpc-5430	106	5	10	10	NUM
dpc-5430	106	6	0	0	NUM
dpc-5430	106	7	m	m	PROPN
dpc-5430	106	8	g	g	PROPN
dpc-5430	106	9	su	su	PROPN
dpc-5430	106	10	bm	bm	PROPN
dpc-5430	107	1	uc	uc	PROPN
dpc-5430	107	2	os	os	PROPN
dpc-5430	107	3	al	al	PROPN
dpc-5430	107	4	in	in	ADP
dpc-5430	107	5	je	je	PROPN
dpc-5430	107	6	ct	ct	PROPN
dpc-5430	107	7	io	io	PROPN
dpc-5430	107	8	n	n	PROPN
dpc-5430	107	9	e	e	X
dpc-5430	107	10	ff	ff	X
dpc-5430	107	11	ec	ec	PROPN
dpc-5430	107	12	ti	ti	PROPN
dpc-5430	107	13	ve	ve	VERB
dpc-5430	107	14	se	se	X
dpc-5430	107	15	pt	pt	PROPN
dpc-5430	108	1	al	al	PROPN
dpc-5430	108	2	p	p	PROPN
dpc-5430	109	1	er	er	INTJ
dpc-5430	109	2	fo	fo	INTJ
dpc-5430	109	3	ra	ra	INTJ
dpc-5430	109	4	ti	ti	NOUN
dpc-5430	109	5	on	on	ADP
dpc-5430	109	6	(	(	PUNCT
dpc-5430	109	7	n	n	NOUN
dpc-5430	109	8	=	=	NOUN
dpc-5430	109	9	4	4	NUM
dpc-5430	109	10	)	)	PUNCT
dpc-5430	109	11	2	2	NUM
dpc-5430	110	1	d	d	NOUN
dpc-5430	110	2	av	av	PROPN
dpc-5430	111	1	i	i	NOUN
dpc-5430	111	2	d	d	PROPN
dpc-5430	112	1	so	so	ADV
dpc-5430	112	2	n	n	ADV
dpc-5430	112	3	et	et	PROPN
dpc-5430	112	4	a	a	DET
dpc-5430	112	5	l.	l.	PROPN
dpc-5430	112	6	/	/	SYM
dpc-5430	112	7	2	2	NUM
dpc-5430	112	8	01	01	NUM
dpc-5430	112	9	0	0	NUM
dpc-5430	112	10	c	c	NOUN
dpc-5430	112	11	as	as	ADP
dpc-5430	112	12	e	e	X
dpc-5430	112	13	re	re	X
dpc-5430	112	14	po	po	PROPN
dpc-5430	112	15	rt	rt	PROPN
dpc-5430	112	16	1	1	NUM
dpc-5430	112	17	45	45	NUM
dpc-5430	112	18	h	h	NOUN
dpc-5430	112	19	h	h	NOUN
dpc-5430	112	20	t	t	PROPN
dpc-5430	112	21	10	10	NUM
dpc-5430	112	22	0	0	NUM
dpc-5430	112	23	m	m	PROPN
dpc-5430	112	24	g	g	PROPN
dpc-5430	112	25	su	su	PROPN
dpc-5430	112	26	bm	bm	PROPN
dpc-5430	113	1	uc	uc	PROPN
dpc-5430	113	2	os	os	PROPN
dpc-5430	113	3	al	al	PROPN
dpc-5430	113	4	in	in	ADP
dpc-5430	113	5	je	je	PROPN
dpc-5430	113	6	ct	ct	PROPN
dpc-5430	113	7	io	io	PROPN
dpc-5430	113	8	n	n	PROPN
dpc-5430	113	9	in	in	ADP
dpc-5430	113	10	a	a	DET
dpc-5430	113	11	dd	dd	NOUN
dpc-5430	113	12	it	it	PRON
dpc-5430	113	13	io	io	NOUN
dpc-5430	113	14	n	n	ADV
dpc-5430	113	15	to	to	ADP
dpc-5430	113	16	2	2	NUM
dpc-5430	113	17	c	c	NOUN
dpc-5430	113	18	ou	ou	X
dpc-5430	113	19	rs	rs	NOUN
dpc-5430	113	20	es	es	ADP
dpc-5430	113	21	o	o	X
dpc-5430	113	22	f	f	X
dpc-5430	114	1	to	to	PART
dpc-5430	114	2	pi	pi	PROPN
dpc-5430	114	3	ca	can	AUX
dpc-5430	114	4	l	l	PROPN
dpc-5430	114	5	a	a	DET
dpc-5430	114	6	pp	pp	ADV
dpc-5430	114	7	lic	lic	NOUN
dpc-5430	114	8	at	at	ADP
dpc-5430	114	9	io	io	PROPN
dpc-5430	114	10	n	n	ADP
dpc-5430	114	11	e	e	X
dpc-5430	114	12	ff	ff	X
dpc-5430	114	13	ec	ec	PROPN
dpc-5430	114	14	ti	ti	PROPN
dpc-5430	114	15	ve	ve	PROPN
dpc-5430	114	16	n	n	NUM
dpc-5430	114	17	/a	/a	NUM
dpc-5430	115	1	3	3	NUM
dpc-5430	115	2	c	c	VERB
dpc-5430	115	3	he	he	PRON
dpc-5430	115	4	n	n	ADV
dpc-5430	115	5	et	et	VERB
dpc-5430	115	6	a	a	DET
dpc-5430	115	7	l.	l.	PROPN
dpc-5430	115	8	/	/	SYM
dpc-5430	115	9	2	2	NUM
dpc-5430	115	10	01	01	NUM
dpc-5430	115	11	1	1	NUM
dpc-5430	115	12	r	r	NOUN
dpc-5430	115	13	et	et	NOUN
dpc-5430	115	14	ro	ro	NOUN
dpc-5430	115	15	sp	sp	ADP
dpc-5430	115	16	ec	ec	PROPN
dpc-5430	115	17	ti	ti	PROPN
dpc-5430	115	18	ve	ve	PROPN
dpc-5430	115	19	58	58	NUM
dpc-5430	115	20	54	54	NUM
dpc-5430	115	21	.9	.9	NUM
dpc-5430	116	1	9±	9±	NUM
dpc-5430	116	2	11	11	NUM
dpc-5430	116	3	.8	.8	NUM
dpc-5430	117	1	h	h	NOUN
dpc-5430	117	2	h	h	PROPN
dpc-5430	117	3	t	t	PROPN
dpc-5430	117	4	50	50	NUM
dpc-5430	117	5	-1	-1	NOUN
dpc-5430	117	6	00	00	NUM
dpc-5430	118	1	m	m	VERB
dpc-5430	118	2	g	g	NOUN
dpc-5430	118	3	to	to	ADP
dpc-5430	118	4	pi	pi	PROPN
dpc-5430	118	5	ca	ca	NOUN
dpc-5430	118	6	l	l	NOUN
dpc-5430	118	7	(	(	PUNCT
dpc-5430	118	8	na	na	INTJ
dpc-5430	118	9	sa	sa	PROPN
dpc-5430	118	10	l	l	PROPN
dpc-5430	118	11	sp	sp	ADP
dpc-5430	118	12	ra	ra	PROPN
dpc-5430	118	13	y	y	PROPN
dpc-5430	118	14	)	)	PUNCT
dpc-5430	118	15	(	(	PUNCT
dpc-5430	118	16	n	n	NOUN
dpc-5430	118	17	=	=	SYM
dpc-5430	118	18	1	1	NUM
dpc-5430	118	19	8)	8)	NUM
dpc-5430	118	20	,	,	PUNCT
dpc-5430	118	21	2	2	NUM
dpc-5430	118	22	510	510	NUM
dpc-5430	118	23	0	0	NUM
dpc-5430	118	24	m	m	NOUN
dpc-5430	118	25	g	g	PROPN
dpc-5430	118	26	su	su	PROPN
dpc-5430	118	27	bm	bm	PROPN
dpc-5430	119	1	uc	uc	PROPN
dpc-5430	119	2	os	os	PROPN
dpc-5430	119	3	al	al	PROPN
dpc-5430	119	4	in	in	ADP
dpc-5430	119	5	je	je	PROPN
dpc-5430	119	6	ct	ct	PROPN
dpc-5430	119	7	io	io	PROPN
dpc-5430	119	8	n	n	PROPN
dpc-5430	119	9	(	(	PUNCT
dpc-5430	119	10	n	n	NOUN
dpc-5430	119	11	=	=	NOUN
dpc-5430	119	12	2	2	NUM
dpc-5430	119	13	6	6	NUM
dpc-5430	119	14	)	)	PUNCT
dpc-5430	119	15	,	,	PUNCT
dpc-5430	120	1	b	b	X
dpc-5430	120	2	ot	ot	INTJ
dpc-5430	120	3	h	h	PROPN
dpc-5430	120	4	(	(	PUNCT
dpc-5430	120	5	n	n	NOUN
dpc-5430	120	6	=	=	NOUN
dpc-5430	120	7	8	8	NUM
dpc-5430	120	8	)	)	PUNCT
dpc-5430	121	1	e	e	NOUN
dpc-5430	121	2	ff	ff	NOUN
dpc-5430	121	3	ec	ec	PROPN
dpc-5430	121	4	ti	ti	PROPN
dpc-5430	121	5	ve	ve	VERB
dpc-5430	121	6	se	se	X
dpc-5430	121	7	pt	pt	PROPN
dpc-5430	122	1	al	al	PROPN
dpc-5430	122	2	p	p	PROPN
dpc-5430	123	1	er	er	INTJ
dpc-5430	123	2	fo	fo	INTJ
dpc-5430	123	3	ra	ra	INTJ
dpc-5430	123	4	ti	ti	NOUN
dpc-5430	123	5	on	on	ADP
dpc-5430	123	6	(	(	PUNCT
dpc-5430	123	7	n	n	NOUN
dpc-5430	123	8	=	=	NOUN
dpc-5430	123	9	5	5	NUM
dpc-5430	123	10	)	)	PUNCT
dpc-5430	123	11	4	4	NUM
dpc-5430	124	1	r	r	NOUN
dpc-5430	125	1	oh	oh	INTJ
dpc-5430	125	2	rm	rm	NOUN
dpc-5430	125	3	ei	ei	INTJ
dpc-5430	125	4	er	er	INTJ
dpc-5430	125	5	e	e	PROPN
dpc-5430	125	6	t	t	PROPN
dpc-5430	125	7	al	al	PROPN
dpc-5430	125	8	.	.	PUNCT
dpc-5430	125	9	/	/	SYM
dpc-5430	126	1	2	2	NUM
dpc-5430	126	2	01	01	NUM
dpc-5430	126	3	1	1	NUM
dpc-5430	126	4	r	r	NOUN
dpc-5430	126	5	et	et	NOUN
dpc-5430	126	6	ro	ro	NOUN
dpc-5430	126	7	sp	sp	ADP
dpc-5430	126	8	ec	ec	PROPN
dpc-5430	126	9	ti	ti	PROPN
dpc-5430	126	10	ve	ve	PROPN
dpc-5430	126	11	11	11	NUM
dpc-5430	126	12	65	65	NUM
dpc-5430	126	13	(	(	PUNCT
dpc-5430	126	14	46	46	NUM
dpc-5430	126	15	–	–	SYM
dpc-5430	126	16	7	7	NUM
dpc-5430	126	17	7	7	NUM
dpc-5430	126	18	)	)	PUNCT
dpc-5430	126	19	h	h	NOUN
dpc-5430	126	20	h	h	NOUN
dpc-5430	126	21	t	t	PROPN
dpc-5430	126	22	<	<	X
dpc-5430	126	23	7	7	NUM
dpc-5430	126	24	.5	.5	NUM
dpc-5430	126	25	m	m	PROPN
dpc-5430	126	26	g	g	PROPN
dpc-5430	126	27	su	su	PROPN
dpc-5430	126	28	bm	bm	PROPN
dpc-5430	127	1	uc	uc	PROPN
dpc-5430	127	2	os	os	PROPN
dpc-5430	127	3	al	al	PROPN
dpc-5430	127	4	in	in	ADP
dpc-5430	127	5	je	je	PROPN
dpc-5430	127	6	ct	ct	PROPN
dpc-5430	127	7	io	io	PROPN
dpc-5430	127	8	n	n	PROPN
dpc-5430	127	9	e	e	X
dpc-5430	127	10	ff	ff	X
dpc-5430	127	11	ec	ec	PROPN
dpc-5430	127	12	ti	ti	PROPN
dpc-5430	127	13	ve	ve	VERB
dpc-5430	127	14	n	n	NUM
dpc-5430	127	15	o	o	NOUN
dpc-5430	127	16	co	co	X
dpc-5430	127	17	m	m	VERB
dpc-5430	127	18	pl	pl	X
dpc-5430	127	19	ic	ic	PROPN
dpc-5430	127	20	at	at	ADP
dpc-5430	127	21	io	io	PROPN
dpc-5430	127	22	n	n	PROPN
dpc-5430	127	23	5	5	NUM
dpc-5430	127	24	k	k	PROPN
dpc-5430	127	25	ar	ar	PROPN
dpc-5430	127	26	ne	ne	PROPN
dpc-5430	127	27	zi	zi	PROPN
dpc-5430	127	28	s	s	PROPN
dpc-5430	127	29	et	et	PROPN
dpc-5430	127	30	a	a	DET
dpc-5430	127	31	l.	l.	PROPN
dpc-5430	127	32	/	/	SYM
dpc-5430	127	33	2	2	NUM
dpc-5430	127	34	01	01	NUM
dpc-5430	127	35	1	1	NUM
dpc-5430	127	36	r	r	NOUN
dpc-5430	127	37	et	et	NOUN
dpc-5430	127	38	ro	ro	NOUN
dpc-5430	127	39	sp	sp	ADP
dpc-5430	127	40	ec	ec	PROPN
dpc-5430	127	41	ti	ti	PROPN
dpc-5430	127	42	ve	ve	PROPN
dpc-5430	127	43	32	32	NUM
dpc-5430	127	44	53	53	NUM
dpc-5430	127	45	.8	.8	NUM
dpc-5430	127	46	±1	±1	VERB
dpc-5430	127	47	3	3	NUM
dpc-5430	127	48	.	.	SYM
dpc-5430	127	49	2	2	NUM
dpc-5430	127	50	h	h	NOUN
dpc-5430	127	51	h	h	NOUN
dpc-5430	127	52	t	t	PROPN
dpc-5430	127	53	50	50	NUM
dpc-5430	127	54	-1	-1	NOUN
dpc-5430	127	55	00	00	NUM
dpc-5430	128	1	m	m	VERB
dpc-5430	128	2	g	g	NOUN
dpc-5430	128	3	to	to	ADP
dpc-5430	128	4	pi	pi	PROPN
dpc-5430	128	5	ca	ca	NOUN
dpc-5430	128	6	l	l	NOUN
dpc-5430	128	7	(	(	PUNCT
dpc-5430	128	8	na	na	INTJ
dpc-5430	128	9	sa	sa	PROPN
dpc-5430	128	10	l	l	PROPN
dpc-5430	128	11	sp	sp	ADP
dpc-5430	128	12	ra	ra	PROPN
dpc-5430	128	13	y	y	PROPN
dpc-5430	128	14	)	)	PUNCT
dpc-5430	128	15	(	(	PUNCT
dpc-5430	128	16	n	n	NOUN
dpc-5430	128	17	=	=	SYM
dpc-5430	128	18	17	17	NUM
dpc-5430	128	19	)	)	PUNCT
dpc-5430	128	20	,	,	PUNCT
dpc-5430	129	1	10	10	NUM
dpc-5430	129	2	0	0	NUM
dpc-5430	129	3	m	m	VERB
dpc-5430	129	4	g	g	PROPN
dpc-5430	130	1	su	su	PROPN
dpc-5430	130	2	bm	bm	PROPN
dpc-5430	130	3	uc	uc	PROPN
dpc-5430	130	4	os	os	PROPN
dpc-5430	130	5	al	al	PROPN
dpc-5430	130	6	in	in	ADP
dpc-5430	130	7	je	je	PROPN
dpc-5430	130	8	ct	ct	PROPN
dpc-5430	130	9	io	io	PROPN
dpc-5430	131	1	n	n	PROPN
dpc-5430	131	2	(	(	PUNCT
dpc-5430	131	3	n	n	NOUN
dpc-5430	131	4	=	=	NOUN
dpc-5430	131	5	1	1	NUM
dpc-5430	131	6	0	0	NUM
dpc-5430	131	7	)	)	PUNCT
dpc-5430	131	8	,	,	PUNCT
dpc-5430	132	1	b	b	X
dpc-5430	132	2	ot	ot	INTJ
dpc-5430	132	3	h	h	PROPN
dpc-5430	132	4	(	(	PUNCT
dpc-5430	132	5	n	n	NOUN
dpc-5430	132	6	=	=	NOUN
dpc-5430	132	7	5	5	NUM
dpc-5430	132	8	)	)	PUNCT
dpc-5430	132	9	e	e	NOUN
dpc-5430	132	10	ff	ff	NOUN
dpc-5430	132	11	ec	ec	PROPN
dpc-5430	132	12	ti	ti	PROPN
dpc-5430	132	13	ve	ve	PROPN
dpc-5430	132	14	n	n	NUM
dpc-5430	132	15	/a	/a	NUM
dpc-5430	132	16	6	6	NUM
dpc-5430	132	17	k	k	PROPN
dpc-5430	132	18	ar	ar	PROPN
dpc-5430	132	19	ne	ne	PROPN
dpc-5430	132	20	zi	zi	PROPN
dpc-5430	132	21	s	s	PROPN
dpc-5430	132	22	et	et	PROPN
dpc-5430	132	23	a	a	DET
dpc-5430	132	24	l.	l.	PROPN
dpc-5430	132	25	/	/	SYM
dpc-5430	132	26	2	2	NUM
dpc-5430	132	27	01	01	NUM
dpc-5430	132	28	2	2	NUM
dpc-5430	132	29	pr	pr	NOUN
dpc-5430	132	30	os	os	INTJ
dpc-5430	133	1	pe	pe	INTJ
dpc-5430	133	2	ct	ct	NUM
dpc-5430	133	3	iv	iv	NUM
dpc-5430	133	4	e	e	NOUN
dpc-5430	133	5	19	19	NUM
dpc-5430	133	6	60	60	NUM
dpc-5430	133	7	(	(	PUNCT
dpc-5430	133	8	40	40	NUM
dpc-5430	133	9	-8	-8	NOUN
dpc-5430	133	10	0	0	NUM
dpc-5430	133	11	)	)	PUNCT
dpc-5430	134	1	h	h	NOUN
dpc-5430	134	2	h	h	NOUN
dpc-5430	134	3	t	t	PROPN
dpc-5430	134	4	10	10	NUM
dpc-5430	134	5	0	0	NUM
dpc-5430	134	6	m	m	PROPN
dpc-5430	134	7	g	g	PROPN
dpc-5430	134	8	su	su	PROPN
dpc-5430	134	9	bm	bm	PROPN
dpc-5430	135	1	uc	uc	PROPN
dpc-5430	135	2	os	os	PROPN
dpc-5430	135	3	al	al	PROPN
dpc-5430	135	4	in	in	ADP
dpc-5430	135	5	je	je	PROPN
dpc-5430	135	6	ct	ct	PROPN
dpc-5430	135	7	io	io	PROPN
dpc-5430	135	8	n.	n.	PROPN
dpc-5430	135	9	in	in	ADP
dpc-5430	135	10	a	a	DET
dpc-5430	135	11	dd	dd	NOUN
dpc-5430	135	12	it	it	PRON
dpc-5430	135	13	io	io	PROPN
dpc-5430	135	14	n	n	X
dpc-5430	135	15	,	,	PUNCT
dpc-5430	135	16	6	6	NUM
dpc-5430	135	17	p	p	NOUN
dpc-5430	135	18	at	at	ADP
dpc-5430	135	19	ie	ie	X
dpc-5430	135	20	nt	not	PART
dpc-5430	135	21	s	s	PART
dpc-5430	135	22	re	re	VERB
dpc-5430	135	23	ce	ce	PROPN
dpc-5430	135	24	iv	iv	PROPN
dpc-5430	135	25	ed	ed	PROPN
dpc-5430	135	26	1	1	NUM
dpc-5430	135	27	00	00	NUM
dpc-5430	135	28	m	m	VERB
dpc-5430	135	29	g	g	NOUN
dpc-5430	135	30	to	to	ADP
dpc-5430	135	31	pi	pi	PROPN
dpc-5430	135	32	ca	ca	NOUN
dpc-5430	135	33	l	l	NOUN
dpc-5430	135	34	(	(	PUNCT
dpc-5430	135	35	na	na	INTJ
dpc-5430	135	36	sa	sa	PROPN
dpc-5430	135	37	l	l	PROPN
dpc-5430	135	38	sp	sp	ADP
dpc-5430	135	39	ra	ra	PROPN
dpc-5430	135	40	y	y	PROPN
dpc-5430	135	41	)	)	PUNCT
dpc-5430	135	42	f	f	PROPN
dpc-5430	135	43	or	or	CCONJ
dpc-5430	135	44	8	8	NUM
dpc-5430	135	45	t	t	NOUN
dpc-5430	136	1	i	i	PRON
dpc-5430	136	2	m	m	VERB
dpc-5430	136	3	es	es	X
dpc-5430	136	4	.	.	PUNCT
dpc-5430	137	1	e	e	X
dpc-5430	137	2	ff	ff	VERB
dpc-5430	137	3	ec	ec	PROPN
dpc-5430	137	4	ti	ti	PROPN
dpc-5430	137	5	ve	ve	VERB
dpc-5430	137	6	n	n	NUM
dpc-5430	137	7	o	o	NOUN
dpc-5430	137	8	co	co	X
dpc-5430	137	9	m	m	VERB
dpc-5430	137	10	pl	pl	X
dpc-5430	137	11	ic	ic	PROPN
dpc-5430	137	12	at	at	ADP
dpc-5430	137	13	io	io	PROPN
dpc-5430	137	14	n	n	PROPN
dpc-5430	137	15	7	7	NUM
dpc-5430	137	16	st	st	PROPN
dpc-5430	137	17	ee	ee	PROPN
dpc-5430	137	18	pl	pl	PROPN
dpc-5430	137	19	es	es	X
dpc-5430	137	20	e	e	PROPN
dpc-5430	137	21	t	t	PROPN
dpc-5430	137	22	al	al	PROPN
dpc-5430	137	23	.	.	PUNCT
dpc-5430	138	1	/	/	SYM
dpc-5430	139	1	2	2	NUM
dpc-5430	139	2	01	01	NUM
dpc-5430	139	3	2	2	NUM
dpc-5430	139	4	c	c	NOUN
dpc-5430	139	5	as	as	ADP
dpc-5430	139	6	e	e	X
dpc-5430	139	7	l	l	NOUN
dpc-5430	139	8	et	et	NOUN
dpc-5430	139	9	te	te	ADP
dpc-5430	139	10	r	r	NOUN
dpc-5430	139	11	1	1	NUM
dpc-5430	139	12	31	31	NUM
dpc-5430	139	13	h	h	NOUN
dpc-5430	139	14	em	em	PRON
dpc-5430	140	1	an	an	DET
dpc-5430	140	2	gi	gi	INTJ
dpc-5430	140	3	om	om	PROPN
dpc-5430	140	4	a	a	DET
dpc-5430	140	5	2	2	NUM
dpc-5430	140	6	.	.	SYM
dpc-5430	140	7	5	5	NUM
dpc-5430	140	8	m	m	NOUN
dpc-5430	140	9	g/	g/	NOUN
dpc-5430	140	10	0	0	NUM
dpc-5430	140	11	.	.	NOUN
dpc-5430	141	1	1	1	NUM
dpc-5430	141	2	m	m	VERB
dpc-5430	141	3	l	l	NOUN
dpc-5430	141	4	m	m	VERB
dpc-5430	141	5	on	on	ADP
dpc-5430	141	6	th	th	INTJ
dpc-5430	141	7	ly	ly	X
dpc-5430	141	8	in	in	ADP
dpc-5430	141	9	tr	tr	NOUN
dpc-5430	141	10	al	al	PROPN
dpc-5430	141	11	es	es	NOUN
dpc-5430	141	12	io	io	X
dpc-5430	141	13	na	na	NOUN
dpc-5430	141	14	l	l	NOUN
dpc-5430	142	1	i	i	PRON
dpc-5430	142	2	nj	nj	INTJ
dpc-5430	142	3	ec	ec	PROPN
dpc-5430	142	4	ti	ti	PROPN
dpc-5430	142	5	on	on	ADP
dpc-5430	142	6	s	s	PROPN
dpc-5430	142	7	,	,	PUNCT
dpc-5430	142	8	4	4	NUM
dpc-5430	142	9	ti	ti	NOUN
dpc-5430	142	10	m	m	VERB
dpc-5430	142	11	es	es	NOUN
dpc-5430	142	12	e	e	NOUN
dpc-5430	142	13	ff	ff	X
dpc-5430	142	14	ec	ec	PROPN
dpc-5430	142	15	ti	ti	PROPN
dpc-5430	142	16	ve	ve	VERB
dpc-5430	142	17	n	n	NUM
dpc-5430	142	18	o	o	NOUN
dpc-5430	142	19	co	co	X
dpc-5430	142	20	m	m	VERB
dpc-5430	142	21	pl	pl	X
dpc-5430	142	22	ic	ic	PROPN
dpc-5430	142	23	at	at	ADP
dpc-5430	142	24	io	io	PROPN
dpc-5430	142	25	n	n	ADV
dpc-5430	142	26	8	8	NUM
dpc-5430	142	27	b	b	X
dpc-5430	142	28	ri	ri	NOUN
dpc-5430	143	1	nk	nk	INTJ
dpc-5430	143	2	er	er	INTJ
dpc-5430	143	3	ho	ho	PROPN
dpc-5430	143	4	ff	ff	PROPN
dpc-5430	143	5	e	e	PROPN
dpc-5430	143	6	t	t	PROPN
dpc-5430	143	7	al	al	PROPN
dpc-5430	143	8	.	.	PUNCT
dpc-5430	144	1	/	/	SYM
dpc-5430	144	2	2	2	NUM
dpc-5430	144	3	01	01	NUM
dpc-5430	144	4	2	2	NUM
dpc-5430	144	5	c	c	NOUN
dpc-5430	144	6	as	as	ADP
dpc-5430	144	7	e	e	X
dpc-5430	144	8	re	re	X
dpc-5430	144	9	po	po	PROPN
dpc-5430	144	10	rt	rt	PROPN
dpc-5430	144	11	1	1	NUM
dpc-5430	144	12	55	55	NUM
dpc-5430	144	13	h	h	NOUN
dpc-5430	144	14	h	h	NOUN
dpc-5430	144	15	t	t	PROPN
dpc-5430	144	16	10	10	NUM
dpc-5430	144	17	0	0	NUM
dpc-5430	144	18	m	m	VERB
dpc-5430	144	19	g	g	NOUN
dpc-5430	144	20	to	to	ADP
dpc-5430	144	21	pi	pi	PROPN
dpc-5430	144	22	ca	ca	NOUN
dpc-5430	144	23	l	l	NOUN
dpc-5430	144	24	(	(	PUNCT
dpc-5430	144	25	na	na	AUX
dpc-5430	144	26	sa	sa	PROPN
dpc-5430	144	27	l	l	NOUN
dpc-5430	144	28	s	s	PART
dpc-5430	144	29	pr	pr	NOUN
dpc-5430	144	30	ay	ay	PROPN
dpc-5430	144	31	)	)	PUNCT
dpc-5430	144	32	,	,	PUNCT
dpc-5430	144	33	ev	ev	INTJ
dpc-5430	144	34	er	er	INTJ
dpc-5430	144	35	y	y	PROPN
dpc-5430	144	36	89	89	NUM
dpc-5430	144	37	w	w	PROPN
dpc-5430	144	38	ee	ee	PROPN
dpc-5430	144	39	ks	ks	PROPN
dpc-5430	144	40	e	e	PROPN
dpc-5430	144	41	ff	ff	X
dpc-5430	144	42	ec	ec	PROPN
dpc-5430	144	43	ti	ti	PROPN
dpc-5430	144	44	ve	ve	VERB
dpc-5430	144	45	n	n	NUM
dpc-5430	144	46	o	o	NOUN
dpc-5430	144	47	co	co	X
dpc-5430	144	48	m	m	VERB
dpc-5430	144	49	pl	pl	X
dpc-5430	144	50	ic	ic	PROPN
dpc-5430	144	51	at	at	ADP
dpc-5430	144	52	io	io	PROPN
dpc-5430	144	53	n	n	ADV
dpc-5430	144	54	9	9	NUM
dpc-5430	145	1	d	d	NOUN
dpc-5430	145	2	he	he	PRON
dpc-5430	145	3	ya	ya	INTJ
dpc-5430	145	4	ul	ul	X
dpc-5430	145	5	de	de	X
dpc-5430	145	6	en	en	X
dpc-5430	145	7	e	e	PROPN
dpc-5430	145	8	t	t	PROPN
dpc-5430	145	9	al	al	PROPN
dpc-5430	145	10	.	.	PUNCT
dpc-5430	145	11	/	/	SYM
dpc-5430	146	1	2	2	NUM
dpc-5430	146	2	01	01	NUM
dpc-5430	146	3	2	2	NUM
dpc-5430	146	4	pr	pr	NOUN
dpc-5430	146	5	os	os	INTJ
dpc-5430	147	1	pe	pe	INTJ
dpc-5430	147	2	ct	ct	NUM
dpc-5430	147	3	iv	iv	NUM
dpc-5430	147	4	e	e	NOUN
dpc-5430	147	5	8	8	NUM
dpc-5430	147	6	56	56	NUM
dpc-5430	147	7	.5	.5	NUM
dpc-5430	147	8	±1	±1	VERB
dpc-5430	147	9	2	2	NUM
dpc-5430	147	10	.	.	NOUN
dpc-5430	147	11	7	7	NUM
dpc-5430	147	12	h	h	NOUN
dpc-5430	147	13	h	h	NOUN
dpc-5430	147	14	t	t	PROPN
dpc-5430	147	15	10	10	NUM
dpc-5430	147	16	0	0	NUM
dpc-5430	147	17	m	m	PROPN
dpc-5430	147	18	g	g	PROPN
dpc-5430	147	19	su	su	PROPN
dpc-5430	147	20	bm	bm	PROPN
dpc-5430	148	1	uc	uc	PROPN
dpc-5430	148	2	os	os	PROPN
dpc-5430	148	3	al	al	PROPN
dpc-5430	148	4	in	in	ADP
dpc-5430	148	5	je	je	PROPN
dpc-5430	148	6	ct	ct	PROPN
dpc-5430	148	7	io	io	PROPN
dpc-5430	148	8	n	n	PROPN
dpc-5430	148	9	e	e	X
dpc-5430	148	10	ff	ff	X
dpc-5430	148	11	ec	ec	PROPN
dpc-5430	148	12	ti	ti	PROPN
dpc-5430	148	13	ve	ve	NOUN
dpc-5430	148	14	n	n	NUM
dpc-5430	148	15	/a	/a	PRON
dpc-5430	149	1	10	10	NUM
dpc-5430	149	2	g	g	NOUN
dpc-5430	149	3	ul	ul	INTJ
dpc-5430	149	4	dm	dm	NOUN
dpc-5430	149	5	an	an	DET
dpc-5430	149	6	n	n	X
dpc-5430	149	7	et	et	NOUN
dpc-5430	149	8	a	a	DET
dpc-5430	149	9	l.	l.	PROPN
dpc-5430	149	10	/	/	SYM
dpc-5430	149	11	2	2	NUM
dpc-5430	149	12	01	01	NUM
dpc-5430	149	13	2	2	NUM
dpc-5430	149	14	pr	pr	NOUN
dpc-5430	149	15	os	os	INTJ
dpc-5430	150	1	pe	pe	INTJ
dpc-5430	150	2	ct	ct	NUM
dpc-5430	150	3	iv	iv	NUM
dpc-5430	150	4	e	e	NOUN
dpc-5430	150	5	6	6	NUM
dpc-5430	150	6	56	56	NUM
dpc-5430	150	7	.3	.3	NUM
dpc-5430	150	8	h	h	NOUN
dpc-5430	150	9	h	h	NOUN
dpc-5430	150	10	t	t	PROPN
dpc-5430	150	11	50	50	NUM
dpc-5430	150	12	m	m	NOUN
dpc-5430	150	13	g	g	NOUN
dpc-5430	150	14	to	to	ADP
dpc-5430	150	15	pi	pi	PROPN
dpc-5430	150	16	ca	ca	NOUN
dpc-5430	150	17	l	l	NOUN
dpc-5430	150	18	(	(	PUNCT
dpc-5430	150	19	na	na	AUX
dpc-5430	150	20	sa	sa	PROPN
dpc-5430	150	21	l	l	NOUN
dpc-5430	150	22	s	s	PART
dpc-5430	150	23	pr	pr	NOUN
dpc-5430	150	24	ay	ay	NOUN
dpc-5430	150	25	)	)	PUNCT
dpc-5430	151	1	e	e	X
dpc-5430	151	2	ff	ff	NOUN
dpc-5430	151	3	ec	ec	PROPN
dpc-5430	151	4	ti	ti	PROPN
dpc-5430	151	5	ve	ve	VERB
dpc-5430	151	6	h	h	NOUN
dpc-5430	151	7	ea	ea	PROPN
dpc-5430	151	8	da	da	PROPN
dpc-5430	151	9	ch	ch	PROPN
dpc-5430	151	10	e	e	PROPN
dpc-5430	151	11	,	,	PUNCT
dpc-5430	151	12	a	a	DET
dpc-5430	151	13	ge	ge	PROPN
dpc-5430	151	14	us	us	PROPN
dpc-5430	151	15	ia	ia	PROPN
dpc-5430	151	16	,	,	PUNCT
dpc-5430	151	17	a	a	DET
dpc-5430	151	18	nd	nd	NOUN
dpc-5430	151	19	an	an	DET
dpc-5430	151	20	os	os	NOUN
dpc-5430	151	21	m	m	NOUN
dpc-5430	151	22	ia	ia	PROPN
dpc-5430	151	23	11	11	NUM
dpc-5430	151	24	g	g	NOUN
dpc-5430	151	25	ai	ai	VERB
dpc-5430	151	26	ta	ta	ADP
dpc-5430	151	27	ni	ni	PROPN
dpc-5430	151	28	s	s	PROPN
dpc-5430	151	29	et	et	PROPN
dpc-5430	151	30	a	a	DET
dpc-5430	151	31	l.	l.	PROPN
dpc-5430	151	32	/	/	SYM
dpc-5430	151	33	2	2	NUM
dpc-5430	151	34	01	01	NUM
dpc-5430	151	35	3	3	NUM
dpc-5430	151	36	c	c	NOUN
dpc-5430	151	37	as	as	SCONJ
dpc-5430	151	38	e	e	PROPN
dpc-5430	151	39	se	se	X
dpc-5430	151	40	ri	ri	PROPN
dpc-5430	151	41	es	es	VERB
dpc-5430	151	42	7	7	NUM
dpc-5430	151	43	70	70	NUM
dpc-5430	151	44	(	(	PUNCT
dpc-5430	151	45	50	50	NUM
dpc-5430	151	46	-8	-8	NUM
dpc-5430	151	47	8)	8)	NUM
dpc-5430	151	48	b	b	NOUN
dpc-5430	151	49	c	c	NOUN
dpc-5430	151	50	c	c	PROPN
dpc-5430	151	51	25	25	NUM
dpc-5430	151	52	m	m	NOUN
dpc-5430	151	53	g	g	NOUN
dpc-5430	151	54	in	in	ADP
dpc-5430	151	55	tr	tr	NOUN
dpc-5430	151	56	al	al	PROPN
dpc-5430	151	57	es	es	ADP
dpc-5430	151	58	io	io	X
dpc-5430	151	59	na	na	NOUN
dpc-5430	151	60	l	l	NOUN
dpc-5430	152	1	i	i	PRON
dpc-5430	152	2	nj	nj	INTJ
dpc-5430	152	3	ec	ec	PROPN
dpc-5430	152	4	ti	ti	PROPN
dpc-5430	152	5	on	on	ADP
dpc-5430	152	6	,	,	PUNCT
dpc-5430	152	7	13	13	NUM
dpc-5430	152	8	ti	ti	NOUN
dpc-5430	152	9	m	m	VERB
dpc-5430	152	10	es	es	NOUN
dpc-5430	152	11	e	e	NOUN
dpc-5430	152	12	ff	ff	NOUN
dpc-5430	152	13	ec	ec	PROPN
dpc-5430	152	14	ti	ti	PROPN
dpc-5430	152	15	ve	ve	VERB
dpc-5430	152	16	pa	pa	PROPN
dpc-5430	152	17	in	in	ADP
dpc-5430	152	18	d	d	PROPN
dpc-5430	152	19	ur	ur	INTJ
dpc-5430	152	20	in	in	ADP
dpc-5430	152	21	g	g	PROPN
dpc-5430	152	22	in	in	ADP
dpc-5430	152	23	je	je	PROPN
dpc-5430	152	24	ct	ct	PROPN
dpc-5430	152	25	io	io	PROPN
dpc-5430	152	26	n	n	PROPN
dpc-5430	152	27	(	(	PUNCT
dpc-5430	152	28	n	n	NOUN
dpc-5430	152	29	=	=	NOUN
dpc-5430	152	30	6	6	NUM
dpc-5430	152	31	)	)	PUNCT
dpc-5430	152	32	,	,	PUNCT
dpc-5430	152	33	fl	fl	NOUN
dpc-5430	152	34	ulik	ulik	ADV
dpc-5430	153	1	e	e	PROPN
dpc-5430	153	2	sy	sy	NOUN
dpc-5430	153	3	m	m	PROPN
dpc-5430	153	4	pt	pt	NOUN
dpc-5430	153	5	om	om	PROPN
dpc-5430	153	6	s	s	PROPN
dpc-5430	153	7	(	(	PUNCT
dpc-5430	153	8	n	n	NOUN
dpc-5430	153	9	=	=	NOUN
dpc-5430	153	10	2	2	NUM
dpc-5430	153	11	)	)	PUNCT
dpc-5430	153	12	,	,	PUNCT
dpc-5430	153	13	r	r	NOUN
dpc-5430	153	14	ev	ev	X
dpc-5430	153	15	er	er	INTJ
dpc-5430	153	16	si	si	INTJ
dpc-5430	153	17	bl	bl	PROPN
dpc-5430	153	18	e	e	PROPN
dpc-5430	153	19	le	le	X
dpc-5430	153	20	uk	uk	PROPN
dpc-5430	153	21	op	op	PROPN
dpc-5430	153	22	en	en	PROPN
dpc-5430	153	23	ia	ia	PROPN
dpc-5430	153	24	(	(	PUNCT
dpc-5430	153	25	n	n	NOUN
dpc-5430	153	26	=	=	NOUN
dpc-5430	153	27	1	1	NUM
dpc-5430	153	28	)	)	PUNCT
dpc-5430	153	29	review	review	NOUN
dpc-5430	153	30	|	|	ADV
dpc-5430	153	31	dermatol	dermatol	ADJ
dpc-5430	153	32	pract	pract	NOUN
dpc-5430	153	33	concept	concept	NOUN
dpc-5430	153	34	.	.	PUNCT
dpc-5430	154	1	2025;15(4):5430	2025;15(4):5430	NUM
dpc-5430	154	2	5	5	NUM
dpc-5430	154	3	n	n	NUM
dpc-5430	154	4	o.	o.	NOUN
dpc-5430	154	5	fi	fi	NOUN
dpc-5430	154	6	rs	rs	PROPN
dpc-5430	154	7	t	t	PROPN
dpc-5430	154	8	a	a	DET
dpc-5430	154	9	ut	ut	PROPN
dpc-5430	154	10	ho	ho	PROPN
dpc-5430	154	11	r	r	PROPN
dpc-5430	154	12	/	/	SYM
dpc-5430	154	13	y	y	PROPN
dpc-5430	154	14	ea	ea	PROPN
dpc-5430	155	1	r	r	PROPN
dpc-5430	155	2	st	st	PROPN
dpc-5430	155	3	ud	ud	INTJ
dpc-5430	156	1	y	y	PROPN
dpc-5430	156	2	d	d	PROPN
dpc-5430	156	3	es	es	VERB
dpc-5430	156	4	ig	ig	PROPN
dpc-5430	156	5	n	n	PROPN
dpc-5430	156	6	sa	sa	NOUN
dpc-5430	156	7	m	m	VERB
dpc-5430	156	8	pl	pl	PROPN
dpc-5430	156	9	e	e	X
dpc-5430	156	10	si	si	PROPN
dpc-5430	156	11	ze	ze	PROPN
dpc-5430	156	12	a	a	DET
dpc-5430	156	13	ge	ge	PROPN
dpc-5430	156	14	d	d	PROPN
dpc-5430	156	15	is	be	AUX
dpc-5430	156	16	ea	ea	X
dpc-5430	156	17	se	se	PROPN
dpc-5430	156	18	b	b	PROPN
dpc-5430	157	1	ev	ev	INTJ
dpc-5430	157	2	ac	ac	PROPN
dpc-5430	158	1	iz	iz	INTJ
dpc-5430	158	2	um	um	INTJ
dpc-5430	158	3	ab	ab	PROPN
dpc-5430	158	4	p	p	X
dpc-5430	158	5	ro	ro	X
dpc-5430	158	6	to	to	PART
dpc-5430	158	7	co	co	VERB
dpc-5430	158	8	l	l	PROPN
dpc-5430	158	9	o	o	X
dpc-5430	158	10	ut	ut	PROPN
dpc-5430	158	11	co	co	NOUN
dpc-5430	158	12	m	m	PROPN
dpc-5430	158	13	e	e	NOUN
dpc-5430	158	14	c	c	X
dpc-5430	158	15	om	om	PROPN
dpc-5430	158	16	pl	pl	PROPN
dpc-5430	158	17	ic	ic	PROPN
dpc-5430	158	18	at	at	ADP
dpc-5430	158	19	io	io	X
dpc-5430	158	20	ns	ns	NUM
dpc-5430	158	21	12	12	NUM
dpc-5430	158	22	k	k	PROPN
dpc-5430	158	23	al	al	PROPN
dpc-5430	158	24	in	in	ADV
dpc-5430	158	25	in	in	ADP
dpc-5430	158	26	a	a	DET
dpc-5430	158	27	et	et	NOUN
dpc-5430	158	28	a	a	DET
dpc-5430	158	29	l.	l.	PROPN
dpc-5430	158	30	/	/	SYM
dpc-5430	158	31	2	2	NUM
dpc-5430	158	32	01	01	NUM
dpc-5430	158	33	4	4	NUM
dpc-5430	158	34	c	c	NOUN
dpc-5430	158	35	as	as	ADP
dpc-5430	158	36	e	e	X
dpc-5430	158	37	re	re	X
dpc-5430	158	38	po	po	PROPN
dpc-5430	158	39	rt	rt	PROPN
dpc-5430	158	40	1	1	NUM
dpc-5430	158	41	5	5	NUM
dpc-5430	158	42	h	h	NOUN
dpc-5430	158	43	h	h	NOUN
dpc-5430	158	44	t	t	PROPN
dpc-5430	158	45	10	10	NUM
dpc-5430	158	46	m	m	NOUN
dpc-5430	158	47	g/	g/	NOUN
dpc-5430	158	48	m	m	NOUN
dpc-5430	158	49	l	l	NOUN
dpc-5430	158	50	s	s	NOUN
dpc-5430	158	51	ub	ub	INTJ
dpc-5430	158	52	m	m	VERB
dpc-5430	158	53	uc	uc	INTJ
dpc-5430	158	54	os	os	PROPN
dpc-5430	158	55	al	al	PROPN
dpc-5430	158	56	in	in	ADP
dpc-5430	158	57	je	je	PROPN
dpc-5430	158	58	ct	ct	PROPN
dpc-5430	158	59	io	io	PROPN
dpc-5430	158	60	n	n	X
dpc-5430	158	61	,	,	PUNCT
dpc-5430	158	62	2	2	NUM
dpc-5430	158	63	t	t	NOUN
dpc-5430	159	1	i	i	PRON
dpc-5430	159	2	m	m	VERB
dpc-5430	159	3	es	es	AUX
dpc-5430	159	4	e	e	X
dpc-5430	159	5	ve	ve	AUX
dpc-5430	159	6	ry	ry	VERB
dpc-5430	159	7	3	3	PROPN
dpc-5430	159	8	w	w	PROPN
dpc-5430	159	9	ee	ee	PROPN
dpc-5430	159	10	ks	ks	PROPN
dpc-5430	159	11	e	e	PROPN
dpc-5430	159	12	ff	ff	X
dpc-5430	159	13	ec	ec	PROPN
dpc-5430	159	14	ti	ti	PROPN
dpc-5430	159	15	ve	ve	PROPN
dpc-5430	159	16	su	su	PROPN
dpc-5430	159	17	bf	bf	PROPN
dpc-5430	159	18	eb	eb	PROPN
dpc-5430	159	19	ri	ri	PROPN
dpc-5430	159	20	le	le	PROPN
dpc-5430	159	21	b	b	PROPN
dpc-5430	159	22	od	od	NUM
dpc-5430	159	23	y	y	PROPN
dpc-5430	159	24	te	te	INTJ
dpc-5430	159	25	m	m	INTJ
dpc-5430	159	26	pe	pe	INTJ
dpc-5430	159	27	ra	ra	PROPN
dpc-5430	159	28	tu	tu	PROPN
dpc-5430	159	29	re	re	VERB
dpc-5430	159	30	u	u	NOUN
dpc-5430	159	31	p	p	X
dpc-5430	159	32	to	to	ADP
dpc-5430	159	33	37	37	NUM
dpc-5430	159	34	.5	.5	NUM
dpc-5430	160	1	°	°	ADP
dpc-5430	160	2	c	c	NOUN
dpc-5430	160	3	13	13	NUM
dpc-5430	160	4	r	r	NOUN
dpc-5430	160	5	is	be	AUX
dpc-5430	160	6	s	s	PROPN
dpc-5430	160	7	et	et	NOUN
dpc-5430	160	8	a	a	DET
dpc-5430	160	9	l.	l.	PROPN
dpc-5430	160	10	/	/	SYM
dpc-5430	160	11	2	2	NUM
dpc-5430	160	12	01	01	NUM
dpc-5430	160	13	4	4	NUM
dpc-5430	160	14	r	r	NOUN
dpc-5430	160	15	c	c	NOUN
dpc-5430	160	16	t	t	NOUN
dpc-5430	160	17	9	9	NUM
dpc-5430	160	18	59	59	NUM
dpc-5430	160	19	(	(	PUNCT
dpc-5430	160	20	41	41	NUM
dpc-5430	160	21	-7	-7	NOUN
dpc-5430	160	22	1	1	NUM
dpc-5430	160	23	)	)	PUNCT
dpc-5430	161	1	h	h	NOUN
dpc-5430	161	2	h	h	NOUN
dpc-5430	162	1	t	t	PROPN
dpc-5430	162	2	10	10	NUM
dpc-5430	162	3	0	0	NUM
dpc-5430	162	4	m	m	PROPN
dpc-5430	162	5	g	g	PROPN
dpc-5430	162	6	su	su	PROPN
dpc-5430	162	7	bm	bm	PROPN
dpc-5430	163	1	uc	uc	PROPN
dpc-5430	163	2	os	os	PROPN
dpc-5430	163	3	al	al	PROPN
dpc-5430	163	4	in	in	ADP
dpc-5430	163	5	je	je	PROPN
dpc-5430	163	6	ct	ct	PROPN
dpc-5430	163	7	io	io	PROPN
dpc-5430	163	8	n	n	PROPN
dpc-5430	163	9	e	e	X
dpc-5430	163	10	ff	ff	X
dpc-5430	163	11	ec	ec	PROPN
dpc-5430	163	12	ti	ti	PROPN
dpc-5430	163	13	ve	ve	PROPN
dpc-5430	163	14	e	e	X
dpc-5430	163	15	le	le	X
dpc-5430	163	16	va	va	PROPN
dpc-5430	164	1	te	te	PROPN
dpc-5430	165	1	d	d	X
dpc-5430	165	2	bl	bl	INTJ
dpc-5430	165	3	oo	oo	INTJ
dpc-5430	165	4	d	d	X
dpc-5430	165	5	pr	pr	NOUN
dpc-5430	165	6	es	es	X
dpc-5430	165	7	su	su	PROPN
dpc-5430	165	8	re	re	PROPN
dpc-5430	165	9	(	(	PUNCT
dpc-5430	165	10	n	n	NOUN
dpc-5430	165	11	=	=	NOUN
dpc-5430	165	12	1	1	NUM
dpc-5430	165	13	)	)	PUNCT
dpc-5430	165	14	,	,	PUNCT
dpc-5430	165	15	r	r	NOUN
dpc-5430	165	16	hi	hi	INTJ
dpc-5430	165	17	ni	ni	PROPN
dpc-5430	165	18	ti	ti	PROPN
dpc-5430	165	19	s	s	PART
dpc-5430	165	20	(	(	PUNCT
dpc-5430	165	21	n	n	NOUN
dpc-5430	165	22	=	=	NOUN
dpc-5430	165	23	1	1	NUM
dpc-5430	165	24	)	)	PUNCT
dpc-5430	165	25	,	,	PUNCT
dpc-5430	165	26	it	it	PRON
dpc-5430	165	27	ch	ch	VERB
dpc-5430	165	28	in	in	ADP
dpc-5430	165	29	g	g	PROPN
dpc-5430	165	30	at	at	ADP
dpc-5430	165	31	t	t	PROPN
dpc-5430	165	32	he	he	PRON
dpc-5430	165	33	n	n	CCONJ
dpc-5430	166	1	os	os	NOUN
dpc-5430	166	2	e	e	X
dpc-5430	166	3	ti	ti	X
dpc-5430	166	4	p	p	PROPN
dpc-5430	166	5	(	(	PUNCT
dpc-5430	166	6	n	n	NOUN
dpc-5430	166	7	=	=	NOUN
dpc-5430	166	8	1	1	NUM
dpc-5430	166	9	)	)	PUNCT
dpc-5430	166	10	,	,	PUNCT
dpc-5430	166	11	b	b	X
dpc-5430	166	12	od	od	NUM
dpc-5430	166	13	y	y	PROPN
dpc-5430	166	14	ti	ti	PROPN
dpc-5430	166	15	ng	ng	PROPN
dpc-5430	166	16	lin	lin	PROPN
dpc-5430	166	17	g	g	PROPN
dpc-5430	166	18	(	(	PUNCT
dpc-5430	166	19	n	n	NOUN
dpc-5430	166	20	=	=	NOUN
dpc-5430	166	21	1	1	NUM
dpc-5430	166	22	)	)	PUNCT
dpc-5430	166	23	14	14	NUM
dpc-5430	166	24	d	d	NOUN
dpc-5430	166	25	up	up	ADP
dpc-5430	166	26	ui	ui	PROPN
dpc-5430	166	27	sg	sg	PROPN
dpc-5430	166	28	ir	ir	PROPN
dpc-5430	166	29	od	od	PROPN
dpc-5430	166	30	/	/	SYM
dpc-5430	166	31	20	20	NUM
dpc-5430	166	32	14	14	NUM
dpc-5430	166	33	r	r	NOUN
dpc-5430	166	34	c	c	NOUN
dpc-5430	166	35	t	t	PROPN
dpc-5430	166	36	30	30	NUM
dpc-5430	166	37	57	57	NUM
dpc-5430	166	38	(	(	PUNCT
dpc-5430	166	39	39	39	NUM
dpc-5430	166	40	-7	-7	NUM
dpc-5430	166	41	5	5	NUM
dpc-5430	166	42	)	)	PUNCT
dpc-5430	167	1	h	h	NOUN
dpc-5430	167	2	h	h	NOUN
dpc-5430	167	3	t	t	PROPN
dpc-5430	167	4	12	12	NUM
dpc-5430	167	5	.5	.5	NUM
dpc-5430	167	6	,	,	PUNCT
dpc-5430	167	7	2	2	NUM
dpc-5430	167	8	5	5	NUM
dpc-5430	167	9	,	,	PUNCT
dpc-5430	167	10	5	5	NUM
dpc-5430	167	11	0	0	NUM
dpc-5430	167	12	,	,	PUNCT
dpc-5430	167	13	7	7	NUM
dpc-5430	167	14	5	5	NUM
dpc-5430	167	15	,	,	PUNCT
dpc-5430	167	16	o	o	NOUN
dpc-5430	167	17	r	r	NOUN
dpc-5430	167	18	10	10	NUM
dpc-5430	167	19	0	0	NUM
dpc-5430	167	20	m	m	NOUN
dpc-5430	167	21	g	g	NOUN
dpc-5430	167	22	to	to	ADP
dpc-5430	167	23	pi	pi	PROPN
dpc-5430	167	24	ca	ca	NOUN
dpc-5430	167	25	l	l	NOUN
dpc-5430	167	26	(	(	PUNCT
dpc-5430	167	27	na	na	AUX
dpc-5430	167	28	sa	sa	PROPN
dpc-5430	167	29	l	l	NOUN
dpc-5430	167	30	s	s	PART
dpc-5430	167	31	pr	pr	NOUN
dpc-5430	167	32	ay	ay	PROPN
dpc-5430	167	33	)	)	PUNCT
dpc-5430	167	34	,	,	PUNCT
dpc-5430	167	35	si	si	PROPN
dpc-5430	167	36	ng	ng	PROPN
dpc-5430	167	37	le	le	PROPN
dpc-5430	167	38	ep	ep	PROPN
dpc-5430	167	39	is	be	AUX
dpc-5430	167	40	od	od	PROPN
dpc-5430	167	41	e	e	NOUN
dpc-5430	167	42	n	n	NUM
dpc-5430	167	43	o	o	PROPN
dpc-5430	167	44	cl	cl	NOUN
dpc-5430	167	45	in	in	ADP
dpc-5430	167	46	ic	ic	PROPN
dpc-5430	167	47	al	al	PROPN
dpc-5430	167	48	e	e	PROPN
dpc-5430	167	49	ff	ff	VERB
dpc-5430	167	50	ec	ec	PROPN
dpc-5430	167	51	t	t	PROPN
dpc-5430	167	52	n	n	ADV
dpc-5430	167	53	o	o	X
dpc-5430	167	54	co	co	X
dpc-5430	167	55	m	m	VERB
dpc-5430	167	56	pl	pl	X
dpc-5430	167	57	ic	ic	PROPN
dpc-5430	167	58	at	at	ADP
dpc-5430	167	59	io	io	PROPN
dpc-5430	167	60	n	n	ADV
dpc-5430	167	61	15	15	NUM
dpc-5430	167	62	a	a	DET
dpc-5430	167	63	bl	bl	INTJ
dpc-5430	167	64	an	an	DET
dpc-5430	167	65	ed	ed	PROPN
dpc-5430	167	66	ote	ote	PROPN
dpc-5430	167	67	rr	rr	PROPN
dpc-5430	167	68	az	az	PROPN
dpc-5430	167	69	as	as	ADP
dpc-5430	167	70	et	et	PROPN
dpc-5430	167	71	a	a	DET
dpc-5430	167	72	l.	l.	PROPN
dpc-5430	167	73	/	/	SYM
dpc-5430	167	74	2	2	NUM
dpc-5430	167	75	01	01	NUM
dpc-5430	167	76	5	5	NUM
dpc-5430	168	1	r	r	NOUN
dpc-5430	168	2	c	c	NOUN
dpc-5430	168	3	t	t	NOUN
dpc-5430	168	4	7	7	NUM
dpc-5430	168	5	35	35	NUM
dpc-5430	168	6	(	(	PUNCT
dpc-5430	168	7	29	29	NUM
dpc-5430	168	8	–	–	SYM
dpc-5430	168	9	3	3	NUM
dpc-5430	168	10	9	9	NUM
dpc-5430	168	11	)	)	PUNCT
dpc-5430	168	12	m	m	VERB
dpc-5430	168	13	uc	uc	INTJ
dpc-5430	168	14	os	os	PROPN
dpc-5430	168	15	al	al	PROPN
dpc-5430	168	16	k	k	PROPN
dpc-5430	168	17	s	s	PROPN
dpc-5430	168	18	0	0	NUM
dpc-5430	168	19	.	.	NOUN
dpc-5430	168	20	2	2	NUM
dpc-5430	168	21	m	m	NOUN
dpc-5430	168	22	l	l	NOUN
dpc-5430	168	23	(	(	PUNCT
dpc-5430	168	24	5	5	NUM
dpc-5430	168	25	m	m	NOUN
dpc-5430	168	26	g	g	NOUN
dpc-5430	168	27	)	)	PUNCT
dpc-5430	168	28	/c	/c	PUNCT
dpc-5430	169	1	m	m	NOUN
dpc-5430	169	2	2	2	NUM
dpc-5430	169	3	in	in	ADP
dpc-5430	169	4	tr	tr	NOUN
dpc-5430	169	5	al	al	PROPN
dpc-5430	169	6	es	es	NOUN
dpc-5430	169	7	io	io	X
dpc-5430	169	8	na	na	NOUN
dpc-5430	169	9	l	l	NOUN
dpc-5430	170	1	i	i	PRON
dpc-5430	170	2	nj	nj	INTJ
dpc-5430	170	3	ec	ec	PROPN
dpc-5430	170	4	ti	ti	PROPN
dpc-5430	170	5	on	on	ADP
dpc-5430	170	6	,	,	PUNCT
dpc-5430	170	7	3	3	NUM
dpc-5430	170	8	t	t	NOUN
dpc-5430	170	9	i	i	PRON
dpc-5430	170	10	m	m	VERB
dpc-5430	170	11	es	es	VERB
dpc-5430	170	12	ev	ev	INTJ
dpc-5430	170	13	er	er	INTJ
dpc-5430	170	14	y	y	PROPN
dpc-5430	170	15	2	2	PROPN
dpc-5430	170	16	w	w	PROPN
dpc-5430	170	17	ee	ee	PROPN
dpc-5430	170	18	ks	ks	PROPN
dpc-5430	170	19	n	n	NUM
dpc-5430	170	20	o	o	PROPN
dpc-5430	170	21	cl	cl	NOUN
dpc-5430	170	22	in	in	ADP
dpc-5430	170	23	ic	ic	PROPN
dpc-5430	170	24	al	al	PROPN
dpc-5430	170	25	e	e	PROPN
dpc-5430	170	26	ff	ff	VERB
dpc-5430	170	27	ec	ec	PROPN
dpc-5430	171	1	t	t	PROPN
dpc-5430	171	2	m	m	PROPN
dpc-5430	171	3	ild	ild	PROPN
dpc-5430	171	4	p	p	X
dpc-5430	171	5	ai	ai	VERB
dpc-5430	171	6	n	n	ADV
dpc-5430	171	7	an	an	PRON
dpc-5430	171	8	d	d	X
dpc-5430	171	9	te	te	INTJ
dpc-5430	171	10	nd	nd	INTJ
dpc-5430	171	11	er	er	INTJ
dpc-5430	171	12	ne	ne	X
dpc-5430	171	13	ss	ss	PROPN
dpc-5430	171	14	a	a	DET
dpc-5430	171	15	t	t	NOUN
dpc-5430	171	16	th	th	X
dpc-5430	171	17	e	e	NOUN
dpc-5430	171	18	in	in	ADP
dpc-5430	171	19	je	je	PROPN
dpc-5430	171	20	ct	ct	PROPN
dpc-5430	171	21	io	io	PROPN
dpc-5430	171	22	n	n	PROPN
dpc-5430	171	23	si	si	X
dpc-5430	171	24	te	te	PROPN
dpc-5430	171	25	(	(	PUNCT
dpc-5430	171	26	n	n	NOUN
dpc-5430	171	27	=	=	NOUN
dpc-5430	171	28	1	1	NUM
dpc-5430	171	29	)	)	PUNCT
dpc-5430	171	30	,	,	PUNCT
dpc-5430	171	31	fe	fe	X
dpc-5430	171	32	ve	ve	VERB
dpc-5430	171	33	r	r	NOUN
dpc-5430	171	34	(	(	PUNCT
dpc-5430	171	35	n	n	NOUN
dpc-5430	171	36	=	=	NOUN
dpc-5430	171	37	1	1	NUM
dpc-5430	171	38	)	)	PUNCT
dpc-5430	171	39	16	16	NUM
dpc-5430	172	1	w	w	INTJ
dpc-5430	172	2	hi	hi	INTJ
dpc-5430	172	3	te	te	INTJ
dpc-5430	172	4	he	he	PRON
dpc-5430	172	5	ad	ad	NOUN
dpc-5430	172	6	e	e	PROPN
dpc-5430	172	7	t	t	PROPN
dpc-5430	172	8	al	al	PROPN
dpc-5430	172	9	.	.	PUNCT
dpc-5430	173	1	/	/	SYM
dpc-5430	174	1	2	2	NUM
dpc-5430	174	2	01	01	NUM
dpc-5430	174	3	6	6	NUM
dpc-5430	174	4	r	r	NOUN
dpc-5430	174	5	c	c	NOUN
dpc-5430	174	6	t	t	PROPN
dpc-5430	174	7	29	29	NUM
dpc-5430	174	8	48	48	NUM
dpc-5430	174	9	(	(	PUNCT
dpc-5430	174	10	42	42	NUM
dpc-5430	174	11	-5	-5	NOUN
dpc-5430	174	12	3	3	X
dpc-5430	174	13	)	)	PUNCT
dpc-5430	174	14	h	h	NOUN
dpc-5430	174	15	h	h	NOUN
dpc-5430	174	16	t	t	PROPN
dpc-5430	174	17	4	4	NUM
dpc-5430	174	18	m	m	NOUN
dpc-5430	174	19	g/	g/	NOUN
dpc-5430	174	20	da	da	NOUN
dpc-5430	174	21	y	y	NOUN
dpc-5430	174	22	to	to	PART
dpc-5430	174	23	pi	pi	PROPN
dpc-5430	174	24	ca	can	AUX
dpc-5430	174	25	l	l	NOUN
dpc-5430	174	26	(	(	PUNCT
dpc-5430	174	27	na	na	INTJ
dpc-5430	174	28	sa	sa	PROPN
dpc-5430	174	29	l	l	PROPN
dpc-5430	174	30	sp	sp	ADP
dpc-5430	174	31	ra	ra	PROPN
dpc-5430	174	32	y	y	PROPN
dpc-5430	174	33	)	)	PUNCT
dpc-5430	174	34	,	,	PUNCT
dpc-5430	174	35	f	f	PROPN
dpc-5430	174	36	or	or	CCONJ
dpc-5430	174	37	a	a	DET
dpc-5430	174	38	w	w	NOUN
dpc-5430	174	39	ee	ee	PROPN
dpc-5430	174	40	k	k	PROPN
dpc-5430	174	41	n	n	PROPN
dpc-5430	174	42	o	o	PROPN
dpc-5430	174	43	cl	cl	NOUN
dpc-5430	174	44	in	in	ADP
dpc-5430	174	45	ic	ic	PROPN
dpc-5430	174	46	al	al	PROPN
dpc-5430	174	47	e	e	PROPN
dpc-5430	174	48	ff	ff	VERB
dpc-5430	174	49	ec	ec	PROPN
dpc-5430	174	50	t	t	PROPN
dpc-5430	174	51	n	n	PROPN
dpc-5430	174	52	as	as	ADP
dpc-5430	174	53	al	al	PROPN
dpc-5430	174	54	s	s	PROPN
dpc-5430	174	55	ym	ym	INTJ
dpc-5430	174	56	pt	pt	NOUN
dpc-5430	174	57	om	om	PROPN
dpc-5430	174	58	s	s	PROPN
dpc-5430	174	59	(	(	PUNCT
dpc-5430	174	60	n	n	NOUN
dpc-5430	174	61	=	=	NOUN
dpc-5430	174	62	1	1	NUM
dpc-5430	174	63	1	1	NUM
dpc-5430	174	64	)	)	PUNCT
dpc-5430	174	65	,	,	PUNCT
dpc-5430	174	66	h	h	NOUN
dpc-5430	174	67	ea	ea	X
dpc-5430	174	68	da	da	PROPN
dpc-5430	174	69	ch	ch	PROPN
dpc-5430	174	70	e	e	PROPN
dpc-5430	174	71	(	(	PUNCT
dpc-5430	174	72	n	n	NOUN
dpc-5430	174	73	=	=	NOUN
dpc-5430	174	74	1	1	NUM
dpc-5430	174	75	0	0	NUM
dpc-5430	174	76	)	)	PUNCT
dpc-5430	174	77	,	,	PUNCT
dpc-5430	174	78	a	a	DET
dpc-5430	174	79	bd	bd	PROPN
dpc-5430	174	80	om	om	PROPN
dpc-5430	174	81	in	in	ADP
dpc-5430	174	82	al	al	PROPN
dpc-5430	174	83	pa	pa	PROPN
dpc-5430	174	84	in	in	ADV
dpc-5430	174	85	(	(	PUNCT
dpc-5430	174	86	n	n	NOUN
dpc-5430	174	87	=	=	NOUN
dpc-5430	174	88	5	5	NUM
dpc-5430	174	89	)	)	PUNCT
dpc-5430	174	90	17	17	NUM
dpc-5430	174	91	m	m	NOUN
dpc-5430	174	92	ah	ah	INTJ
dpc-5430	174	93	m	m	INTJ
dpc-5430	174	94	ou	ou	PROPN
dpc-5430	174	95	d	d	X
dpc-5430	174	96	et	et	PROPN
dpc-5430	174	97	a	a	DET
dpc-5430	174	98	l.	l.	PROPN
dpc-5430	174	99	/	/	SYM
dpc-5430	174	100	2	2	NUM
dpc-5430	174	101	01	01	NUM
dpc-5430	174	102	6	6	NUM
dpc-5430	174	103	r	r	NOUN
dpc-5430	174	104	c	c	NOUN
dpc-5430	174	105	t	t	NOUN
dpc-5430	174	106	20	20	NUM
dpc-5430	174	107	43	43	NUM
dpc-5430	174	108	±1	±1	VERB
dpc-5430	174	109	.3	.3	NUM
dpc-5430	174	110	o	o	NOUN
dpc-5430	175	1	l	l	NOUN
dpc-5430	175	2	p	p	NOUN
dpc-5430	175	3	2	2	NUM
dpc-5430	175	4	.	.	SYM
dpc-5430	175	5	5	5	NUM
dpc-5430	175	6	m	m	NOUN
dpc-5430	175	7	g/	g/	NOUN
dpc-5430	175	8	0	0	NUM
dpc-5430	175	9	.	.	NOUN
dpc-5430	176	1	5	5	NUM
dpc-5430	176	2	m	m	NOUN
dpc-5430	176	3	l	l	NOUN
dpc-5430	177	1	i	i	PRON
dpc-5430	177	2	nt	not	PART
dpc-5430	177	3	ra	ra	PROPN
dpc-5430	177	4	le	le	X
dpc-5430	177	5	si	si	PROPN
dpc-5430	177	6	on	on	ADP
dpc-5430	177	7	al	al	PROPN
dpc-5430	177	8	in	in	ADP
dpc-5430	177	9	je	je	PROPN
dpc-5430	177	10	ct	ct	PROPN
dpc-5430	177	11	io	io	PROPN
dpc-5430	177	12	n	n	PROPN
dpc-5430	177	13	e	e	X
dpc-5430	177	14	ff	ff	X
dpc-5430	177	15	ec	ec	PROPN
dpc-5430	177	16	ti	ti	PROPN
dpc-5430	177	17	ve	ve	VERB
dpc-5430	177	18	n	n	NUM
dpc-5430	177	19	o	o	NOUN
dpc-5430	177	20	co	co	X
dpc-5430	177	21	m	m	VERB
dpc-5430	177	22	pl	pl	X
dpc-5430	177	23	ic	ic	PROPN
dpc-5430	177	24	at	at	ADP
dpc-5430	177	25	io	io	PROPN
dpc-5430	177	26	n	n	ADV
dpc-5430	177	27	18	18	NUM
dpc-5430	177	28	h	h	NOUN
dpc-5430	177	29	w	w	ADP
dpc-5430	177	30	an	an	DET
dpc-5430	177	31	g	g	NOUN
dpc-5430	177	32	et	et	PROPN
dpc-5430	177	33	a	a	DET
dpc-5430	177	34	l.	l.	PROPN
dpc-5430	177	35	/	/	SYM
dpc-5430	177	36	2	2	NUM
dpc-5430	177	37	01	01	NUM
dpc-5430	177	38	7	7	NUM
dpc-5430	177	39	c	c	NOUN
dpc-5430	177	40	as	as	ADP
dpc-5430	177	41	e	e	X
dpc-5430	177	42	re	re	X
dpc-5430	177	43	po	po	PROPN
dpc-5430	177	44	rt	rt	PROPN
dpc-5430	177	45	1	1	NUM
dpc-5430	177	46	10	10	NUM
dpc-5430	177	47	ly	ly	ADP
dpc-5430	177	48	m	m	VERB
dpc-5430	177	49	ph	ph	ADJ
dpc-5430	177	50	an	an	DET
dpc-5430	177	51	gi	gi	NOUN
dpc-5430	177	52	om	om	PROPN
dpc-5430	177	53	a	a	DET
dpc-5430	177	54	2	2	NUM
dpc-5430	177	55	.	.	NOUN
dpc-5430	177	56	510	510	NUM
dpc-5430	177	57	m	m	NOUN
dpc-5430	177	58	g	g	NOUN
dpc-5430	177	59	in	in	ADP
dpc-5430	177	60	tr	tr	NOUN
dpc-5430	177	61	al	al	PROPN
dpc-5430	177	62	es	es	ADP
dpc-5430	177	63	io	io	X
dpc-5430	177	64	na	na	X
dpc-5430	177	65	l	l	NOUN
dpc-5430	177	66	in	in	ADP
dpc-5430	177	67	je	je	PROPN
dpc-5430	177	68	ct	ct	PROPN
dpc-5430	177	69	io	io	PROPN
dpc-5430	177	70	n	n	PROPN
dpc-5430	177	71	,	,	PUNCT
dpc-5430	177	72	5	5	NUM
dpc-5430	177	73	t	t	NOUN
dpc-5430	177	74	i	i	PRON
dpc-5430	177	75	m	m	VERB
dpc-5430	177	76	es	es	ADJ
dpc-5430	177	77	m	m	PROPN
dpc-5430	177	78	on	on	ADP
dpc-5430	177	79	th	th	PRON
dpc-5430	177	80	ly	ly	ADP
dpc-5430	177	81	a	a	DET
dpc-5430	177	82	nd	nd	INTJ
dpc-5430	177	83	th	th	X
dpc-5430	177	84	en	en	ADP
dpc-5430	177	85	4	4	NUM
dpc-5430	177	86	t	t	NOUN
dpc-5430	178	1	i	i	PRON
dpc-5430	178	2	m	m	AUX
dpc-5430	178	3	es	es	AUX
dpc-5430	178	4	e	e	X
dpc-5430	178	5	ve	ve	AUX
dpc-5430	178	6	ry	ry	VERB
dpc-5430	178	7	3	3	NUM
dpc-5430	178	8	m	m	NOUN
dpc-5430	178	9	on	on	ADP
dpc-5430	178	10	th	th	NUM
dpc-5430	178	11	s	s	X
dpc-5430	178	12	e	e	NOUN
dpc-5430	178	13	ff	ff	X
dpc-5430	178	14	ec	ec	PROPN
dpc-5430	178	15	ti	ti	PROPN
dpc-5430	178	16	ve	ve	VERB
dpc-5430	178	17	n	n	NUM
dpc-5430	178	18	o	o	NOUN
dpc-5430	178	19	co	co	X
dpc-5430	178	20	m	m	VERB
dpc-5430	178	21	pl	pl	X
dpc-5430	178	22	ic	ic	PROPN
dpc-5430	178	23	at	at	ADP
dpc-5430	178	24	io	io	PROPN
dpc-5430	178	25	n	n	ADV
dpc-5430	178	26	19	19	NUM
dpc-5430	178	27	k	k	NOUN
dpc-5430	178	28	in	in	ADP
dpc-5430	178	29	zi	zi	PROPN
dpc-5430	178	30	ng	ng	PROPN
dpc-5430	179	1	er	er	INTJ
dpc-5430	179	2	e	e	PROPN
dpc-5430	179	3	t	t	PROPN
dpc-5430	179	4	al	al	PROPN
dpc-5430	179	5	.	.	PUNCT
dpc-5430	179	6	/	/	SYM
dpc-5430	180	1	2	2	NUM
dpc-5430	180	2	01	01	NUM
dpc-5430	180	3	8	8	NUM
dpc-5430	180	4	c	c	NOUN
dpc-5430	180	5	as	as	ADP
dpc-5430	180	6	e	e	X
dpc-5430	180	7	re	re	X
dpc-5430	180	8	po	po	PROPN
dpc-5430	180	9	rt	rt	PROPN
dpc-5430	180	10	1	1	NUM
dpc-5430	180	11	67	67	NUM
dpc-5430	180	12	si	si	INTJ
dpc-5430	180	13	no	no	INTJ
dpc-5430	180	14	na	na	INTJ
dpc-5430	180	15	sa	sa	NOUN
dpc-5430	180	16	l	l	NOUN
dpc-5430	181	1	he	he	PRON
dpc-5430	181	2	m	m	VERB
dpc-5430	181	3	an	an	DET
dpc-5430	181	4	gi	gi	NOUN
dpc-5430	181	5	om	om	PROPN
dpc-5430	181	6	a	a	DET
dpc-5430	181	7	50	50	NUM
dpc-5430	181	8	m	m	NOUN
dpc-5430	181	9	g	g	NOUN
dpc-5430	181	10	in	in	ADP
dpc-5430	181	11	tr	tr	NOUN
dpc-5430	181	12	al	al	PROPN
dpc-5430	181	13	es	es	ADP
dpc-5430	181	14	io	io	X
dpc-5430	181	15	na	na	NOUN
dpc-5430	181	16	l	l	NOUN
dpc-5430	182	1	i	i	PRON
dpc-5430	182	2	nj	nj	PROPN
dpc-5430	182	3	ec	ec	PROPN
dpc-5430	182	4	ti	ti	PROPN
dpc-5430	182	5	on	on	ADP
dpc-5430	182	6	e	e	PROPN
dpc-5430	182	7	ff	ff	X
dpc-5430	182	8	ec	ec	PROPN
dpc-5430	182	9	ti	ti	PROPN
dpc-5430	182	10	ve	ve	PROPN
dpc-5430	182	11	n	n	NUM
dpc-5430	182	12	/a	/a	NUM
dpc-5430	182	13	20	20	NUM
dpc-5430	182	14	sa	sa	NOUN
dpc-5430	182	15	br	br	PROPN
dpc-5430	183	1	y	y	PROPN
dpc-5430	183	2	et	et	PROPN
dpc-5430	183	3	a	a	DET
dpc-5430	183	4	l.	l.	PROPN
dpc-5430	183	5	/	/	SYM
dpc-5430	183	6	2	2	NUM
dpc-5430	183	7	01	01	NUM
dpc-5430	183	8	9	9	NUM
dpc-5430	183	9	r	r	NOUN
dpc-5430	183	10	c	c	NOUN
dpc-5430	183	11	t	t	NOUN
dpc-5430	183	12	15	15	NUM
dpc-5430	183	13	39	39	NUM
dpc-5430	183	14	m	m	NOUN
dpc-5430	183	15	on	on	ADP
dpc-5430	183	16	th	th	NUM
dpc-5430	183	17	s	s	NOUN
dpc-5430	183	18	h	h	NOUN
dpc-5430	183	19	em	em	PRON
dpc-5430	183	20	an	an	DET
dpc-5430	183	21	gi	gi	INTJ
dpc-5430	183	22	om	om	PROPN
dpc-5430	183	23	a	a	DET
dpc-5430	183	24	25	25	NUM
dpc-5430	183	25	m	m	NOUN
dpc-5430	183	26	g/	g/	NOUN
dpc-5430	183	27	m	m	VERB
dpc-5430	183	28	l	l	NOUN
dpc-5430	183	29	(	(	PUNCT
dpc-5430	183	30	2	2	NUM
dpc-5430	183	31	m	m	NOUN
dpc-5430	183	32	g/	g/	NOUN
dpc-5430	183	33	cm	cm	NOUN
dpc-5430	183	34	2	2	NUM
dpc-5430	183	35	)	)	PUNCT
dpc-5430	183	36	in	in	ADP
dpc-5430	183	37	tr	tr	NOUN
dpc-5430	183	38	al	al	PROPN
dpc-5430	183	39	es	es	NOUN
dpc-5430	183	40	io	io	X
dpc-5430	183	41	na	na	NOUN
dpc-5430	183	42	l	l	NOUN
dpc-5430	184	1	i	i	PRON
dpc-5430	184	2	nj	nj	INTJ
dpc-5430	184	3	ec	ec	PROPN
dpc-5430	184	4	ti	ti	PROPN
dpc-5430	184	5	on	on	ADP
dpc-5430	184	6	,	,	PUNCT
dpc-5430	184	7	6	6	NUM
dpc-5430	184	8	t	t	NOUN
dpc-5430	184	9	i	i	PRON
dpc-5430	184	10	m	m	VERB
dpc-5430	184	11	es	es	ADJ
dpc-5430	184	12	m	m	PROPN
dpc-5430	184	13	on	on	ADP
dpc-5430	184	14	th	th	INTJ
dpc-5430	184	15	ly	ly	X
dpc-5430	184	16	e	e	X
dpc-5430	184	17	ff	ff	X
dpc-5430	184	18	ec	ec	PROPN
dpc-5430	184	19	ti	ti	PROPN
dpc-5430	184	20	ve	ve	VERB
dpc-5430	184	21	n	n	NUM
dpc-5430	184	22	o	o	NOUN
dpc-5430	184	23	co	co	X
dpc-5430	184	24	m	m	VERB
dpc-5430	184	25	pl	pl	X
dpc-5430	184	26	ic	ic	PROPN
dpc-5430	184	27	at	at	ADP
dpc-5430	184	28	io	io	PROPN
dpc-5430	184	29	n	n	ADV
dpc-5430	184	30	21	21	NUM
dpc-5430	184	31	b	b	NOUN
dpc-5430	184	32	ow	ow	INTJ
dpc-5430	184	33	er	er	INTJ
dpc-5430	184	34	s	s	VERB
dpc-5430	184	35	et	et	NOUN
dpc-5430	184	36	a	a	DET
dpc-5430	184	37	l.	l.	PROPN
dpc-5430	184	38	/	/	SYM
dpc-5430	184	39	2	2	NUM
dpc-5430	184	40	02	02	NUM
dpc-5430	184	41	0	0	NUM
dpc-5430	184	42	c	c	NOUN
dpc-5430	184	43	as	as	ADP
dpc-5430	184	44	e	e	X
dpc-5430	184	45	re	re	X
dpc-5430	184	46	po	po	PROPN
dpc-5430	184	47	rt	rt	PROPN
dpc-5430	184	48	1	1	NUM
dpc-5430	184	49	61	61	NUM
dpc-5430	184	50	h	h	NOUN
dpc-5430	184	51	h	h	NOUN
dpc-5430	184	52	t	t	PROPN
dpc-5430	185	1	10	10	NUM
dpc-5430	185	2	0	0	NUM
dpc-5430	185	3	m	m	PROPN
dpc-5430	185	4	g	g	PROPN
dpc-5430	186	1	su	su	PROPN
dpc-5430	186	2	bm	bm	PROPN
dpc-5430	186	3	uc	uc	PROPN
dpc-5430	186	4	os	os	PROPN
dpc-5430	186	5	al	al	PROPN
dpc-5430	186	6	in	in	ADP
dpc-5430	186	7	je	je	PROPN
dpc-5430	186	8	ct	ct	PROPN
dpc-5430	186	9	io	io	PROPN
dpc-5430	186	10	n	n	PROPN
dpc-5430	186	11	e	e	X
dpc-5430	186	12	ff	ff	X
dpc-5430	186	13	ec	ec	PROPN
dpc-5430	186	14	ti	ti	PROPN
dpc-5430	186	15	ve	ve	VERB
dpc-5430	186	16	n	n	NUM
dpc-5430	186	17	o	o	NOUN
dpc-5430	186	18	co	co	X
dpc-5430	186	19	m	m	VERB
dpc-5430	186	20	pl	pl	X
dpc-5430	186	21	ic	ic	PROPN
dpc-5430	186	22	at	at	ADP
dpc-5430	186	23	io	io	PROPN
dpc-5430	186	24	n	n	ADP
dpc-5430	186	25	a	a	DET
dpc-5430	186	26	bb	bb	INTJ
dpc-5430	186	27	re	re	ADJ
dpc-5430	186	28	vi	vi	PROPN
dpc-5430	186	29	at	at	ADP
dpc-5430	186	30	io	io	X
dpc-5430	186	31	ns	ns	NUM
dpc-5430	186	32	:	:	PUNCT
dpc-5430	186	33	r	r	NOUN
dpc-5430	186	34	c	c	NOUN
dpc-5430	186	35	t	t	PROPN
dpc-5430	186	36	:	:	PUNCT
dpc-5430	186	37	r	r	NOUN
dpc-5430	186	38	an	an	DET
dpc-5430	186	39	do	do	NOUN
dpc-5430	186	40	m	m	NOUN
dpc-5430	186	41	iz	iz	INTJ
dpc-5430	187	1	ed	ed	NOUN
dpc-5430	187	2	c	c	PROPN
dpc-5430	187	3	on	on	ADP
dpc-5430	187	4	tr	tr	VERB
dpc-5430	187	5	ol	ol	PROPN
dpc-5430	187	6	le	le	PROPN
dpc-5430	187	7	d	d	PROPN
dpc-5430	187	8	t	t	PROPN
dpc-5430	187	9	ri	ri	PROPN
dpc-5430	187	10	al	al	PROPN
dpc-5430	187	11	,	,	PUNCT
dpc-5430	187	12	h	h	PROPN
dpc-5430	187	13	h	h	NOUN
dpc-5430	187	14	t	t	PROPN
dpc-5430	187	15	:	:	PUNCT
dpc-5430	187	16	h	h	NOUN
dpc-5430	188	1	er	er	INTJ
dpc-5430	188	2	ed	ed	INTJ
dpc-5430	188	3	it	it	PRON
dpc-5430	188	4	ar	ar	VERB
dpc-5430	188	5	y	y	PROPN
dpc-5430	188	6	h	h	PROPN
dpc-5430	189	1	em	em	PRON
dpc-5430	189	2	or	or	CCONJ
dpc-5430	189	3	rh	rh	PROPN
dpc-5430	189	4	ag	ag	PROPN
dpc-5430	189	5	ic	ic	PROPN
dpc-5430	189	6	t	t	PROPN
dpc-5430	189	7	el	el	PROPN
dpc-5430	190	1	an	an	DET
dpc-5430	190	2	gi	gi	NOUN
dpc-5430	190	3	ec	ec	PROPN
dpc-5430	190	4	ta	ta	ADP
dpc-5430	190	5	si	si	PROPN
dpc-5430	191	1	a	a	PROPN
dpc-5430	191	2	,	,	PUNCT
dpc-5430	191	3	b	b	PROPN
dpc-5430	191	4	c	c	NOUN
dpc-5430	191	5	c	c	NOUN
dpc-5430	191	6	:	:	PUNCT
dpc-5430	191	7	b	b	X
dpc-5430	191	8	as	as	ADP
dpc-5430	191	9	al	al	PROPN
dpc-5430	191	10	c	c	PROPN
dpc-5430	191	11	el	el	PROPN
dpc-5430	191	12	l	l	PROPN
dpc-5430	191	13	c	c	PROPN
dpc-5430	191	14	ar	ar	PROPN
dpc-5430	191	15	ci	ci	PROPN
dpc-5430	192	1	no	no	DET
dpc-5430	192	2	m	m	NOUN
dpc-5430	193	1	a	a	PRON
dpc-5430	193	2	,	,	PUNCT
dpc-5430	193	3	k	k	PROPN
dpc-5430	193	4	s	s	X
dpc-5430	193	5	:	:	PUNCT
dpc-5430	194	1	k	k	PROPN
dpc-5430	194	2	ap	ap	INTJ
dpc-5430	194	3	os	os	INTJ
dpc-5430	195	1	i	i	PRON
dpc-5430	195	2	s	s	PROPN
dpc-5430	195	3	ar	ar	PROPN
dpc-5430	195	4	co	co	NOUN
dpc-5430	195	5	m	m	PROPN
dpc-5430	195	6	a	a	PRON
dpc-5430	195	7	,	,	PUNCT
dpc-5430	195	8	o	o	NOUN
dpc-5430	196	1	l	l	NOUN
dpc-5430	197	1	p	p	X
dpc-5430	197	2	:	:	PUNCT
dpc-5430	197	3	o	o	X
dpc-5430	197	4	ra	ra	PROPN
dpc-5430	197	5	l	l	NOUN
dpc-5430	197	6	l	l	NOUN
dpc-5430	198	1	ic	ic	INTJ
dpc-5430	198	2	he	he	PRON
dpc-5430	198	3	n	n	ADV
dpc-5430	198	4	pl	pl	VERB
dpc-5430	198	5	an	an	DET
dpc-5430	198	6	us	us	PROPN
dpc-5430	198	7	,	,	PUNCT
dpc-5430	198	8	n	n	PROPN
dpc-5430	198	9	/a	/a	PUNCT
dpc-5430	198	10	:	:	PUNCT
dpc-5430	199	1	n	n	X
dpc-5430	199	2	ot	ot	VERB
dpc-5430	199	3	a	a	DET
dpc-5430	199	4	va	va	NOUN
dpc-5430	199	5	ila	ila	PROPN
dpc-5430	199	6	bl	bl	PROPN
dpc-5430	199	7	e.	e.	PROPN
dpc-5430	199	8	6	6	NUM
dpc-5430	199	9	review	review	NOUN
dpc-5430	199	10	|	|	ADV
dpc-5430	199	11	dermatol	dermatol	ADJ
dpc-5430	199	12	pract	pract	NOUN
dpc-5430	199	13	concept	concept	NOUN
dpc-5430	199	14	.	.	PUNCT
dpc-5430	200	1	2025;15(4):5430	2025;15(4):5430	NUM
dpc-5430	200	2	50	50	NUM
dpc-5430	200	3	mg	mg	NOUN
dpc-5430	200	4	bevacizumab	bevacizumab	NOUN
dpc-5430	200	5	into	into	ADP
dpc-5430	200	6	the	the	DET
dpc-5430	200	7	lesion	lesion	NOUN
dpc-5430	200	8	and	and	CCONJ
dpc-5430	200	9	nasal	nasal	ADJ
dpc-5430	200	10	septal	septal	ADJ
dpc-5430	200	11	mucosa	mucosa	NOUN
dpc-5430	200	12	.	.	PUNCT
dpc-5430	201	1	ten	ten	NUM
dpc-5430	201	2	months	month	NOUN
dpc-5430	201	3	later	later	ADV
dpc-5430	201	4	,	,	PUNCT
dpc-5430	201	5	the	the	DET
dpc-5430	201	6	lesion	lesion	NOUN
dpc-5430	201	7	had	have	AUX
dpc-5430	201	8	improved	improve	VERB
dpc-5430	201	9	,	,	PUNCT
dpc-5430	201	10	and	and	CCONJ
dpc-5430	201	11	at	at	ADP
dpc-5430	201	12	the	the	DET
dpc-5430	201	13	6	6	NUM
dpc-5430	201	14	-	-	PUNCT
dpc-5430	201	15	year	year	NOUN
dpc-5430	201	16	follow	follow	NOUN
dpc-5430	201	17	-	-	PUNCT
dpc-5430	201	18	up	up	NOUN
dpc-5430	201	19	,	,	PUNCT
dpc-5430	201	20	the	the	DET
dpc-5430	201	21	patient	patient	NOUN
dpc-5430	201	22	was	be	AUX
dpc-5430	201	23	asymptomatic	asymptomatic	ADJ
dpc-5430	201	24	,	,	PUNCT
dpc-5430	201	25	with	with	SCONJ
dpc-5430	201	26	no	no	DET
dpc-5430	201	27	recurrence	recurrence	NOUN
dpc-5430	201	28	or	or	CCONJ
dpc-5430	201	29	complication	complication	NOUN
dpc-5430	201	30	observed	observe	VERB
dpc-5430	201	31	[	[	X
dpc-5430	201	32	28	28	NUM
dpc-5430	201	33	]	]	PUNCT
dpc-5430	201	34	.	.	PUNCT
dpc-5430	202	1	therefore	therefore	ADV
dpc-5430	202	2	,	,	PUNCT
dpc-5430	202	3	il	il	PROPN
dpc-5430	202	4	bevacizumab	bevacizumab	NOUN
dpc-5430	202	5	may	may	AUX
dpc-5430	202	6	be	be	AUX
dpc-5430	202	7	an	an	DET
dpc-5430	202	8	effective	effective	ADJ
dpc-5430	202	9	noninvasive	noninvasive	ADJ
dpc-5430	202	10	option	option	NOUN
dpc-5430	202	11	for	for	ADP
dpc-5430	202	12	treating	treat	VERB
dpc-5430	202	13	sinonasal	sinonasal	ADJ
dpc-5430	202	14	hemangioma	hemangioma	NOUN
dpc-5430	202	15	.	.	PUNCT
dpc-5430	203	1	infantile	infantile	ADJ
dpc-5430	203	2	hemangioma	hemangioma	NOUN
dpc-5430	203	3	infantile	infantile	ADJ
dpc-5430	203	4	hemangioma	hemangioma	NOUN
dpc-5430	203	5	(	(	PUNCT
dpc-5430	203	6	ih	ih	NOUN
dpc-5430	203	7	)	)	PUNCT
dpc-5430	203	8	is	be	AUX
dpc-5430	203	9	the	the	DET
dpc-5430	203	10	most	most	ADV
dpc-5430	203	11	common	common	ADJ
dpc-5430	203	12	vascular	vascular	ADJ
dpc-5430	203	13	tumor	tumor	NOUN
dpc-5430	203	14	in	in	ADP
dpc-5430	203	15	infants	infant	NOUN
dpc-5430	203	16	.	.	PUNCT
dpc-5430	204	1	vegf	vegf	NOUN
dpc-5430	204	2	overexpression	overexpression	NOUN
dpc-5430	204	3	may	may	AUX
dpc-5430	204	4	be	be	AUX
dpc-5430	204	5	responsible	responsible	ADJ
dpc-5430	204	6	during	during	ADP
dpc-5430	204	7	the	the	DET
dpc-5430	204	8	initial	initial	ADJ
dpc-5430	204	9	proliferative	proliferative	ADJ
dpc-5430	204	10	stage	stage	NOUN
dpc-5430	204	11	of	of	ADP
dpc-5430	204	12	ih	ih	NOUN
dpc-5430	205	1	[	[	X
dpc-5430	205	2	30	30	NUM
dpc-5430	205	3	]	]	PUNCT
dpc-5430	205	4	.	.	PUNCT
dpc-5430	206	1	an	an	DET
dpc-5430	206	2	rct	rct	PROPN
dpc-5430	206	3	was	be	AUX
dpc-5430	206	4	conducted	conduct	VERB
dpc-5430	206	5	on	on	ADP
dpc-5430	206	6	children	child	NOUN
dpc-5430	206	7	aged	age	VERB
dpc-5430	206	8	3–9	3–9	NUM
dpc-5430	206	9	months	month	NOUN
dpc-5430	206	10	with	with	ADP
dpc-5430	206	11	ih	ih	PRON
dpc-5430	206	12	to	to	PART
dpc-5430	206	13	compare	compare	VERB
dpc-5430	206	14	the	the	DET
dpc-5430	206	15	effectiveness	effectiveness	NOUN
dpc-5430	206	16	of	of	ADP
dpc-5430	206	17	il	il	PROPN
dpc-5430	206	18	bevacizumab	bevacizumab	PROPN
dpc-5430	206	19	with	with	ADP
dpc-5430	206	20	triamcinolone	triamcinolone	NOUN
dpc-5430	206	21	acetonide	acetonide	VERB
dpc-5430	206	22	.	.	PUNCT
dpc-5430	207	1	the	the	DET
dpc-5430	207	2	children	child	NOUN
dpc-5430	207	3	in	in	ADP
dpc-5430	207	4	each	each	DET
dpc-5430	207	5	group	group	NOUN
dpc-5430	207	6	were	be	AUX
dpc-5430	207	7	treated	treat	VERB
dpc-5430	207	8	with	with	ADP
dpc-5430	207	9	25	25	NUM
dpc-5430	207	10	mg	mg	NUM
dpc-5430	207	11	/	/	SYM
dpc-5430	207	12	ml	ml	PROPN
dpc-5430	207	13	of	of	ADP
dpc-5430	207	14	il	il	PROPN
dpc-5430	207	15	bevacizumab	bevacizumab	NOUN
dpc-5430	207	16	and	and	CCONJ
dpc-5430	207	17	2	2	NUM
dpc-5430	207	18	mg/2	mg/2	NOUN
dpc-5430	207	19	cm2	cm2	NOUN
dpc-5430	207	20	of	of	ADP
dpc-5430	207	21	triamcinolone	triamcinolone	PROPN
dpc-5430	207	22	acetonide	acetonide	VERB
dpc-5430	207	23	monthly	monthly	ADV
dpc-5430	207	24	for	for	ADP
dpc-5430	207	25	six	six	NUM
dpc-5430	207	26	months	month	NOUN
dpc-5430	207	27	.	.	PUNCT
dpc-5430	208	1	after	after	ADP
dpc-5430	208	2	three	three	NUM
dpc-5430	208	3	months	month	NOUN
dpc-5430	208	4	,	,	PUNCT
dpc-5430	208	5	lesions	lesion	NOUN
dpc-5430	208	6	were	be	AUX
dpc-5430	208	7	successfully	successfully	ADV
dpc-5430	208	8	healed	heal	VERB
dpc-5430	208	9	,	,	PUNCT
dpc-5430	208	10	with	with	ADP
dpc-5430	208	11	no	no	DET
dpc-5430	208	12	recurrence	recurrence	NOUN
dpc-5430	208	13	or	or	CCONJ
dpc-5430	208	14	side	side	NOUN
dpc-5430	208	15	effect	effect	NOUN
dpc-5430	208	16	.	.	PUNCT
dpc-5430	209	1	this	this	DET
dpc-5430	209	2	study	study	NOUN
dpc-5430	209	3	concluded	conclude	VERB
dpc-5430	209	4	that	that	SCONJ
dpc-5430	209	5	il	il	PROPN
dpc-5430	209	6	bevacizumab	bevacizumab	NOUN
dpc-5430	209	7	and	and	CCONJ
dpc-5430	209	8	triamcinolone	triamcinolone	NOUN
dpc-5430	209	9	acetonide	acetonide	VERB
dpc-5430	209	10	both	both	PRON
dpc-5430	209	11	could	could	AUX
dpc-5430	209	12	be	be	AUX
dpc-5430	209	13	safe	safe	ADJ
dpc-5430	209	14	and	and	CCONJ
dpc-5430	209	15	effective	effective	ADJ
dpc-5430	209	16	for	for	ADP
dpc-5430	209	17	infantile	infantile	ADJ
dpc-5430	209	18	hemangioma	hemangioma	NOUN
dpc-5430	209	19	.	.	PUNCT
dpc-5430	210	1	however	however	ADV
dpc-5430	210	2	,	,	PUNCT
dpc-5430	210	3	triamcinolone	triamcinolone	PROPN
dpc-5430	210	4	acetonide	acetonide	VERB
dpc-5430	210	5	was	be	AUX
dpc-5430	210	6	more	more	ADV
dpc-5430	210	7	effective	effective	ADJ
dpc-5430	210	8	in	in	ADP
dpc-5430	210	9	this	this	DET
dpc-5430	210	10	study	study	NOUN
dpc-5430	210	11	[	[	X
dpc-5430	210	12	15	15	NUM
dpc-5430	210	13	]	]	PUNCT
dpc-5430	210	14	.	.	PUNCT
dpc-5430	211	1	capillary	capillary	ADJ
dpc-5430	211	2	hemangioma	hemangioma	NOUN
dpc-5430	211	3	in	in	ADP
dpc-5430	211	4	pregnancy	pregnancy	NOUN
dpc-5430	211	5	capillary	capillary	ADJ
dpc-5430	211	6	hemangioma	hemangioma	NOUN
dpc-5430	211	7	is	be	AUX
dpc-5430	211	8	a	a	DET
dpc-5430	211	9	proliferative	proliferative	ADJ
dpc-5430	211	10	lesion	lesion	NOUN
dpc-5430	211	11	with	with	ADP
dpc-5430	211	12	an	an	DET
dpc-5430	211	13	overexpression	overexpression	NOUN
dpc-5430	211	14	of	of	ADP
dpc-5430	211	15	angiogenic	angiogenic	ADJ
dpc-5430	211	16	growth	growth	NOUN
dpc-5430	211	17	factors	factor	NOUN
dpc-5430	211	18	such	such	ADJ
dpc-5430	211	19	as	as	ADP
dpc-5430	211	20	vegf	vegf	PROPN
dpc-5430	211	21	.	.	PUNCT
dpc-5430	212	1	pregnancy	pregnancy	NOUN
dpc-5430	212	2	is	be	AUX
dpc-5430	212	3	associated	associate	VERB
dpc-5430	212	4	with	with	ADP
dpc-5430	212	5	an	an	DET
dpc-5430	212	6	increased	increase	VERB
dpc-5430	212	7	risk	risk	NOUN
dpc-5430	212	8	of	of	ADP
dpc-5430	212	9	tumoral	tumoral	ADJ
dpc-5430	212	10	lesions	lesion	NOUN
dpc-5430	212	11	,	,	PUNCT
dpc-5430	212	12	including	include	VERB
dpc-5430	212	13	vascular	vascular	ADJ
dpc-5430	212	14	proliferative	proliferative	ADJ
dpc-5430	212	15	lesions	lesion	NOUN
dpc-5430	212	16	.	.	PUNCT
dpc-5430	213	1	hormonal	hormonal	ADJ
dpc-5430	213	2	factors	factor	NOUN
dpc-5430	213	3	may	may	AUX
dpc-5430	213	4	contribute	contribute	VERB
dpc-5430	213	5	to	to	ADP
dpc-5430	213	6	these	these	DET
dpc-5430	213	7	complications	complication	NOUN
dpc-5430	213	8	[	[	X
dpc-5430	213	9	31	31	NUM
dpc-5430	213	10	]	]	PUNCT
dpc-5430	213	11	.	.	PUNCT
dpc-5430	214	1	in	in	ADP
dpc-5430	214	2	a	a	DET
dpc-5430	214	3	case	case	NOUN
dpc-5430	214	4	study	study	NOUN
dpc-5430	214	5	,	,	PUNCT
dpc-5430	214	6	a	a	DET
dpc-5430	214	7	female	female	NOUN
dpc-5430	214	8	with	with	ADP
dpc-5430	214	9	hemangioma	hemangioma	NOUN
dpc-5430	214	10	during	during	ADP
dpc-5430	214	11	her	her	PRON
dpc-5430	214	12	third	third	ADJ
dpc-5430	214	13	trimester	trimester	NOUN
dpc-5430	214	14	lasting	last	VERB
dpc-5430	214	15	until	until	SCONJ
dpc-5430	214	16	six	six	NUM
dpc-5430	214	17	months	month	NOUN
dpc-5430	214	18	post	post	ADJ
dpc-5430	214	19	-	-	ADJ
dpc-5430	214	20	partum	partum	ADJ
dpc-5430	214	21	resisted	resist	VERB
dpc-5430	214	22	invasive	invasive	ADJ
dpc-5430	214	23	treatments	treatment	NOUN
dpc-5430	214	24	.	.	PUNCT
dpc-5430	215	1	a	a	DET
dpc-5430	215	2	4	4	NUM
dpc-5430	215	3	mg	mg	PROPN
dpc-5430	215	4	il	il	PROPN
dpc-5430	215	5	triamcinolone	triamcinolone	PROPN
dpc-5430	215	6	acetonide	acetonide	PROPN
dpc-5430	215	7	was	be	AUX
dpc-5430	215	8	administered	administer	VERB
dpc-5430	215	9	,	,	PUNCT
dpc-5430	215	10	with	with	ADP
dpc-5430	215	11	no	no	DET
dpc-5430	215	12	improvement	improvement	NOUN
dpc-5430	215	13	.	.	PUNCT
dpc-5430	216	1	finally	finally	ADV
dpc-5430	216	2	,	,	PUNCT
dpc-5430	216	3	il	il	PROPN
dpc-5430	216	4	bevacizumab	bevacizumab	PROPN
dpc-5430	216	5	was	be	AUX
dpc-5430	216	6	initiated	initiate	VERB
dpc-5430	216	7	at	at	ADP
dpc-5430	216	8	a	a	DET
dpc-5430	216	9	dose	dose	NOUN
dpc-5430	216	10	of	of	ADP
dpc-5430	216	11	1.25	1.25	NUM
dpc-5430	216	12	mg	mg	NOUN
dpc-5430	216	13	in	in	ADP
dpc-5430	216	14	0.05	0.05	NUM
dpc-5430	216	15	ml	ml	NOUN
dpc-5430	216	16	,	,	PUNCT
dpc-5430	216	17	leading	lead	VERB
dpc-5430	216	18	to	to	ADP
dpc-5430	216	19	a	a	DET
dpc-5430	216	20	significant	significant	ADJ
dpc-5430	216	21	improvement	improvement	NOUN
dpc-5430	216	22	.	.	PUNCT
dpc-5430	217	1	additional	additional	ADJ
dpc-5430	217	2	monthly	monthly	ADJ
dpc-5430	217	3	injections	injection	NOUN
dpc-5430	217	4	with	with	ADP
dpc-5430	217	5	a	a	DET
dpc-5430	217	6	dose	dose	NOUN
dpc-5430	217	7	of	of	ADP
dpc-5430	217	8	2.5	2.5	NUM
dpc-5430	217	9	mg	mg	NOUN
dpc-5430	217	10	in	in	ADP
dpc-5430	217	11	0.1	0.1	NUM
dpc-5430	217	12	ml	ml	NOUN
dpc-5430	217	13	were	be	AUX
dpc-5430	217	14	given	give	VERB
dpc-5430	217	15	four	four	NUM
dpc-5430	217	16	times	time	NOUN
dpc-5430	217	17	,	,	PUNCT
dpc-5430	217	18	resulting	result	VERB
dpc-5430	217	19	in	in	ADP
dpc-5430	217	20	complete	complete	ADJ
dpc-5430	217	21	regression	regression	NOUN
dpc-5430	217	22	,	,	PUNCT
dpc-5430	217	23	without	without	ADP
dpc-5430	217	24	any	any	DET
dpc-5430	217	25	complication	complication	NOUN
dpc-5430	217	26	or	or	CCONJ
dpc-5430	217	27	recurrence	recurrence	NOUN
dpc-5430	217	28	[	[	X
dpc-5430	217	29	31	31	NUM
dpc-5430	217	30	]	]	PUNCT
dpc-5430	217	31	.	.	PUNCT
dpc-5430	218	1	kaposi	kaposi	PROPN
dpc-5430	218	2	sarcoma	sarcoma	PROPN
dpc-5430	218	3	therapeutic	therapeutic	ADJ
dpc-5430	218	4	options	option	NOUN
dpc-5430	218	5	for	for	ADP
dpc-5430	218	6	kaposi	kaposi	PROPN
dpc-5430	218	7	sarcoma	sarcoma	PROPN
dpc-5430	218	8	(	(	PUNCT
dpc-5430	218	9	ks	ks	NOUN
dpc-5430	218	10	)	)	PUNCT
dpc-5430	218	11	include	include	VERB
dpc-5430	218	12	chemotherapy	chemotherapy	NOUN
dpc-5430	218	13	and	and	CCONJ
dpc-5430	218	14	radiation	radiation	NOUN
dpc-5430	218	15	therapy	therapy	NOUN
dpc-5430	218	16	along	along	ADP
dpc-5430	218	17	with	with	ADP
dpc-5430	218	18	antiretroviral	antiretroviral	ADJ
dpc-5430	218	19	agents	agent	NOUN
dpc-5430	218	20	and	and	CCONJ
dpc-5430	218	21	immunomodulators	immunomodulator	NOUN
dpc-5430	218	22	[	[	X
dpc-5430	218	23	32	32	NUM
dpc-5430	218	24	]	]	PUNCT
dpc-5430	218	25	.	.	PUNCT
dpc-5430	219	1	an	an	DET
dpc-5430	219	2	rct	rct	PROPN
dpc-5430	219	3	was	be	AUX
dpc-5430	219	4	conducted	conduct	VERB
dpc-5430	219	5	on	on	ADP
dpc-5430	219	6	14	14	NUM
dpc-5430	219	7	human	human	ADJ
dpc-5430	219	8	immunodeficiency	immunodeficiency	NOUN
dpc-5430	219	9	virus	virus	NOUN
dpc-5430	219	10	(	(	PUNCT
dpc-5430	219	11	hiv)-infected	hiv)-infecte	VERB
dpc-5430	219	12	individuals	individual	NOUN
dpc-5430	219	13	with	with	ADP
dpc-5430	219	14	mucosal	mucosal	ADJ
dpc-5430	219	15	ks	k	NOUN
dpc-5430	219	16	.	.	PUNCT
dpc-5430	220	1	the	the	DET
dpc-5430	220	2	disease	disease	NOUN
dpc-5430	220	3	involved	involve	VERB
dpc-5430	220	4	the	the	DET
dpc-5430	220	5	upper	upper	ADJ
dpc-5430	220	6	airway	airway	NOUN
dpc-5430	220	7	regions	region	NOUN
dpc-5430	220	8	(	(	PUNCT
dpc-5430	220	9	oral	oral	ADJ
dpc-5430	220	10	cavity	cavity	NOUN
dpc-5430	220	11	,	,	PUNCT
dpc-5430	220	12	pharyngeal	pharyngeal	ADJ
dpc-5430	220	13	,	,	PUNCT
dpc-5430	220	14	and	and	CCONJ
dpc-5430	220	15	laryngeal	laryngeal	ADJ
dpc-5430	220	16	areas	area	NOUN
dpc-5430	220	17	)	)	PUNCT
dpc-5430	220	18	.	.	PUNCT
dpc-5430	221	1	the	the	DET
dpc-5430	221	2	participants	participant	NOUN
dpc-5430	221	3	were	be	AUX
dpc-5430	221	4	divided	divide	VERB
dpc-5430	221	5	into	into	ADP
dpc-5430	221	6	two	two	NUM
dpc-5430	221	7	groups	group	NOUN
dpc-5430	221	8	:	:	PUNCT
dpc-5430	221	9	one	one	NUM
dpc-5430	221	10	received	receive	VERB
dpc-5430	221	11	il	il	PROPN
dpc-5430	221	12	bevacizumab	bevacizumab	NOUN
dpc-5430	221	13	in	in	ADP
dpc-5430	221	14	addition	addition	NOUN
dpc-5430	221	15	to	to	ADP
dpc-5430	221	16	antiretroviral	antiretroviral	ADJ
dpc-5430	221	17	therapy	therapy	NOUN
dpc-5430	221	18	(	(	PUNCT
dpc-5430	221	19	art	art	NOUN
dpc-5430	221	20	)	)	PUNCT
dpc-5430	221	21	,	,	PUNCT
dpc-5430	221	22	while	while	SCONJ
dpc-5430	221	23	the	the	DET
dpc-5430	221	24	control	control	NOUN
dpc-5430	221	25	group	group	NOUN
dpc-5430	221	26	received	receive	VERB
dpc-5430	221	27	art	art	NOUN
dpc-5430	221	28	alone	alone	ADV
dpc-5430	221	29	[	[	X
dpc-5430	221	30	32	32	NUM
dpc-5430	221	31	]	]	PUNCT
dpc-5430	221	32	.	.	PUNCT
dpc-5430	222	1	the	the	DET
dpc-5430	222	2	intervention	intervention	PROPN
dpc-5430	222	3	group	group	NOUN
dpc-5430	222	4	received	receive	VERB
dpc-5430	222	5	three	three	NUM
dpc-5430	222	6	injections	injection	NOUN
dpc-5430	222	7	every	every	DET
dpc-5430	222	8	two	two	NUM
dpc-5430	222	9	weeks	week	NOUN
dpc-5430	222	10	,	,	PUNCT
dpc-5430	222	11	each	each	PRON
dpc-5430	222	12	with	with	ADP
dpc-5430	222	13	a	a	DET
dpc-5430	222	14	dose	dose	NOUN
dpc-5430	222	15	of	of	ADP
dpc-5430	222	16	0.2	0.2	NUM
dpc-5430	222	17	ml	ml	NOUN
dpc-5430	222	18	(	(	PUNCT
dpc-5430	222	19	5	5	NUM
dpc-5430	222	20	mg/	mg/	NOUN
dpc-5430	222	21	cm2	cm2	NOUN
dpc-5430	222	22	)	)	PUNCT
dpc-5430	222	23	.	.	PUNCT
dpc-5430	223	1	il	il	PROPN
dpc-5430	223	2	bevacizumab	bevacizumab	PROPN
dpc-5430	223	3	resulted	result	VERB
dpc-5430	223	4	in	in	ADP
dpc-5430	223	5	side	side	NOUN
dpc-5430	223	6	effects	effect	NOUN
dpc-5430	223	7	,	,	PUNCT
dpc-5430	223	8	including	include	VERB
dpc-5430	223	9	pain	pain	NOUN
dpc-5430	223	10	and	and	CCONJ
dpc-5430	223	11	tenderness	tenderness	NOUN
dpc-5430	223	12	at	at	ADP
dpc-5430	223	13	the	the	DET
dpc-5430	223	14	injection	injection	NOUN
dpc-5430	223	15	site	site	NOUN
dpc-5430	223	16	,	,	PUNCT
dpc-5430	223	17	which	which	PRON
dpc-5430	223	18	were	be	AUX
dpc-5430	223	19	relieved	relieve	VERB
dpc-5430	223	20	with	with	ADP
dpc-5430	223	21	a	a	DET
dpc-5430	223	22	single	single	ADJ
dpc-5430	223	23	dose	dose	NOUN
dpc-5430	223	24	of	of	ADP
dpc-5430	223	25	acetaminophen	acetaminophen	NOUN
dpc-5430	223	26	1000	1000	NUM
dpc-5430	223	27	mg	mg	NOUN
dpc-5430	223	28	.	.	PUNCT
dpc-5430	224	1	in	in	ADP
dpc-5430	224	2	addition	addition	NOUN
dpc-5430	224	3	,	,	PUNCT
dpc-5430	224	4	one	one	NUM
dpc-5430	224	5	patient	patient	NOUN
dpc-5430	224	6	experienced	experience	VERB
dpc-5430	224	7	a	a	DET
dpc-5430	224	8	fever	fever	NOUN
dpc-5430	224	9	of	of	ADP
dpc-5430	224	10	39	39	NUM
dpc-5430	224	11	°	°	NUM
dpc-5430	224	12	c	c	NOUN
dpc-5430	224	13	three	three	NUM
dpc-5430	224	14	days	day	NOUN
dpc-5430	224	15	after	after	ADP
dpc-5430	224	16	the	the	DET
dpc-5430	224	17	injection	injection	NOUN
dpc-5430	224	18	,	,	PUNCT
dpc-5430	224	19	persistent	persistent	ADJ
dpc-5430	224	20	bleeding	bleeding	NOUN
dpc-5430	224	21	may	may	AUX
dpc-5430	224	22	occur	occur	VERB
dpc-5430	224	23	even	even	ADV
dpc-5430	224	24	for	for	ADP
dpc-5430	224	25	a	a	DET
dpc-5430	224	26	few	few	ADJ
dpc-5430	224	27	weeks	week	NOUN
dpc-5430	224	28	after	after	ADP
dpc-5430	224	29	submucosal	submucosal	NOUN
dpc-5430	224	30	injection	injection	NOUN
dpc-5430	224	31	because	because	SCONJ
dpc-5430	224	32	of	of	ADP
dpc-5430	224	33	the	the	DET
dpc-5430	224	34	pre	pre	ADJ
dpc-5430	224	35	-	-	ADJ
dpc-5430	224	36	existing	exist	VERB
dpc-5430	224	37	telangiectasia	telangiectasia	NOUN
dpc-5430	224	38	.	.	PUNCT
dpc-5430	225	1	therefore	therefore	ADV
dpc-5430	225	2	,	,	PUNCT
dpc-5430	225	3	combination	combination	NOUN
dpc-5430	225	4	therapies	therapy	NOUN
dpc-5430	225	5	can	can	AUX
dpc-5430	225	6	help	help	VERB
dpc-5430	225	7	to	to	PART
dpc-5430	225	8	improve	improve	VERB
dpc-5430	225	9	these	these	DET
dpc-5430	225	10	symptoms	symptom	NOUN
dpc-5430	225	11	.	.	PUNCT
dpc-5430	226	1	cauterization	cauterization	NOUN
dpc-5430	227	1	[	[	X
dpc-5430	227	2	16	16	NUM
dpc-5430	227	3	]	]	PUNCT
dpc-5430	227	4	,	,	PUNCT
dpc-5430	227	5	potassium	potassium	NOUN
dpc-5430	227	6	titanyl	titanyl	NOUN
dpc-5430	227	7	phosphate	phosphate	NOUN
dpc-5430	227	8	(	(	PUNCT
dpc-5430	227	9	ktp	ktp	NOUN
dpc-5430	227	10	)	)	PUNCT
dpc-5430	227	11	laser	laser	NOUN
dpc-5430	227	12	[	[	X
dpc-5430	227	13	13,17,20,21	13,17,20,21	NUM
dpc-5430	227	14	]	]	PUNCT
dpc-5430	227	15	,	,	PUNCT
dpc-5430	227	16	neodymium	neodymium	NOUN
dpc-5430	227	17	-	-	PUNCT
dpc-5430	227	18	doped	dope	VERB
dpc-5430	227	19	yttrium	yttrium	NOUN
dpc-5430	227	20	aluminum	aluminum	NOUN
dpc-5430	227	21	garnet	garnet	NOUN
dpc-5430	227	22	(	(	PUNCT
dpc-5430	227	23	nd	nd	NOUN
dpc-5430	227	24	:	:	PUNCT
dpc-5430	227	25	yag	yag	NOUN
dpc-5430	227	26	)	)	PUNCT
dpc-5430	227	27	laser	laser	NOUN
dpc-5430	228	1	[	[	X
dpc-5430	228	2	25	25	NUM
dpc-5430	228	3	]	]	PUNCT
dpc-5430	228	4	,	,	PUNCT
dpc-5430	228	5	and	and	CCONJ
dpc-5430	228	6	topical	topical	ADJ
dpc-5430	228	7	bevacizumab	bevacizumab	NOUN
dpc-5430	229	1	[	[	X
dpc-5430	229	2	16,26	16,26	NOUN
dpc-5430	229	3	]	]	X
dpc-5430	229	4	are	be	AUX
dpc-5430	229	5	used	use	VERB
dpc-5430	229	6	as	as	ADP
dpc-5430	229	7	adjuvant	adjuvant	ADJ
dpc-5430	229	8	therapies	therapy	NOUN
dpc-5430	229	9	accompanied	accompany	VERB
dpc-5430	229	10	by	by	ADP
dpc-5430	229	11	submucosal	submucosal	NOUN
dpc-5430	229	12	injection	injection	NOUN
dpc-5430	229	13	.	.	PUNCT
dpc-5430	230	1	another	another	DET
dpc-5430	230	2	case	case	NOUN
dpc-5430	230	3	was	be	AUX
dpc-5430	230	4	a	a	DET
dpc-5430	230	5	55	55	NUM
dpc-5430	230	6	-	-	PUNCT
dpc-5430	230	7	year	year	NOUN
dpc-5430	230	8	-	-	PUNCT
dpc-5430	230	9	old	old	ADJ
dpc-5430	230	10	female	female	ADJ
dpc-5430	230	11	dealing	dealing	NOUN
dpc-5430	230	12	with	with	ADP
dpc-5430	230	13	hht	hht	PROPN
dpc-5430	230	14	,	,	PUNCT
dpc-5430	230	15	breast	breast	NOUN
dpc-5430	230	16	cancer	cancer	NOUN
dpc-5430	230	17	,	,	PUNCT
dpc-5430	230	18	and	and	CCONJ
dpc-5430	230	19	chemotherapy	chemotherapy	NOUN
dpc-5430	230	20	-	-	ADJ
dpc-5430	230	21	induced	induce	VERB
dpc-5430	230	22	anemia	anemia	NOUN
dpc-5430	230	23	and	and	CCONJ
dpc-5430	230	24	increased	increase	VERB
dpc-5430	230	25	epistaxis	epistaxis	NOUN
dpc-5430	230	26	.	.	PUNCT
dpc-5430	231	1	episodes	episode	NOUN
dpc-5430	231	2	of	of	ADP
dpc-5430	231	3	intravenous	intravenous	ADJ
dpc-5430	231	4	bevacizumab	bevacizumab	NOUN
dpc-5430	231	5	were	be	AUX
dpc-5430	231	6	initially	initially	ADV
dpc-5430	231	7	used	use	VERB
dpc-5430	231	8	,	,	PUNCT
dpc-5430	231	9	then	then	ADV
dpc-5430	231	10	100	100	NUM
dpc-5430	231	11	mg	mg	ADJ
dpc-5430	231	12	topical	topical	ADJ
dpc-5430	231	13	therapy	therapy	NOUN
dpc-5430	231	14	(	(	PUNCT
dpc-5430	231	15	nasal	nasal	NOUN
dpc-5430	231	16	spray	spray	NOUN
dpc-5430	231	17	)	)	PUNCT
dpc-5430	232	1	every	every	DET
dpc-5430	232	2	8–9	8–9	NUM
dpc-5430	232	3	weeks	week	NOUN
dpc-5430	232	4	was	be	AUX
dpc-5430	232	5	used	use	VERB
dpc-5430	232	6	as	as	ADP
dpc-5430	232	7	an	an	DET
dpc-5430	232	8	effective	effective	ADJ
dpc-5430	232	9	maintenance	maintenance	NOUN
dpc-5430	232	10	control	control	NOUN
dpc-5430	232	11	for	for	ADP
dpc-5430	232	12	epistaxis	epistaxis	ADJ
dpc-5430	232	13	and	and	CCONJ
dpc-5430	232	14	anemia	anemia	NOUN
dpc-5430	233	1	[	[	X
dpc-5430	233	2	1	1	NUM
dpc-5430	233	3	]	]	PUNCT
dpc-5430	233	4	.	.	PUNCT
dpc-5430	234	1	in	in	ADP
dpc-5430	234	2	addition	addition	NOUN
dpc-5430	234	3	to	to	ADP
dpc-5430	234	4	nasal	nasal	PROPN
dpc-5430	234	5	mucosa	mucosa	PROPN
dpc-5430	234	6	,	,	PUNCT
dpc-5430	234	7	hht	hht	PROPN
dpc-5430	234	8	can	can	AUX
dpc-5430	234	9	present	present	VERB
dpc-5430	234	10	with	with	ADP
dpc-5430	234	11	other	other	ADJ
dpc-5430	234	12	mucosal	mucosal	NOUN
dpc-5430	234	13	involvements	involvement	NOUN
dpc-5430	234	14	,	,	PUNCT
dpc-5430	234	15	including	include	VERB
dpc-5430	234	16	the	the	DET
dpc-5430	234	17	tongue	tongue	NOUN
dpc-5430	234	18	.	.	PUNCT
dpc-5430	235	1	a	a	DET
dpc-5430	235	2	study	study	NOUN
dpc-5430	235	3	reported	report	VERB
dpc-5430	235	4	a	a	DET
dpc-5430	235	5	case	case	NOUN
dpc-5430	235	6	involving	involve	VERB
dpc-5430	235	7	recurrent	recurrent	ADJ
dpc-5430	235	8	bleeding	bleeding	NOUN
dpc-5430	235	9	of	of	ADP
dpc-5430	235	10	tongue	tongue	NOUN
dpc-5430	235	11	telangiectasia	telangiectasia	PROPN
dpc-5430	235	12	successfully	successfully	ADV
dpc-5430	235	13	treated	treat	VERB
dpc-5430	235	14	with	with	ADP
dpc-5430	235	15	dual	dual	ADJ
dpc-5430	235	16	therapy	therapy	NOUN
dpc-5430	235	17	of	of	ADP
dpc-5430	235	18	ktp	ktp	PROPN
dpc-5430	235	19	laser	laser	NOUN
dpc-5430	235	20	and	and	CCONJ
dpc-5430	235	21	100	100	NUM
dpc-5430	235	22	mg	mg	PROPN
dpc-5430	235	23	submucosal	submucosal	NOUN
dpc-5430	235	24	bevacizumab	bevacizumab	PROPN
dpc-5430	235	25	injection	injection	PROPN
dpc-5430	235	26	,	,	PUNCT
dpc-5430	235	27	without	without	ADP
dpc-5430	235	28	any	any	DET
dpc-5430	235	29	complication	complication	NOUN
dpc-5430	235	30	[	[	X
dpc-5430	235	31	13	13	NUM
dpc-5430	235	32	]	]	PUNCT
dpc-5430	235	33	.	.	PUNCT
dpc-5430	236	1	the	the	DET
dpc-5430	236	2	patient	patient	NOUN
dpc-5430	236	3	had	have	AUX
dpc-5430	236	4	had	have	VERB
dpc-5430	236	5	two	two	NUM
dpc-5430	236	6	episodes	episode	NOUN
dpc-5430	236	7	of	of	ADP
dpc-5430	236	8	ktp	ktp	PROPN
dpc-5430	236	9	laser	laser	NOUN
dpc-5430	236	10	previously	previously	ADV
dpc-5430	236	11	but	but	CCONJ
dpc-5430	236	12	without	without	ADP
dpc-5430	236	13	any	any	DET
dpc-5430	236	14	improvement	improvement	NOUN
dpc-5430	236	15	.	.	PUNCT
dpc-5430	237	1	vascular	vascular	ADJ
dpc-5430	237	2	malformation	malformation	NOUN
dpc-5430	237	3	lymphangioma	lymphangioma	PROPN
dpc-5430	237	4	lymphangioma	lymphangioma	PROPN
dpc-5430	237	5	is	be	AUX
dpc-5430	237	6	a	a	DET
dpc-5430	237	7	benign	benign	ADJ
dpc-5430	237	8	tumor	tumor	NOUN
dpc-5430	237	9	that	that	PRON
dpc-5430	237	10	can	can	AUX
dpc-5430	237	11	be	be	AUX
dpc-5430	237	12	treated	treat	VERB
dpc-5430	237	13	by	by	ADP
dpc-5430	237	14	sclerotherapy	sclerotherapy	NOUN
dpc-5430	237	15	or	or	CCONJ
dpc-5430	237	16	surgical	surgical	ADJ
dpc-5430	237	17	intervention	intervention	NOUN
dpc-5430	237	18	.	.	PUNCT
dpc-5430	238	1	non	non	ADJ
dpc-5430	238	2	-	-	ADJ
dpc-5430	238	3	surgical	surgical	ADJ
dpc-5430	238	4	treatments	treatment	NOUN
dpc-5430	238	5	such	such	ADJ
dpc-5430	238	6	as	as	ADP
dpc-5430	238	7	il	il	PROPN
dpc-5430	238	8	steroid	steroid	NOUN
dpc-5430	238	9	or	or	CCONJ
dpc-5430	238	10	bleomycin	bleomycin	PROPN
dpc-5430	238	11	may	may	AUX
dpc-5430	238	12	also	also	ADV
dpc-5430	238	13	be	be	AUX
dpc-5430	238	14	useful	useful	ADJ
dpc-5430	238	15	[	[	X
dpc-5430	238	16	25	25	NUM
dpc-5430	238	17	]	]	PUNCT
dpc-5430	238	18	.	.	PUNCT
dpc-5430	239	1	a	a	DET
dpc-5430	239	2	10	10	NUM
dpc-5430	239	3	-	-	PUNCT
dpc-5430	239	4	year	year	NOUN
dpc-5430	239	5	-	-	PUNCT
dpc-5430	239	6	old	old	ADJ
dpc-5430	239	7	female	female	NOUN
dpc-5430	239	8	was	be	AUX
dpc-5430	239	9	reported	report	VERB
dpc-5430	239	10	with	with	ADP
dpc-5430	239	11	a	a	DET
dpc-5430	239	12	hemorrhagic	hemorrhagic	NOUN
dpc-5430	239	13	,	,	PUNCT
dpc-5430	239	14	swollen	swollen	ADJ
dpc-5430	239	15	lesion	lesion	NOUN
dpc-5430	239	16	on	on	ADP
dpc-5430	239	17	her	her	PRON
dpc-5430	239	18	tongue	tongue	NOUN
dpc-5430	239	19	.	.	PUNCT
dpc-5430	240	1	she	she	PRON
dpc-5430	240	2	was	be	AUX
dpc-5430	240	3	initially	initially	ADV
dpc-5430	240	4	treated	treat	VERB
dpc-5430	240	5	with	with	ADP
dpc-5430	240	6	40	40	NUM
dpc-5430	240	7	mg	mg	NOUN
dpc-5430	240	8	/	/	SYM
dpc-5430	240	9	ml	ml	NOUN
dpc-5430	240	10	triamcinolone	triamcinolone	PROPN
dpc-5430	240	11	acetonide	acetonide	ADJ
dpc-5430	240	12	injection	injection	NOUN
dpc-5430	240	13	and	and	CCONJ
dpc-5430	240	14	1	1	NUM
dpc-5430	240	15	mg	mg	NUM
dpc-5430	240	16	/	/	SYM
dpc-5430	240	17	ml	ml	NOUN
dpc-5430	240	18	bleomycin	bleomycin	PROPN
dpc-5430	240	19	.	.	PUNCT
dpc-5430	241	1	the	the	DET
dpc-5430	241	2	lesion	lesion	NOUN
dpc-5430	241	3	shrank	shrink	VERB
dpc-5430	241	4	but	but	CCONJ
dpc-5430	241	5	did	do	AUX
dpc-5430	241	6	not	not	PART
dpc-5430	241	7	disappear	disappear	VERB
dpc-5430	241	8	[	[	X
dpc-5430	241	9	25	25	NUM
dpc-5430	241	10	]	]	PUNCT
dpc-5430	241	11	.	.	PUNCT
dpc-5430	242	1	after	after	ADP
dpc-5430	242	2	adding	add	VERB
dpc-5430	242	3	25	25	NUM
dpc-5430	242	4	mg	mg	NOUN
dpc-5430	242	5	/	/	SYM
dpc-5430	242	6	ml	ml	PROPN
dpc-5430	242	7	il	il	PROPN
dpc-5430	242	8	bevacizumab	bevacizumab	NOUN
dpc-5430	242	9	to	to	ADP
dpc-5430	242	10	the	the	DET
dpc-5430	242	11	previous	previous	ADJ
dpc-5430	242	12	medication	medication	NOUN
dpc-5430	242	13	,	,	PUNCT
dpc-5430	242	14	every	every	DET
dpc-5430	242	15	three	three	NUM
dpc-5430	242	16	months	month	NOUN
dpc-5430	242	17	for	for	ADP
dpc-5430	242	18	a	a	DET
dpc-5430	242	19	year	year	NOUN
dpc-5430	242	20	,	,	PUNCT
dpc-5430	242	21	the	the	DET
dpc-5430	242	22	lesion	lesion	NOUN
dpc-5430	242	23	completely	completely	ADV
dpc-5430	242	24	regressed	regress	VERB
dpc-5430	242	25	.	.	PUNCT
dpc-5430	243	1	no	no	DET
dpc-5430	243	2	side	side	ADJ
dpc-5430	243	3	effect	effect	NOUN
dpc-5430	243	4	or	or	CCONJ
dpc-5430	243	5	recurrence	recurrence	NOUN
dpc-5430	243	6	was	be	AUX
dpc-5430	243	7	observed	observe	VERB
dpc-5430	243	8	after	after	ADP
dpc-5430	243	9	three	three	NUM
dpc-5430	243	10	years	year	NOUN
dpc-5430	243	11	of	of	ADP
dpc-5430	243	12	follow	follow	NOUN
dpc-5430	243	13	-	-	PUNCT
dpc-5430	243	14	up	up	NOUN
dpc-5430	243	15	.	.	PUNCT
dpc-5430	244	1	therefore	therefore	ADV
dpc-5430	244	2	,	,	PUNCT
dpc-5430	244	3	bevacizumab	bevacizumab	NOUN
dpc-5430	244	4	can	can	AUX
dpc-5430	244	5	be	be	AUX
dpc-5430	244	6	used	use	VERB
dpc-5430	244	7	as	as	ADP
dpc-5430	244	8	a	a	DET
dpc-5430	244	9	potential	potential	ADJ
dpc-5430	244	10	adjuvant	adjuvant	ADJ
dpc-5430	244	11	treatment	treatment	NOUN
dpc-5430	244	12	for	for	ADP
dpc-5430	244	13	extensive	extensive	ADJ
dpc-5430	244	14	lymphangioma	lymphangioma	NOUN
dpc-5430	244	15	[	[	X
dpc-5430	244	16	27	27	NUM
dpc-5430	244	17	]	]	PUNCT
dpc-5430	244	18	.	.	PUNCT
dpc-5430	245	1	vascular	vascular	ADJ
dpc-5430	245	2	proliferation	proliferation	NOUN
dpc-5430	245	3	recurrent	recurrent	ADJ
dpc-5430	245	4	sinonasal	sinonasal	ADJ
dpc-5430	245	5	hemangioma	hemangioma	NOUN
dpc-5430	245	6	sinonasal	sinonasal	ADJ
dpc-5430	245	7	hemangioma	hemangioma	NOUN
dpc-5430	245	8	usually	usually	ADV
dpc-5430	245	9	originates	originate	VERB
dpc-5430	245	10	from	from	ADP
dpc-5430	245	11	the	the	DET
dpc-5430	245	12	nasal	nasal	ADJ
dpc-5430	245	13	septum	septum	NOUN
dpc-5430	245	14	or	or	CCONJ
dpc-5430	245	15	lateral	lateral	ADJ
dpc-5430	245	16	wall	wall	NOUN
dpc-5430	245	17	.	.	PUNCT
dpc-5430	246	1	it	it	PRON
dpc-5430	246	2	is	be	AUX
dpc-5430	246	3	a	a	DET
dpc-5430	246	4	benign	benign	ADJ
dpc-5430	246	5	tumor	tumor	NOUN
dpc-5430	246	6	that	that	PRON
dpc-5430	246	7	presents	present	VERB
dpc-5430	246	8	with	with	ADP
dpc-5430	246	9	epistaxis	epistaxis	ADJ
dpc-5430	246	10	and	and	CCONJ
dpc-5430	246	11	nasal	nasal	ADJ
dpc-5430	246	12	obstruction	obstruction	NOUN
dpc-5430	246	13	.	.	PUNCT
dpc-5430	247	1	surgical	surgical	ADJ
dpc-5430	247	2	intervention	intervention	NOUN
dpc-5430	247	3	is	be	AUX
dpc-5430	247	4	the	the	DET
dpc-5430	247	5	choice	choice	NOUN
dpc-5430	247	6	treatment	treatment	NOUN
dpc-5430	247	7	[	[	X
dpc-5430	247	8	28	28	NUM
dpc-5430	247	9	]	]	PUNCT
dpc-5430	247	10	.	.	PUNCT
dpc-5430	248	1	these	these	DET
dpc-5430	248	2	procedures	procedure	NOUN
dpc-5430	248	3	may	may	AUX
dpc-5430	248	4	lead	lead	VERB
dpc-5430	248	5	to	to	ADP
dpc-5430	248	6	aesthetic	aesthetic	ADJ
dpc-5430	248	7	and	and	CCONJ
dpc-5430	248	8	functional	functional	ADJ
dpc-5430	248	9	complications	complication	NOUN
dpc-5430	248	10	such	such	ADJ
dpc-5430	248	11	as	as	ADP
dpc-5430	248	12	excessive	excessive	ADJ
dpc-5430	248	13	tearing	tearing	NOUN
dpc-5430	248	14	,	,	PUNCT
dpc-5430	248	15	diminished	diminished	ADJ
dpc-5430	248	16	sensation	sensation	NOUN
dpc-5430	248	17	,	,	PUNCT
dpc-5430	248	18	scarring	scarring	NOUN
dpc-5430	248	19	,	,	PUNCT
dpc-5430	248	20	deformities	deformity	NOUN
dpc-5430	248	21	,	,	PUNCT
dpc-5430	248	22	and	and	CCONJ
dpc-5430	248	23	blockage	blockage	NOUN
dpc-5430	248	24	of	of	ADP
dpc-5430	248	25	nasal	nasal	ADJ
dpc-5430	248	26	passages	passage	NOUN
dpc-5430	248	27	[	[	X
dpc-5430	248	28	29	29	NUM
dpc-5430	248	29	]	]	PUNCT
dpc-5430	248	30	.	.	PUNCT
dpc-5430	249	1	a	a	DET
dpc-5430	249	2	67	67	NUM
dpc-5430	249	3	-	-	PUNCT
dpc-5430	249	4	year	year	NOUN
dpc-5430	249	5	-	-	PUNCT
dpc-5430	249	6	old	old	ADJ
dpc-5430	249	7	male	male	NOUN
dpc-5430	249	8	with	with	ADP
dpc-5430	249	9	nasal	nasal	PROPN
dpc-5430	249	10	hemangioma	hemangioma	NOUN
dpc-5430	249	11	complained	complain	VERB
dpc-5430	249	12	of	of	ADP
dpc-5430	249	13	recurrent	recurrent	ADJ
dpc-5430	249	14	epistaxis	epistaxis	ADJ
dpc-5430	249	15	and	and	CCONJ
dpc-5430	249	16	nasal	nasal	ADJ
dpc-5430	249	17	obstruction	obstruction	NOUN
dpc-5430	249	18	even	even	ADV
dpc-5430	249	19	after	after	ADP
dpc-5430	249	20	surgery	surgery	NOUN
dpc-5430	249	21	.	.	PUNCT
dpc-5430	250	1	he	he	PRON
dpc-5430	250	2	was	be	AUX
dpc-5430	250	3	successfully	successfully	ADV
dpc-5430	250	4	treated	treat	VERB
dpc-5430	250	5	with	with	ADP
dpc-5430	250	6	a	a	DET
dpc-5430	250	7	single	single	ADJ
dpc-5430	250	8	injection	injection	NOUN
dpc-5430	250	9	of	of	ADP
dpc-5430	250	10	review	review	NOUN
dpc-5430	250	11	|	|	ADV
dpc-5430	250	12	dermatol	dermatol	ADJ
dpc-5430	250	13	pract	pract	NOUN
dpc-5430	250	14	concept	concept	NOUN
dpc-5430	250	15	.	.	PUNCT
dpc-5430	251	1	2025;15(4):5430	2025;15(4):5430	NUM
dpc-5430	251	2	7	7	NUM
dpc-5430	251	3	dermatological	dermatological	ADJ
dpc-5430	251	4	applications	application	NOUN
dpc-5430	251	5	can	can	AUX
dpc-5430	251	6	be	be	AUX
dpc-5430	251	7	summarized	summarize	VERB
dpc-5430	251	8	based	base	VERB
dpc-5430	251	9	on	on	ADP
dpc-5430	251	10	previous	previous	ADJ
dpc-5430	251	11	reports	report	NOUN
dpc-5430	251	12	into	into	ADP
dpc-5430	251	13	four	four	NUM
dpc-5430	251	14	categories	category	NOUN
dpc-5430	251	15	:	:	PUNCT
dpc-5430	251	16	hereditary	hereditary	ADJ
dpc-5430	251	17	hemorrhagic	hemorrhagic	NOUN
dpc-5430	251	18	telangiectasia	telangiectasia	NOUN
dpc-5430	251	19	,	,	PUNCT
dpc-5430	251	20	vascular	vascular	ADJ
dpc-5430	251	21	malformation	malformation	NOUN
dpc-5430	251	22	,	,	PUNCT
dpc-5430	251	23	vascular	vascular	ADJ
dpc-5430	251	24	proliferation	proliferation	NOUN
dpc-5430	251	25	,	,	PUNCT
dpc-5430	251	26	and	and	CCONJ
dpc-5430	251	27	others	other	NOUN
dpc-5430	251	28	(	(	PUNCT
dpc-5430	251	29	lichen	lichen	NOUN
dpc-5430	251	30	planus	planus	NOUN
dpc-5430	251	31	and	and	CCONJ
dpc-5430	251	32	basal	basal	ADJ
dpc-5430	251	33	cell	cell	NOUN
dpc-5430	251	34	carcinoma	carcinoma	NOUN
dpc-5430	251	35	)	)	PUNCT
dpc-5430	251	36	.	.	PUNCT
dpc-5430	252	1	references	reference	NOUN
dpc-5430	252	2	1	1	NUM
dpc-5430	252	3	.	.	PUNCT
dpc-5430	252	4	brinkerhoff	brinkerhoff	PROPN
dpc-5430	252	5	bt	bt	PROPN
dpc-5430	252	6	,	,	PUNCT
dpc-5430	252	7	choong	choong	PROPN
dpc-5430	252	8	nw	nw	PROPN
dpc-5430	252	9	,	,	PUNCT
dpc-5430	252	10	treisman	treisman	PROPN
dpc-5430	252	11	js	js	PROPN
dpc-5430	252	12	,	,	PUNCT
dpc-5430	252	13	poetker	poetker	PROPN
dpc-5430	252	14	dm	dm	PROPN
dpc-5430	252	15	.	.	PUNCT
dpc-5430	252	16	intravenous	intravenous	ADJ
dpc-5430	252	17	and	and	CCONJ
dpc-5430	252	18	topical	topical	ADJ
dpc-5430	252	19	intranasal	intranasal	NOUN
dpc-5430	252	20	bevacizumab	bevacizumab	NOUN
dpc-5430	252	21	(	(	PUNCT
dpc-5430	252	22	avastin	avastin	NOUN
dpc-5430	252	23	)	)	PUNCT
dpc-5430	252	24	in	in	ADP
dpc-5430	252	25	hereditary	hereditary	ADJ
dpc-5430	252	26	hemorrhagic	hemorrhagic	NOUN
dpc-5430	252	27	telangiectasia	telangiectasia	NOUN
dpc-5430	252	28	.	.	PUNCT
dpc-5430	253	1	am	be	AUX
dpc-5430	253	2	j	j	PROPN
dpc-5430	253	3	otolaryngol	otolaryngol	NOUN
dpc-5430	253	4	.	.	PUNCT
dpc-5430	254	1	2012;33(3):349	2012;33(3):349	NUM
dpc-5430	254	2	-	-	SYM
dpc-5430	254	3	51	51	NUM
dpc-5430	254	4	.	.	PUNCT
dpc-5430	255	1	doi	doi	NOUN
dpc-5430	255	2	:	:	PUNCT
dpc-5430	255	3	10.1016	10.1016	NUM
dpc-5430	255	4	/	/	SYM
dpc-5430	255	5	j.amjoto.2011.07.012	j.amjoto.2011.07.012	PROPN
dpc-5430	255	6	.	.	PUNCT
dpc-5430	256	1	pmid	pmid	NOUN
dpc-5430	256	2	:	:	PUNCT
dpc-5430	256	3	 	 	SPACE
dpc-5430	256	4	21917353	21917353	NUM
dpc-5430	256	5	.	.	PUNCT
dpc-5430	257	1	2	2	X
dpc-5430	257	2	.	.	X
dpc-5430	257	3	mukherji	mukherji	PROPN
dpc-5430	257	4	sk	sk	PROPN
dpc-5430	257	5	.	.	PROPN
dpc-5430	257	6	bevacizumab	bevacizumab	PROPN
dpc-5430	257	7	(	(	PUNCT
dpc-5430	257	8	avastin	avastin	PROPN
dpc-5430	257	9	)	)	PUNCT
dpc-5430	257	10	.	.	PUNCT
dpc-5430	258	1	ajnr	ajnr	PROPN
dpc-5430	258	2	am	be	AUX
dpc-5430	258	3	j	j	PROPN
dpc-5430	258	4	neuroradiol	neuroradiol	PROPN
dpc-5430	258	5	.	.	PUNCT
dpc-5430	259	1	2010;31(2):235	2010;31(2):235	NUM
dpc-5430	259	2	-	-	SYM
dpc-5430	259	3	6	6	NUM
dpc-5430	259	4	.	.	PUNCT
dpc-5430	259	5	doi	doi	NOUN
dpc-5430	259	6	:	:	PUNCT
dpc-5430	259	7	 	 	SPACE
dpc-5430	259	8	10.3174	10.3174	NUM
dpc-5430	259	9	/	/	SYM
dpc-5430	259	10	ajnr.a1987	ajnr.a1987	NOUN
dpc-5430	259	11	.	.	PUNCT
dpc-5430	260	1	pmid	pmid	NOUN
dpc-5430	260	2	:	:	PUNCT
dpc-5430	260	3	 	 	SPACE
dpc-5430	260	4	20037132	20037132	NUM
dpc-5430	260	5	.	.	PUNCT
dpc-5430	261	1	3	3	X
dpc-5430	261	2	.	.	X
dpc-5430	261	3	sidell	sidell	PROPN
dpc-5430	261	4	dr	dr	PROPN
dpc-5430	261	5	,	,	PUNCT
dpc-5430	261	6	balakrishnan	balakrishnan	PROPN
dpc-5430	261	7	k	k	PROPN
dpc-5430	261	8	,	,	PUNCT
dpc-5430	261	9	best	good	ADJ
dpc-5430	261	10	sr	sr	PROPN
dpc-5430	261	11	,	,	PUNCT
dpc-5430	261	12	zur	zur	PROPN
dpc-5430	261	13	k	k	NOUN
dpc-5430	261	14	,	,	PUNCT
dpc-5430	261	15	buckingham	buckingham	PROPN
dpc-5430	261	16	j	j	PROPN
dpc-5430	261	17	,	,	PUNCT
dpc-5430	261	18	de	de	PROPN
dpc-5430	261	19	alarcon	alarcon	PROPN
dpc-5430	261	20	a	a	PROPN
dpc-5430	261	21	,	,	PUNCT
dpc-5430	261	22	et	et	PROPN
dpc-5430	261	23	al	al	PROPN
dpc-5430	261	24	.	.	PUNCT
dpc-5430	262	1	systemic	systemic	ADJ
dpc-5430	262	2	bevacizumab	bevacizumab	NOUN
dpc-5430	262	3	for	for	ADP
dpc-5430	262	4	treatment	treatment	NOUN
dpc-5430	262	5	of	of	ADP
dpc-5430	262	6	respiratory	respiratory	ADJ
dpc-5430	262	7	papillomatosis	papillomatosis	NOUN
dpc-5430	262	8	:	:	PUNCT
dpc-5430	262	9	international	international	ADJ
dpc-5430	262	10	consensus	consensus	NOUN
dpc-5430	262	11	statement	statement	NOUN
dpc-5430	262	12	.	.	PUNCT
dpc-5430	263	1	laryngoscope	laryngoscope	NOUN
dpc-5430	263	2	.	.	PUNCT
dpc-5430	264	1	2021;131(6):e1941	2021;131(6):e1941	NUM
dpc-5430	264	2	-	-	SYM
dpc-5430	264	3	e9	e9	NUM
dpc-5430	264	4	.	.	PUNCT
dpc-5430	264	5	doi	doi	PROPN
dpc-5430	264	6	:	:	PUNCT
dpc-5430	264	7	  	  	SPACE
dpc-5430	264	8	10.1002	10.1002	NUM
dpc-5430	264	9	/lary.29343	/lary.29343	NOUN
dpc-5430	264	10	.	.	PUNCT
dpc-5430	265	1	pmid	pmid	NOUN
dpc-5430	265	2	:	:	PUNCT
dpc-5430	265	3	 	 	SPACE
dpc-5430	265	4	33405268	33405268	NUM
dpc-5430	265	5	.	.	PUNCT
dpc-5430	266	1	4	4	X
dpc-5430	266	2	.	.	X
dpc-5430	266	3	sajib	sajib	PROPN
dpc-5430	266	4	s	s	PROPN
dpc-5430	266	5	,	,	PUNCT
dpc-5430	266	6	zahra	zahra	PROPN
dpc-5430	266	7	ft	ft	PROPN
dpc-5430	266	8	,	,	PUNCT
dpc-5430	266	9	lionakis	lionaki	NOUN
dpc-5430	266	10	ms	ms	PROPN
dpc-5430	266	11	,	,	PUNCT
dpc-5430	266	12	german	german	ADJ
dpc-5430	266	13	na	na	NOUN
dpc-5430	266	14	,	,	PUNCT
dpc-5430	266	15	mikelis	mikelis	PROPN
dpc-5430	266	16	cm	cm	PROPN
dpc-5430	266	17	.	.	PUNCT
dpc-5430	267	1	mechanisms	mechanism	NOUN
dpc-5430	267	2	of	of	ADP
dpc-5430	267	3	angiogenesis	angiogenesis	NOUN
dpc-5430	267	4	in	in	ADP
dpc-5430	267	5	microbe	microbe	NOUN
dpc-5430	267	6	-	-	PUNCT
dpc-5430	267	7	regulated	regulate	VERB
dpc-5430	267	8	inflammatory	inflammatory	ADJ
dpc-5430	267	9	and	and	CCONJ
dpc-5430	267	10	neoplastic	neoplastic	ADJ
dpc-5430	267	11	conditions	condition	NOUN
dpc-5430	267	12	.	.	PUNCT
dpc-5430	268	1	angiogenesis	angiogenesis	NOUN
dpc-5430	268	2	.	.	PUNCT
dpc-5430	269	1	2018;21(1):1	2018;21(1):1	NUM
dpc-5430	269	2	-	-	SYM
dpc-5430	269	3	14	14	NUM
dpc-5430	269	4	.	.	PUNCT
dpc-5430	270	1	doi	doi	NOUN
dpc-5430	270	2	:	:	PUNCT
dpc-5430	270	3	 	 	SPACE
dpc-5430	270	4	10.1007	10.1007	NUM
dpc-5430	270	5	/	/	SYM
dpc-5430	270	6	s10456	s10456	NOUN
dpc-5430	270	7	-	-	PUNCT
dpc-5430	270	8	017	017	NUM
dpc-5430	270	9	-	-	PUNCT
dpc-5430	270	10	9583	9583	NUM
dpc-5430	270	11	-	-	PUNCT
dpc-5430	270	12	4	4	NUM
dpc-5430	270	13	.	.	PUNCT
dpc-5430	271	1	pmid	pmid	NOUN
dpc-5430	271	2	:	:	PUNCT
dpc-5430	271	3	 	 	SPACE
dpc-5430	271	4	29110215	29110215	NUM
dpc-5430	271	5	.	.	PUNCT
dpc-5430	272	1	5	5	X
dpc-5430	272	2	.	.	X
dpc-5430	272	3	rosen	rosen	PROPN
dpc-5430	272	4	ls	ls	PROPN
dpc-5430	272	5	,	,	PUNCT
dpc-5430	272	6	jacobs	jacobs	PROPN
dpc-5430	272	7	ia	ia	PROPN
dpc-5430	272	8	,	,	PUNCT
dpc-5430	272	9	burkes	burkes	PROPN
dpc-5430	272	10	rl	rl	PROPN
dpc-5430	272	11	.	.	PROPN
dpc-5430	272	12	bevacizumab	bevacizumab	PROPN
dpc-5430	272	13	in	in	ADP
dpc-5430	272	14	colorectal	colorectal	ADJ
dpc-5430	272	15	cancer	cancer	NOUN
dpc-5430	272	16	:	:	PUNCT
dpc-5430	272	17	current	current	ADJ
dpc-5430	272	18	role	role	NOUN
dpc-5430	272	19	in	in	ADP
dpc-5430	272	20	treatment	treatment	NOUN
dpc-5430	272	21	and	and	CCONJ
dpc-5430	272	22	the	the	DET
dpc-5430	272	23	potential	potential	NOUN
dpc-5430	272	24	of	of	ADP
dpc-5430	272	25	biosimilars	biosimilar	NOUN
dpc-5430	272	26	.	.	PUNCT
dpc-5430	273	1	target	target	NOUN
dpc-5430	273	2	oncol	oncol	ADJ
dpc-5430	273	3	.	.	PUNCT
dpc-5430	274	1	2017;12(5):599	2017;12(5):599	NUM
dpc-5430	274	2	-	-	SYM
dpc-5430	274	3	610	610	NUM
dpc-5430	274	4	.	.	PUNCT
dpc-5430	275	1	doi	doi	NOUN
dpc-5430	275	2	:	:	PUNCT
dpc-5430	275	3	 	 	SPACE
dpc-5430	275	4	10.1007	10.1007	NUM
dpc-5430	275	5	/	/	SYM
dpc-5430	275	6	s11523	s11523	NOUN
dpc-5430	275	7	-017	-017	PROPN
dpc-5430	275	8	-	-	PUNCT
dpc-5430	275	9	0518	0518	NUM
dpc-5430	275	10	-	-	PUNCT
dpc-5430	275	11	1	1	NUM
dpc-5430	275	12	.	.	PUNCT
dpc-5430	276	1	pmid	pmid	NOUN
dpc-5430	276	2	:	:	PUNCT
dpc-5430	276	3	 	 	SPACE
dpc-5430	276	4	28801849	28801849	NUM
dpc-5430	276	5	.	.	PUNCT
dpc-5430	277	1	6	6	X
dpc-5430	277	2	.	.	X
dpc-5430	277	3	koukourakis	koukourakis	NOUN
dpc-5430	277	4	gv	gv	ADP
dpc-5430	277	5	,	,	PUNCT
dpc-5430	277	6	sotiropoulou	sotiropoulou	ADJ
dpc-5430	277	7	-	-	PUNCT
dpc-5430	277	8	lontou	lontou	NOUN
dpc-5430	277	9	a.	a.	NOUN
dpc-5430	277	10	targeted	target	VERB
dpc-5430	277	11	therapy	therapy	NOUN
dpc-5430	277	12	with	with	ADP
dpc-5430	277	13	bevacizumab	bevacizumab	PROPN
dpc-5430	277	14	(	(	PUNCT
dpc-5430	277	15	avastin	avastin	PROPN
dpc-5430	277	16	)	)	PUNCT
dpc-5430	277	17	for	for	ADP
dpc-5430	277	18	metastatic	metastatic	ADJ
dpc-5430	277	19	colorectal	colorectal	ADJ
dpc-5430	277	20	cancer	cancer	NOUN
dpc-5430	277	21	.	.	PUNCT
dpc-5430	278	1	clin	clin	PROPN
dpc-5430	278	2	transl	transl	PROPN
dpc-5430	278	3	oncol	oncol	PROPN
dpc-5430	278	4	.	.	PUNCT
dpc-5430	279	1	2011;13(10):710	2011;13(10):710	PROPN
dpc-5430	279	2	-	-	PUNCT
dpc-5430	279	3	4	4	NUM
dpc-5430	279	4	.	.	PUNCT
dpc-5430	279	5	doi	doi	NOUN
dpc-5430	279	6	:	:	PUNCT
dpc-5430	279	7	  	  	SPACE
dpc-5430	279	8	10.1007	10.1007	NUM
dpc-5430	279	9	/	/	SYM
dpc-5430	279	10	s12094	s12094	NOUN
dpc-5430	279	11	-	-	PUNCT
dpc-5430	279	12	011	011	NUM
dpc-5430	279	13	-0720	-0720	PROPN
dpc-5430	279	14	-	-	PUNCT
dpc-5430	279	15	z.	z.	PROPN
dpc-5430	279	16	pmid	pmid	PROPN
dpc-5430	279	17	:	:	PUNCT
dpc-5430	279	18	 	 	SPACE
dpc-5430	279	19	21975331	21975331	NUM
dpc-5430	279	20	.	.	PUNCT
dpc-5430	280	1	7	7	X
dpc-5430	280	2	.	.	X
dpc-5430	280	3	kabunga	kabunga	PROPN
dpc-5430	280	4	rr	rr	PROPN
dpc-5430	280	5	,	,	PUNCT
dpc-5430	280	6	onyango	onyango	PROPN
dpc-5430	280	7	j	j	PROPN
dpc-5430	280	8	,	,	PUNCT
dpc-5430	280	9	ruvuma	ruvuma	PROPN
dpc-5430	280	10	s	s	SYM
dpc-5430	280	11	,	,	PUNCT
dpc-5430	280	12	arunga	arunga	PROPN
dpc-5430	280	13	s.	s.	PROPN
dpc-5430	280	14	outcome	outcome	NOUN
dpc-5430	280	15	of	of	ADP
dpc-5430	280	16	intravitreal	intravitreal	ADJ
dpc-5430	280	17	avastin	avastin	PROPN
dpc-5430	280	18	®	®	NOUN
dpc-5430	280	19	injections	injection	NOUN
dpc-5430	280	20	in	in	ADP
dpc-5430	280	21	patients	patient	NOUN
dpc-5430	280	22	with	with	ADP
dpc-5430	280	23	macular	macular	ADJ
dpc-5430	280	24	oedema	oedema	NOUN
dpc-5430	280	25	in	in	ADP
dpc-5430	280	26	uganda	uganda	PROPN
dpc-5430	280	27	:	:	PUNCT
dpc-5430	280	28	a	a	DET
dpc-5430	280	29	cohort	cohort	NOUN
dpc-5430	280	30	study	study	NOUN
dpc-5430	280	31	.	.	PUNCT
dpc-5430	281	1	eye	eye	NOUN
dpc-5430	281	2	(	(	PUNCT
dpc-5430	281	3	lond	lond	PROPN
dpc-5430	281	4	)	)	PUNCT
dpc-5430	281	5	.	.	PUNCT
dpc-5430	282	1	2022;36(suppl	2022;36(suppl	PROPN
dpc-5430	282	2	1):45	1):45	NUM
dpc-5430	282	3	-	-	SYM
dpc-5430	282	4	50	50	NUM
dpc-5430	282	5	.	.	PUNCT
dpc-5430	283	1	doi	doi	NOUN
dpc-5430	283	2	:	:	PUNCT
dpc-5430	283	3	10.1038	10.1038	NUM
dpc-5430	283	4	/	/	SYM
dpc-5430	283	5	s41433	s41433	PROPN
dpc-5430	283	6	-	-	PUNCT
dpc-5430	283	7	022	022	NUM
dpc-5430	283	8	-	-	PUNCT
dpc-5430	283	9	02006	02006	NUM
dpc-5430	283	10	-	-	SYM
dpc-5430	283	11	5	5	NUM
dpc-5430	283	12	.	.	PUNCT
dpc-5430	284	1	pmid	pmid	NOUN
dpc-5430	284	2	:	:	PUNCT
dpc-5430	284	3	 	 	SPACE
dpc-5430	284	4	35590055	35590055	NUM
dpc-5430	284	5	.	.	PUNCT
dpc-5430	285	1	8	8	X
dpc-5430	285	2	.	.	X
dpc-5430	285	3	fazel	fazel	PROPN
dpc-5430	285	4	f	f	PROPN
dpc-5430	285	5	,	,	PUNCT
dpc-5430	285	6	nikpour	nikpour	NOUN
dpc-5430	285	7	h	h	NOUN
dpc-5430	285	8	,	,	PUNCT
dpc-5430	285	9	pourazizi	pourazizi	NOUN
dpc-5430	285	10	m.	m.	NOUN
dpc-5430	285	11	combination	combination	NOUN
dpc-5430	285	12	of	of	ADP
dpc-5430	285	13	intravitreal	intravitreal	ADJ
dpc-5430	285	14	bevacizumab	bevacizumab	NOUN
dpc-5430	285	15	and	and	CCONJ
dpc-5430	285	16	topical	topical	ADJ
dpc-5430	285	17	dorzolamide	dorzolamide	NOUN
dpc-5430	285	18	versus	versus	ADP
dpc-5430	285	19	intravitreal	intravitreal	ADJ
dpc-5430	285	20	bevacizumab	bevacizumab	NOUN
dpc-5430	285	21	alone	alone	ADJ
dpc-5430	285	22	for	for	ADP
dpc-5430	285	23	diabetic	diabetic	ADJ
dpc-5430	285	24	macular	macular	ADJ
dpc-5430	285	25	edema	edema	NOUN
dpc-5430	285	26	:	:	PUNCT
dpc-5430	285	27	a	a	DET
dpc-5430	285	28	randomized	randomized	ADJ
dpc-5430	285	29	contralateral	contralateral	ADJ
dpc-5430	285	30	clinical	clinical	ADJ
dpc-5430	285	31	trial	trial	NOUN
dpc-5430	285	32	.	.	PUNCT
dpc-5430	285	33	biomed	biome	VERB
dpc-5430	285	34	res	re	NOUN
dpc-5430	285	35	int	int	NOUN
dpc-5430	285	36	.	.	PUNCT
dpc-5430	286	1	2020;2020:6794391	2020;2020:6794391	NUM
dpc-5430	286	2	.	.	PUNCT
dpc-5430	287	1	doi	doi	NOUN
dpc-5430	287	2	:	:	PUNCT
dpc-5430	287	3	 	 	SPACE
dpc-5430	287	4	10.1155/2020/6794391	10.1155/2020/6794391	NUM
dpc-5430	287	5	.	.	PUNCT
dpc-5430	288	1	pmid	pmid	NOUN
dpc-5430	288	2	:	:	PUNCT
dpc-5430	288	3	 	 	SPACE
dpc-5430	288	4	32016118	32016118	NUM
dpc-5430	288	5	.	.	PUNCT
dpc-5430	289	1	9	9	X
dpc-5430	289	2	.	.	X
dpc-5430	289	3	fazel	fazel	PROPN
dpc-5430	289	4	f	f	PROPN
dpc-5430	289	5	,	,	PUNCT
dpc-5430	289	6	oliya	oliya	PROPN
dpc-5430	289	7	b	b	PROPN
dpc-5430	289	8	,	,	PUNCT
dpc-5430	289	9	mirmohammadkhani	mirmohammadkhani	PROPN
dpc-5430	289	10	m	m	PROPN
dpc-5430	289	11	,	,	PUNCT
dpc-5430	289	12	fazel	fazel	PROPN
dpc-5430	289	13	m	m	PROPN
dpc-5430	289	14	,	,	PUNCT
dpc-5430	289	15	yadegarfar	yadegarfar	ADV
dpc-5430	289	16	g	g	NOUN
dpc-5430	289	17	,	,	PUNCT
dpc-5430	289	18	pourazizi	pourazizi	NOUN
dpc-5430	289	19	m.	m.	NOUN
dpc-5430	289	20	intravitreal	intravitreal	NOUN
dpc-5430	289	21	injections	injection	NOUN
dpc-5430	289	22	of	of	ADP
dpc-5430	289	23	bevacizumab	bevacizumab	NOUN
dpc-5430	289	24	plus	plus	CCONJ
dpc-5430	289	25	methotrexate	methotrexate	X
dpc-5430	289	26	versus	versus	ADP
dpc-5430	289	27	bevacizumab	bevacizumab	NOUN
dpc-5430	289	28	alone	alone	ADJ
dpc-5430	289	29	for	for	ADP
dpc-5430	289	30	the	the	DET
dpc-5430	289	31	treatment	treatment	NOUN
dpc-5430	289	32	of	of	ADP
dpc-5430	289	33	diabetic	diabetic	ADJ
dpc-5430	289	34	macular	macular	ADJ
dpc-5430	289	35	edema	edema	NOUN
dpc-5430	289	36	:	:	PUNCT
dpc-5430	289	37	a	a	DET
dpc-5430	289	38	randomized	randomized	ADJ
dpc-5430	289	39	,	,	PUNCT
dpc-5430	289	40	sham	sham	NOUN
dpc-5430	289	41	-	-	PUNCT
dpc-5430	289	42	controlled	control	VERB
dpc-5430	289	43	trial	trial	NOUN
dpc-5430	289	44	.	.	PUNCT
dpc-5430	290	1	j	j	PROPN
dpc-5430	290	2	curr	curr	PROPN
dpc-5430	290	3	ophthalmol	ophthalmol	PROPN
dpc-5430	290	4	.	.	PUNCT
dpc-5430	291	1	2020;32(2):164	2020;32(2):164	NUM
dpc-5430	291	2	-	-	SYM
dpc-5430	291	3	9	9	NUM
dpc-5430	291	4	.	.	PUNCT
dpc-5430	291	5	doi	doi	NOUN
dpc-5430	291	6	:	:	PUNCT
dpc-5430	291	7	  	  	SPACE
dpc-5430	291	8	10.4103	10.4103	NUM
dpc-5430	291	9	/	/	SYM
dpc-5430	291	10	joco	joco	NOUN
dpc-5430	291	11	.joco_101_20	.joco_101_20	PUNCT
dpc-5430	291	12	.	.	PUNCT
dpc-5430	292	1	pmid	pmid	NOUN
dpc-5430	292	2	:	:	PUNCT
dpc-5430	292	3	 	 	SPACE
dpc-5430	292	4	32671300	32671300	NUM
dpc-5430	292	5	.	.	PUNCT
dpc-5430	293	1	10	10	NUM
dpc-5430	293	2	.	.	PUNCT
dpc-5430	294	1	bancalari	bancalari	PROPN
dpc-5430	294	2	a	a	DET
dpc-5430	294	3	,	,	PUNCT
dpc-5430	294	4	schade	schade	PROPN
dpc-5430	294	5	r.	r.	PROPN
dpc-5430	294	6	update	update	NOUN
dpc-5430	294	7	in	in	ADP
dpc-5430	294	8	the	the	DET
dpc-5430	294	9	treatment	treatment	NOUN
dpc-5430	294	10	of	of	ADP
dpc-5430	294	11	retinopathy	retinopathy	NOUN
dpc-5430	294	12	of	of	ADP
dpc-5430	294	13	prematurity	prematurity	NOUN
dpc-5430	294	14	.	.	PUNCT
dpc-5430	295	1	am	be	AUX
dpc-5430	295	2	j	j	PROPN
dpc-5430	295	3	perinatol	perinatol	NOUN
dpc-5430	295	4	.	.	PUNCT
dpc-5430	296	1	2022;39(1):22	2022;39(1):22	NUM
dpc-5430	296	2	-	-	SYM
dpc-5430	296	3	30	30	NUM
dpc-5430	296	4	.	.	PUNCT
dpc-5430	296	5	doi	doi	NOUN
dpc-5430	296	6	:	:	PUNCT
dpc-5430	296	7	 	 	SPACE
dpc-5430	296	8	10.1055	10.1055	NUM
dpc-5430	296	9	/	/	SYM
dpc-5430	296	10	s	s	PART
dpc-5430	296	11	-0040	-0040	NOUN
dpc-5430	296	12	-	-	PUNCT
dpc-5430	296	13	1713181	1713181	NUM
dpc-5430	296	14	.	.	PUNCT
dpc-5430	297	1	pmid	pmid	NOUN
dpc-5430	297	2	:	:	PUNCT
dpc-5430	297	3	 	 	SPACE
dpc-5430	297	4	32544962	32544962	NUM
dpc-5430	297	5	.	.	PUNCT
dpc-5430	298	1	11	11	NUM
dpc-5430	298	2	.	.	PUNCT
dpc-5430	299	1	freedman	freedman	PROPN
dpc-5430	299	2	sf	sf	PROPN
dpc-5430	299	3	,	,	PUNCT
dpc-5430	299	4	hercinovic	hercinovic	ADV
dpc-5430	299	5	a	a	X
dpc-5430	299	6	,	,	PUNCT
dpc-5430	299	7	wallace	wallace	PROPN
dpc-5430	299	8	dk	dk	PROPN
dpc-5430	299	9	,	,	PUNCT
dpc-5430	299	10	kraker	kraker	PROPN
dpc-5430	299	11	rt	rt	PROPN
dpc-5430	299	12	,	,	PUNCT
dpc-5430	299	13	li	li	PROPN
dpc-5430	299	14	z	z	PROPN
dpc-5430	299	15	,	,	PUNCT
dpc-5430	299	16	bhatt	bhatt	PROPN
dpc-5430	299	17	ar	ar	PROPN
dpc-5430	299	18	,	,	PUNCT
dpc-5430	299	19	et	et	PROPN
dpc-5430	299	20	al	al	PROPN
dpc-5430	299	21	.	.	PROPN
dpc-5430	299	22	lowand	lowand	PROPN
dpc-5430	299	23	very	very	ADV
dpc-5430	299	24	low	low	ADV
dpc-5430	299	25	-	-	PUNCT
dpc-5430	299	26	dose	dose	NOUN
dpc-5430	299	27	bevacizumab	bevacizumab	NOUN
dpc-5430	299	28	for	for	ADP
dpc-5430	299	29	retinopathy	retinopathy	NOUN
dpc-5430	299	30	of	of	ADP
dpc-5430	299	31	prematurity	prematurity	NOUN
dpc-5430	299	32	:	:	PUNCT
dpc-5430	299	33	reactivations	reactivation	NOUN
dpc-5430	299	34	,	,	PUNCT
dpc-5430	299	35	additional	additional	ADJ
dpc-5430	299	36	treatments	treatment	NOUN
dpc-5430	299	37	,	,	PUNCT
dpc-5430	299	38	and	and	CCONJ
dpc-5430	299	39	12	12	NUM
dpc-5430	299	40	-	-	PUNCT
dpc-5430	299	41	month	month	NOUN
dpc-5430	299	42	outcomes	outcome	NOUN
dpc-5430	299	43	.	.	PUNCT
dpc-5430	300	1	ophthalmology	ophthalmology	NOUN
dpc-5430	300	2	.	.	PUNCT
dpc-5430	301	1	2022;129(10):1120	2022;129(10):1120	NUM
dpc-5430	302	1	-8	-8	NOUN
dpc-5430	302	2	.	.	PUNCT
dpc-5430	303	1	doi	doi	NOUN
dpc-5430	303	2	:	:	PUNCT
dpc-5430	303	3	 	 	SPACE
dpc-5430	303	4	10.1016	10.1016	NUM
dpc-5430	303	5	/	/	SYM
dpc-5430	303	6	j.ophtha.2022.05.019	j.ophtha.2022.05.019	PROPN
dpc-5430	303	7	.	.	PUNCT
dpc-5430	304	1	pmid	pmid	NOUN
dpc-5430	304	2	:	:	PUNCT
dpc-5430	304	3	 	 	SPACE
dpc-5430	304	4	35660415	35660415	NUM
dpc-5430	304	5	.	.	PUNCT
dpc-5430	305	1	12	12	NUM
dpc-5430	305	2	.	.	PUNCT
dpc-5430	305	3	abtahi	abtahi	NOUN
dpc-5430	305	4	-	-	PUNCT
dpc-5430	305	5	naeini	naeini	PROPN
dpc-5430	305	6	b	b	NOUN
dpc-5430	305	7	,	,	PUNCT
dpc-5430	305	8	saffaei	saffaei	NOUN
dpc-5430	305	9	a	a	PRON
dpc-5430	305	10	,	,	PUNCT
dpc-5430	305	11	hadian	hadian	ADJ
dpc-5430	305	12	m.	m.	NOUN
dpc-5430	305	13	promising	promise	VERB
dpc-5430	305	14	novel	novel	ADJ
dpc-5430	305	15	treatment	treatment	NOUN
dpc-5430	305	16	against	against	ADP
dpc-5430	305	17	keloids	keloid	NOUN
dpc-5430	305	18	:	:	PUNCT
dpc-5430	305	19	antivascular	antivascular	ADJ
dpc-5430	305	20	endothelial	endothelial	ADJ
dpc-5430	305	21	growth	growth	NOUN
dpc-5430	305	22	factor	factor	NOUN
dpc-5430	305	23	agents	agent	NOUN
dpc-5430	305	24	.	.	PUNCT
dpc-5430	306	1	j	j	PROPN
dpc-5430	306	2	res	res	PROPN
dpc-5430	306	3	pharm	pharm	PROPN
dpc-5430	306	4	pract	pract	PROPN
dpc-5430	306	5	.	.	PUNCT
dpc-5430	307	1	2019;8(3):178	2019;8(3):178	NUM
dpc-5430	307	2	-	-	SYM
dpc-5430	307	3	9	9	NUM
dpc-5430	307	4	.	.	PUNCT
dpc-5430	307	5	doi	doi	NOUN
dpc-5430	307	6	:	:	PUNCT
dpc-5430	307	7	 	 	SPACE
dpc-5430	307	8	10.4103	10.4103	NUM
dpc-5430	307	9	/	/	SYM
dpc-5430	307	10	jrpp	jrpp	PROPN
dpc-5430	307	11	.jrpp_19_58	.jrpp_19_58	PROPN
dpc-5430	307	12	.	.	PUNCT
dpc-5430	308	1	pmid	pmid	NOUN
dpc-5430	308	2	:	:	PUNCT
dpc-5430	308	3	 	 	SPACE
dpc-5430	308	4	31728351	31728351	NUM
dpc-5430	308	5	.	.	PUNCT
dpc-5430	309	1	13	13	NUM
dpc-5430	309	2	.	.	PUNCT
dpc-5430	309	3	bowers	bowers	PROPN
dpc-5430	309	4	emr	emr	PROPN
dpc-5430	309	5	,	,	PUNCT
dpc-5430	309	6	lee	lee	PROPN
dpc-5430	309	7	s.	s.	PROPN
dpc-5430	309	8	treatment	treatment	PROPN
dpc-5430	309	9	of	of	ADP
dpc-5430	309	10	tongue	tongue	NOUN
dpc-5430	309	11	telangiectasia	telangiectasia	NOUN
dpc-5430	309	12	in	in	ADP
dpc-5430	309	13	a	a	DET
dpc-5430	309	14	patient	patient	NOUN
dpc-5430	309	15	with	with	ADP
dpc-5430	309	16	hereditary	hereditary	ADJ
dpc-5430	309	17	haemorrhagic	haemorrhagic	ADJ
dpc-5430	309	18	telangiectasia	telangiectasia	NOUN
dpc-5430	309	19	.	.	PUNCT
dpc-5430	310	1	bmj	bmj	PROPN
dpc-5430	310	2	leading	lead	VERB
dpc-5430	310	3	to	to	ADP
dpc-5430	310	4	hospitalization	hospitalization	NOUN
dpc-5430	310	5	[	[	X
dpc-5430	310	6	32	32	NUM
dpc-5430	310	7	]	]	PUNCT
dpc-5430	310	8	.	.	PUNCT
dpc-5430	311	1	in	in	ADP
dpc-5430	311	2	the	the	DET
dpc-5430	311	3	end	end	NOUN
dpc-5430	311	4	,	,	PUNCT
dpc-5430	311	5	the	the	DET
dpc-5430	311	6	study	study	NOUN
dpc-5430	311	7	revealed	reveal	VERB
dpc-5430	311	8	that	that	SCONJ
dpc-5430	311	9	the	the	DET
dpc-5430	311	10	combination	combination	NOUN
dpc-5430	311	11	of	of	ADP
dpc-5430	311	12	il	il	PROPN
dpc-5430	311	13	bevacizumab	bevacizumab	PROPN
dpc-5430	311	14	and	and	CCONJ
dpc-5430	311	15	art	art	NOUN
dpc-5430	311	16	did	do	AUX
dpc-5430	311	17	not	not	PART
dpc-5430	311	18	show	show	VERB
dpc-5430	311	19	any	any	DET
dpc-5430	311	20	significant	significant	ADJ
dpc-5430	311	21	effect	effect	NOUN
dpc-5430	311	22	on	on	ADP
dpc-5430	311	23	mucosal	mucosal	NOUN
dpc-5430	311	24	ks	k	NOUN
dpc-5430	311	25	involving	involve	VERB
dpc-5430	311	26	the	the	DET
dpc-5430	311	27	upper	upper	ADJ
dpc-5430	311	28	respiratory	respiratory	ADJ
dpc-5430	311	29	tract	tract	NOUN
dpc-5430	311	30	in	in	ADP
dpc-5430	311	31	hiv	hiv	PROPN
dpc-5430	311	32	-	-	PUNCT
dpc-5430	311	33	infected	infect	VERB
dpc-5430	311	34	patients	patient	NOUN
dpc-5430	311	35	[	[	X
dpc-5430	311	36	32	32	NUM
dpc-5430	311	37	]	]	PUNCT
dpc-5430	311	38	.	.	PUNCT
dpc-5430	312	1	others	other	NOUN
dpc-5430	312	2	lichen	lichen	VERB
dpc-5430	312	3	planus	planus	ADJ
dpc-5430	312	4	oral	oral	ADJ
dpc-5430	312	5	lichen	lichen	NOUN
dpc-5430	312	6	planus	planus	NOUN
dpc-5430	312	7	(	(	PUNCT
dpc-5430	312	8	olp	olp	PROPN
dpc-5430	312	9	)	)	PUNCT
dpc-5430	312	10	is	be	AUX
dpc-5430	312	11	a	a	DET
dpc-5430	312	12	chronic	chronic	ADJ
dpc-5430	312	13	inflammatory	inflammatory	ADJ
dpc-5430	312	14	disease	disease	NOUN
dpc-5430	312	15	affecting	affect	VERB
dpc-5430	312	16	mucocutaneous	mucocutaneous	ADJ
dpc-5430	312	17	regions	region	NOUN
dpc-5430	312	18	.	.	PUNCT
dpc-5430	313	1	the	the	DET
dpc-5430	313	2	standard	standard	ADJ
dpc-5430	313	3	approach	approach	NOUN
dpc-5430	313	4	suggests	suggest	VERB
dpc-5430	313	5	treatment	treatment	NOUN
dpc-5430	313	6	with	with	ADP
dpc-5430	313	7	topical	topical	ADJ
dpc-5430	313	8	corticosteroids	corticosteroid	NOUN
dpc-5430	313	9	.	.	PUNCT
dpc-5430	314	1	however	however	ADV
dpc-5430	314	2	,	,	PUNCT
dpc-5430	314	3	due	due	ADP
dpc-5430	314	4	to	to	ADP
dpc-5430	314	5	the	the	DET
dpc-5430	314	6	strong	strong	ADJ
dpc-5430	314	7	correlation	correlation	NOUN
dpc-5430	314	8	between	between	ADP
dpc-5430	314	9	olp	olp	PROPN
dpc-5430	314	10	and	and	CCONJ
dpc-5430	314	11	angiogenesis	angiogenesis	NOUN
dpc-5430	314	12	,	,	PUNCT
dpc-5430	314	13	anti	anti	ADJ
dpc-5430	314	14	-	-	ADJ
dpc-5430	314	15	angiogenic	angiogenic	ADJ
dpc-5430	314	16	drugs	drug	NOUN
dpc-5430	314	17	could	could	AUX
dpc-5430	314	18	emerge	emerge	VERB
dpc-5430	314	19	as	as	ADP
dpc-5430	314	20	an	an	DET
dpc-5430	314	21	alternate	alternate	ADJ
dpc-5430	314	22	option	option	NOUN
dpc-5430	314	23	for	for	ADP
dpc-5430	314	24	patients	patient	NOUN
dpc-5430	314	25	who	who	PRON
dpc-5430	314	26	can	can	AUX
dpc-5430	314	27	not	not	PART
dpc-5430	314	28	use	use	VERB
dpc-5430	314	29	conventional	conventional	ADJ
dpc-5430	314	30	therapy	therapy	NOUN
dpc-5430	314	31	or	or	CCONJ
dpc-5430	314	32	who	who	PRON
dpc-5430	314	33	have	have	AUX
dpc-5430	314	34	shown	show	VERB
dpc-5430	314	35	inadequate	inadequate	ADJ
dpc-5430	314	36	response	response	NOUN
dpc-5430	314	37	[	[	X
dpc-5430	314	38	33	33	NUM
dpc-5430	314	39	]	]	PUNCT
dpc-5430	314	40	.	.	PUNCT
dpc-5430	315	1	an	an	DET
dpc-5430	315	2	rct	rct	PROPN
dpc-5430	315	3	was	be	AUX
dpc-5430	315	4	conducted	conduct	VERB
dpc-5430	315	5	on	on	ADP
dpc-5430	315	6	40	40	NUM
dpc-5430	315	7	patients	patient	NOUN
dpc-5430	315	8	with	with	ADP
dpc-5430	315	9	atrophic	atrophic	ADJ
dpc-5430	315	10	/	/	SYM
dpc-5430	315	11	erosive	erosive	ADJ
dpc-5430	315	12	lesions	lesion	NOUN
dpc-5430	315	13	of	of	ADP
dpc-5430	315	14	olp	olp	PROPN
dpc-5430	315	15	.	.	PUNCT
dpc-5430	316	1	twenty	twenty	NUM
dpc-5430	316	2	patients	patient	NOUN
dpc-5430	316	3	were	be	AUX
dpc-5430	316	4	randomly	randomly	ADV
dpc-5430	316	5	selected	select	VERB
dpc-5430	316	6	to	to	PART
dpc-5430	316	7	receive	receive	VERB
dpc-5430	316	8	2.5	2.5	NUM
dpc-5430	316	9	mg	mg	PROPN
dpc-5430	316	10	il	il	PROPN
dpc-5430	316	11	bevacizumab	bevacizumab	PROPN
dpc-5430	316	12	,	,	PUNCT
dpc-5430	316	13	and	and	CCONJ
dpc-5430	316	14	other	other	ADJ
dpc-5430	316	15	participants	participant	NOUN
dpc-5430	316	16	were	be	AUX
dpc-5430	316	17	instructed	instruct	VERB
dpc-5430	316	18	to	to	PART
dpc-5430	316	19	use	use	VERB
dpc-5430	316	20	triamcinolone	triamcinolone	NOUN
dpc-5430	316	21	acetonide	acetonide	NOUN
dpc-5430	316	22	on	on	ADP
dpc-5430	316	23	the	the	DET
dpc-5430	316	24	buccal	buccal	ADJ
dpc-5430	316	25	mucosa	mucosa	NOUN
dpc-5430	316	26	.	.	PUNCT
dpc-5430	317	1	the	the	DET
dpc-5430	317	2	patients	patient	NOUN
dpc-5430	317	3	underwent	undergo	VERB
dpc-5430	317	4	seven	seven	NUM
dpc-5430	317	5	follow	follow	VERB
dpc-5430	317	6	-	-	PUNCT
dpc-5430	317	7	up	up	ADP
dpc-5430	317	8	sessions	session	NOUN
dpc-5430	317	9	,	,	PUNCT
dpc-5430	317	10	for	for	ADP
dpc-5430	317	11	a	a	DET
dpc-5430	317	12	total	total	ADJ
dpc-5430	317	13	duration	duration	NOUN
dpc-5430	317	14	of	of	ADP
dpc-5430	317	15	three	three	NUM
dpc-5430	317	16	months	month	NOUN
dpc-5430	317	17	[	[	X
dpc-5430	317	18	33	33	NUM
dpc-5430	317	19	]	]	PUNCT
dpc-5430	317	20	.	.	PUNCT
dpc-5430	318	1	tissue	tissue	NOUN
dpc-5430	318	2	biopsy	biopsy	NOUN
dpc-5430	318	3	revealed	reveal	VERB
dpc-5430	318	4	that	that	SCONJ
dpc-5430	318	5	bevacizumab	bevacizumab	NOUN
dpc-5430	318	6	effectively	effectively	ADV
dpc-5430	318	7	reduced	reduce	VERB
dpc-5430	318	8	levels	level	NOUN
dpc-5430	318	9	of	of	ADP
dpc-5430	318	10	il-8	il-8	PUNCT
dpc-5430	318	11	and	and	CCONJ
dpc-5430	318	12	stopped	stop	VERB
dpc-5430	318	13	the	the	DET
dpc-5430	318	14	activity	activity	NOUN
dpc-5430	318	15	of	of	ADP
dpc-5430	318	16	pro	pro	ADJ
dpc-5430	318	17	-	-	ADJ
dpc-5430	318	18	inflammatory	inflammatory	ADJ
dpc-5430	318	19	cells	cell	NOUN
dpc-5430	318	20	and	and	CCONJ
dpc-5430	318	21	cytokines	cytokine	NOUN
dpc-5430	318	22	,	,	PUNCT
dpc-5430	318	23	which	which	PRON
dpc-5430	318	24	inhibited	inhibit	VERB
dpc-5430	318	25	vegf	vegf	NOUN
dpc-5430	318	26	and	and	CCONJ
dpc-5430	318	27	angiogenesis	angiogenesis	NOUN
dpc-5430	318	28	.	.	PUNCT
dpc-5430	319	1	a	a	DET
dpc-5430	319	2	week	week	NOUN
dpc-5430	319	3	after	after	ADP
dpc-5430	319	4	il	il	PROPN
dpc-5430	319	5	bevacizumab	bevacizumab	PROPN
dpc-5430	319	6	injection	injection	PROPN
dpc-5430	319	7	,	,	PUNCT
dpc-5430	319	8	the	the	DET
dpc-5430	319	9	size	size	NOUN
dpc-5430	319	10	of	of	ADP
dpc-5430	319	11	lesions	lesion	NOUN
dpc-5430	319	12	and	and	CCONJ
dpc-5430	319	13	pain	pain	NOUN
dpc-5430	319	14	intensity	intensity	NOUN
dpc-5430	319	15	improved	improve	VERB
dpc-5430	319	16	,	,	PUNCT
dpc-5430	319	17	without	without	ADP
dpc-5430	319	18	complication	complication	NOUN
dpc-5430	319	19	.	.	PUNCT
dpc-5430	320	1	therefore	therefore	ADV
dpc-5430	320	2	,	,	PUNCT
dpc-5430	320	3	il	il	PROPN
dpc-5430	320	4	bevacizumab	bevacizumab	NOUN
dpc-5430	320	5	may	may	AUX
dpc-5430	320	6	be	be	AUX
dpc-5430	320	7	an	an	DET
dpc-5430	320	8	effective	effective	ADJ
dpc-5430	320	9	and	and	CCONJ
dpc-5430	320	10	a	a	DET
dpc-5430	320	11	safe	safe	ADJ
dpc-5430	320	12	treatment	treatment	NOUN
dpc-5430	320	13	for	for	ADP
dpc-5430	320	14	atrophic/	atrophic/	NUM
dpc-5430	320	15	erosive	erosive	NOUN
dpc-5430	320	16	lp	lp	NOUN
dpc-5430	321	1	[	[	X
dpc-5430	321	2	33	33	NUM
dpc-5430	321	3	]	]	PUNCT
dpc-5430	321	4	.	.	PUNCT
dpc-5430	322	1	basal	basal	PROPN
dpc-5430	322	2	cell	cell	NOUN
dpc-5430	322	3	carcinoma	carcinoma	NOUN
dpc-5430	322	4	the	the	DET
dpc-5430	322	5	goal	goal	NOUN
dpc-5430	322	6	for	for	ADP
dpc-5430	322	7	the	the	DET
dpc-5430	322	8	treatment	treatment	NOUN
dpc-5430	322	9	of	of	ADP
dpc-5430	322	10	basal	basal	ADJ
dpc-5430	322	11	cell	cell	NOUN
dpc-5430	322	12	carcinoma	carcinoma	NOUN
dpc-5430	322	13	(	(	PUNCT
dpc-5430	322	14	bcc	bcc	PROPN
dpc-5430	322	15	)	)	PUNCT
dpc-5430	322	16	is	be	AUX
dpc-5430	322	17	to	to	PART
dpc-5430	322	18	achieve	achieve	VERB
dpc-5430	322	19	complete	complete	ADJ
dpc-5430	322	20	tumor	tumor	NOUN
dpc-5430	322	21	removal	removal	NOUN
dpc-5430	322	22	.	.	PUNCT
dpc-5430	323	1	this	this	PRON
dpc-5430	323	2	can	can	AUX
dpc-5430	323	3	be	be	AUX
dpc-5430	323	4	accomplished	accomplish	VERB
dpc-5430	323	5	through	through	ADP
dpc-5430	323	6	conventional	conventional	ADJ
dpc-5430	323	7	surgical	surgical	ADJ
dpc-5430	323	8	excision	excision	NOUN
dpc-5430	323	9	,	,	PUNCT
dpc-5430	323	10	mohs	mohs	PROPN
dpc-5430	323	11	micrographic	micrographic	ADV
dpc-5430	323	12	surgery	surgery	NOUN
dpc-5430	323	13	,	,	PUNCT
dpc-5430	323	14	cryosurgery	cryosurgery	NOUN
dpc-5430	323	15	,	,	PUNCT
dpc-5430	323	16	electrodesiccation	electrodesiccation	NOUN
dpc-5430	323	17	and	and	CCONJ
dpc-5430	323	18	curettage	curettage	NOUN
dpc-5430	323	19	,	,	PUNCT
dpc-5430	323	20	topical	topical	ADJ
dpc-5430	323	21	application	application	NOUN
dpc-5430	323	22	of	of	ADP
dpc-5430	323	23	imiquimod	imiquimod	ADJ
dpc-5430	323	24	or	or	CCONJ
dpc-5430	323	25	fluorouracil	fluorouracil	NOUN
dpc-5430	323	26	,	,	PUNCT
dpc-5430	323	27	photodynamic	photodynamic	ADJ
dpc-5430	323	28	therapy	therapy	NOUN
dpc-5430	323	29	,	,	PUNCT
dpc-5430	323	30	or	or	CCONJ
dpc-5430	323	31	radiation	radiation	NOUN
dpc-5430	323	32	therapy	therapy	NOUN
dpc-5430	323	33	[	[	X
dpc-5430	323	34	34	34	NUM
dpc-5430	323	35	]	]	PUNCT
dpc-5430	323	36	.	.	PUNCT
dpc-5430	324	1	in	in	ADP
dpc-5430	324	2	a	a	DET
dpc-5430	324	3	case	case	NOUN
dpc-5430	324	4	series	series	NOUN
dpc-5430	324	5	,	,	PUNCT
dpc-5430	324	6	seven	seven	NUM
dpc-5430	324	7	patients	patient	NOUN
dpc-5430	324	8	with	with	ADP
dpc-5430	324	9	extensive	extensive	ADJ
dpc-5430	324	10	local	local	ADJ
dpc-5430	324	11	bcc	bcc	NOUN
dpc-5430	324	12	were	be	AUX
dpc-5430	324	13	initially	initially	ADV
dpc-5430	324	14	treated	treat	VERB
dpc-5430	324	15	with	with	ADP
dpc-5430	324	16	immunocryosurgery	immunocryosurgery	NOUN
dpc-5430	324	17	alone	alone	ADV
dpc-5430	324	18	,	,	PUNCT
dpc-5430	324	19	which	which	PRON
dpc-5430	324	20	was	be	AUX
dpc-5430	324	21	ineffective	ineffective	ADJ
dpc-5430	324	22	.	.	PUNCT
dpc-5430	325	1	il	il	PROPN
dpc-5430	325	2	bevacizumab	bevacizumab	PROPN
dpc-5430	325	3	was	be	AUX
dpc-5430	325	4	then	then	ADV
dpc-5430	325	5	used	use	VERB
dpc-5430	325	6	as	as	ADP
dpc-5430	325	7	an	an	DET
dpc-5430	325	8	adjuvant	adjuvant	ADJ
dpc-5430	325	9	treatment	treatment	NOUN
dpc-5430	325	10	[	[	X
dpc-5430	325	11	35	35	NUM
dpc-5430	325	12	]	]	PUNCT
dpc-5430	325	13	.	.	PUNCT
dpc-5430	326	1	the	the	DET
dpc-5430	326	2	treatment	treatment	NOUN
dpc-5430	326	3	protocol	protocol	NOUN
dpc-5430	326	4	was	be	AUX
dpc-5430	326	5	12.5	12.5	NUM
dpc-5430	326	6	mg	mg	NOUN
dpc-5430	326	7	of	of	ADP
dpc-5430	326	8	topical	topical	ADJ
dpc-5430	326	9	imiquimod	imiquimod	ADJ
dpc-5430	326	10	5	5	NUM
dpc-5430	326	11	%	%	NOUN
dpc-5430	326	12	every	every	DET
dpc-5430	326	13	night	night	NOUN
dpc-5430	326	14	,	,	PUNCT
dpc-5430	326	15	1	1	NUM
dpc-5430	326	16	g	g	NOUN
dpc-5430	326	17	of	of	ADP
dpc-5430	326	18	tazarotene	tazarotene	NOUN
dpc-5430	326	19	0.1	0.1	NUM
dpc-5430	326	20	%	%	NOUN
dpc-5430	326	21	daily	daily	ADV
dpc-5430	326	22	,	,	PUNCT
dpc-5430	326	23	and	and	CCONJ
dpc-5430	326	24	two	two	NUM
dpc-5430	326	25	cycles	cycle	NOUN
dpc-5430	326	26	of	of	ADP
dpc-5430	326	27	cryosurgery	cryosurgery	NOUN
dpc-5430	326	28	every	every	DET
dpc-5430	326	29	two	two	NUM
dpc-5430	326	30	weeks	week	NOUN
dpc-5430	326	31	.	.	PUNCT
dpc-5430	327	1	as	as	ADP
dpc-5430	327	2	an	an	DET
dpc-5430	327	3	adjuvant	adjuvant	ADJ
dpc-5430	327	4	medication	medication	NOUN
dpc-5430	327	5	,	,	PUNCT
dpc-5430	327	6	three	three	NUM
dpc-5430	327	7	sessions	session	NOUN
dpc-5430	327	8	of	of	ADP
dpc-5430	327	9	25	25	NUM
dpc-5430	327	10	mg	mg	PROPN
dpc-5430	327	11	il	il	PROPN
dpc-5430	327	12	bevacizumab	bevacizumab	PROPN
dpc-5430	327	13	were	be	AUX
dpc-5430	327	14	immediately	immediately	ADV
dpc-5430	327	15	used	use	VERB
dpc-5430	327	16	after	after	ADP
dpc-5430	327	17	cryosurgery	cryosurgery	NOUN
dpc-5430	327	18	[	[	X
dpc-5430	327	19	35	35	NUM
dpc-5430	327	20	]	]	PUNCT
dpc-5430	327	21	.	.	PUNCT
dpc-5430	328	1	the	the	DET
dpc-5430	328	2	tumor	tumor	NOUN
dpc-5430	328	3	shrank	shrink	VERB
dpc-5430	328	4	successfully	successfully	ADV
dpc-5430	328	5	after	after	ADP
dpc-5430	328	6	two	two	NUM
dpc-5430	328	7	bevacizumab	bevacizumab	NOUN
dpc-5430	328	8	injections	injection	NOUN
dpc-5430	328	9	.	.	PUNCT
dpc-5430	329	1	pain	pain	NOUN
dpc-5430	329	2	during	during	ADP
dpc-5430	329	3	injection	injection	NOUN
dpc-5430	329	4	,	,	PUNCT
dpc-5430	329	5	flu	flu	NOUN
dpc-5430	329	6	-	-	PUNCT
dpc-5430	329	7	like	like	ADJ
dpc-5430	329	8	symptoms	symptom	NOUN
dpc-5430	329	9	,	,	PUNCT
dpc-5430	329	10	and	and	CCONJ
dpc-5430	329	11	reversible	reversible	ADJ
dpc-5430	329	12	leukopenia	leukopenia	NOUN
dpc-5430	329	13	were	be	AUX
dpc-5430	329	14	the	the	DET
dpc-5430	329	15	only	only	ADJ
dpc-5430	329	16	reported	report	VERB
dpc-5430	329	17	complications	complication	NOUN
dpc-5430	329	18	.	.	PUNCT
dpc-5430	330	1	therefore	therefore	ADV
dpc-5430	330	2	,	,	PUNCT
dpc-5430	330	3	bevacizumab	bevacizumab	NOUN
dpc-5430	330	4	may	may	AUX
dpc-5430	330	5	be	be	AUX
dpc-5430	330	6	an	an	DET
dpc-5430	330	7	effective	effective	ADJ
dpc-5430	330	8	and	and	CCONJ
dpc-5430	330	9	minimally	minimally	ADV
dpc-5430	330	10	invasive	invasive	ADJ
dpc-5430	330	11	therapeutic	therapeutic	ADJ
dpc-5430	330	12	option	option	NOUN
dpc-5430	330	13	for	for	ADP
dpc-5430	330	14	bcc	bcc	PROPN
dpc-5430	330	15	[	[	X
dpc-5430	330	16	35	35	NUM
dpc-5430	330	17	]	]	PUNCT
dpc-5430	330	18	.	.	PUNCT
dpc-5430	331	1	conclusion	conclusion	NOUN
dpc-5430	331	2	intralesional	intralesional	ADJ
dpc-5430	331	3	bevacizumab	bevacizumab	NOUN
dpc-5430	331	4	has	have	VERB
dpc-5430	331	5	some	some	DET
dpc-5430	331	6	off	off	ADP
dpc-5430	331	7	-	-	PUNCT
dpc-5430	331	8	label	label	NOUN
dpc-5430	331	9	applications	application	NOUN
dpc-5430	331	10	in	in	ADP
dpc-5430	331	11	dermatology	dermatology	NOUN
dpc-5430	331	12	beyond	beyond	ADP
dpc-5430	331	13	its	its	PRON
dpc-5430	331	14	previous	previous	ADJ
dpc-5430	331	15	advantages	advantage	NOUN
dpc-5430	331	16	for	for	ADP
dpc-5430	331	17	the	the	DET
dpc-5430	331	18	treatment	treatment	NOUN
dpc-5430	331	19	of	of	ADP
dpc-5430	331	20	cancer	cancer	NOUN
dpc-5430	331	21	and	and	CCONJ
dpc-5430	331	22	ophthalmological	ophthalmological	ADJ
dpc-5430	331	23	conditions	condition	NOUN
dpc-5430	331	24	.	.	PUNCT
dpc-5430	332	1	these	these	DET
dpc-5430	332	2	8	8	NUM
dpc-5430	332	3	review	review	NOUN
dpc-5430	332	4	|	|	ADV
dpc-5430	332	5	dermatol	dermatol	ADJ
dpc-5430	332	6	pract	pract	NOUN
dpc-5430	332	7	concept	concept	NOUN
dpc-5430	332	8	.	.	PUNCT
dpc-5430	333	1	2025;15(4):5430	2025;15(4):5430	NUM
dpc-5430	333	2	24	24	NUM
dpc-5430	333	3	.	.	PUNCT
dpc-5430	333	4	kalinina	kalinina	PROPN
dpc-5430	333	5	mp	mp	PROPN
dpc-5430	333	6	,	,	PUNCT
dpc-5430	333	7	grachev	grachev	PROPN
dpc-5430	333	8	ns	ns	PROPN
dpc-5430	333	9	,	,	PUNCT
dpc-5430	333	10	kumskova	kumskova	PROPN
dpc-5430	333	11	ma	ma	PROPN
dpc-5430	333	12	,	,	PUNCT
dpc-5430	333	13	timofeeva	timofeeva	PROPN
dpc-5430	333	14	ok	ok	PROPN
dpc-5430	333	15	.	.	PROPN
dpc-5430	334	1	successful	successful	ADJ
dpc-5430	334	2	treatment	treatment	NOUN
dpc-5430	334	3	of	of	ADP
dpc-5430	334	4	recurrent	recurrent	ADJ
dpc-5430	334	5	epistaxis	epistaxis	NOUN
dpc-5430	334	6	with	with	ADP
dpc-5430	334	7	submucosal	submucosal	NOUN
dpc-5430	334	8	bevacizumab	bevacizumab	NOUN
dpc-5430	334	9	therapy	therapy	NOUN
dpc-5430	334	10	in	in	ADP
dpc-5430	334	11	a	a	DET
dpc-5430	334	12	female	female	ADJ
dpc-5430	334	13	patient	patient	NOUN
dpc-5430	334	14	with	with	ADP
dpc-5430	334	15	hereditary	hereditary	ADJ
dpc-5430	334	16	hemorrhagic	hemorrhagic	NOUN
dpc-5430	334	17	telangiectasia	telangiectasia	NOUN
dpc-5430	334	18	.	.	PUNCT
dpc-5430	335	1	pediatric	pediatric	ADJ
dpc-5430	335	2	hematology	hematology	NOUN
dpc-5430	335	3	/	/	SYM
dpc-5430	335	4	oncology	oncology	NOUN
dpc-5430	335	5	and	and	CCONJ
dpc-5430	335	6	immunopathology	immunopathology	NOUN
dpc-5430	335	7	.	.	PUNCT
dpc-5430	336	1	2014;13(4):75	2014;13(4):75	NUM
dpc-5430	336	2	-	-	SYM
dpc-5430	336	3	8	8	NUM
dpc-5430	336	4	.	.	X
dpc-5430	336	5	25	25	NUM
dpc-5430	336	6	.	.	PUNCT
dpc-5430	336	7	rohrmeier	rohrmeier	PROPN
dpc-5430	336	8	c	c	PROPN
dpc-5430	336	9	,	,	PUNCT
dpc-5430	336	10	sachs	sachs	PROPN
dpc-5430	336	11	hg	hg	PROPN
dpc-5430	336	12	,	,	PUNCT
dpc-5430	336	13	kuehnel	kuehnel	PROPN
dpc-5430	336	14	ts	ts	PROPN
dpc-5430	336	15	.	.	PUNCT
dpc-5430	337	1	a	a	DET
dpc-5430	337	2	retrospective	retrospective	ADJ
dpc-5430	337	3	analysis	analysis	NOUN
dpc-5430	337	4	of	of	ADP
dpc-5430	337	5	low	low	ADJ
dpc-5430	337	6	dose	dose	NOUN
dpc-5430	337	7	,	,	PUNCT
dpc-5430	337	8	intranasal	intranasal	NOUN
dpc-5430	337	9	injected	inject	VERB
dpc-5430	337	10	bevacizumab	bevacizumab	NOUN
dpc-5430	337	11	(	(	PUNCT
dpc-5430	337	12	avastin	avastin	NOUN
dpc-5430	337	13	)	)	PUNCT
dpc-5430	337	14	in	in	ADP
dpc-5430	337	15	hereditary	hereditary	ADJ
dpc-5430	337	16	haemorrhagic	haemorrhagic	ADJ
dpc-5430	337	17	telangiectasia	telangiectasia	NOUN
dpc-5430	337	18	.	.	PUNCT
dpc-5430	338	1	eur	eur	PROPN
dpc-5430	338	2	arch	arch	ADJ
dpc-5430	338	3	otorhinolaryngol	otorhinolaryngol	NOUN
dpc-5430	338	4	.	.	PUNCT
dpc-5430	339	1	2012;269(2):531	2012;269(2):531	NUM
dpc-5430	339	2	-	-	SYM
dpc-5430	339	3	6	6	NUM
dpc-5430	339	4	.	.	PUNCT
dpc-5430	339	5	doi	doi	NOUN
dpc-5430	339	6	:	:	PUNCT
dpc-5430	339	7	  	  	SPACE
dpc-5430	339	8	10.1007	10.1007	NUM
dpc-5430	339	9	/	/	SYM
dpc-5430	339	10	s00405	s00405	NOUN
dpc-5430	339	11	-	-	PUNCT
dpc-5430	339	12	011	011	NUM
dpc-5430	339	13	-	-	PUNCT
dpc-5430	339	14	1721	1721	NUM
dpc-5430	339	15	-	-	SYM
dpc-5430	339	16	9	9	NUM
dpc-5430	339	17	.	.	PUNCT
dpc-5430	340	1	pmid	pmid	NOUN
dpc-5430	340	2	:	:	PUNCT
dpc-5430	340	3	 	 	SPACE
dpc-5430	340	4	21805356	21805356	NUM
dpc-5430	340	5	.	.	PUNCT
dpc-5430	341	1	26	26	NUM
dpc-5430	341	2	.	.	PUNCT
dpc-5430	341	3	davidson	davidson	PROPN
dpc-5430	341	4	tm	tm	PROPN
dpc-5430	341	5	,	,	PUNCT
dpc-5430	341	6	olitsky	olitsky	PROPN
dpc-5430	341	7	se	se	PROPN
dpc-5430	341	8	,	,	PUNCT
dpc-5430	341	9	wei	wei	PROPN
dpc-5430	341	10	jl	jl	PROPN
dpc-5430	341	11	.	.	PUNCT
dpc-5430	342	1	hereditary	hereditary	ADJ
dpc-5430	342	2	hemorrhagic	hemorrhagic	NOUN
dpc-5430	342	3	telangiectasia	telangiectasia	PROPN
dpc-5430	342	4	/	/	SYM
dpc-5430	342	5	avastin	avastin	PROPN
dpc-5430	342	6	.	.	PUNCT
dpc-5430	343	1	laryngoscope	laryngoscope	NOUN
dpc-5430	343	2	.	.	PUNCT
dpc-5430	344	1	2010;120(2):432	2010;120(2):432	NUM
dpc-5430	344	2	-	-	SYM
dpc-5430	344	3	5	5	NUM
dpc-5430	344	4	.	.	PUNCT
dpc-5430	344	5	 	 	SPACE
dpc-5430	344	6	doi	doi	NOUN
dpc-5430	344	7	:	:	PUNCT
dpc-5430	344	8	 	 	SPACE
dpc-5430	344	9	10.1002	10.1002	NUM
dpc-5430	344	10	/	/	SYM
dpc-5430	344	11	lary.20757	lary.20757	PROPN
dpc-5430	344	12	.	.	PUNCT
dpc-5430	344	13	pmid	pmid	NOUN
dpc-5430	344	14	:	:	PUNCT
dpc-5430	344	15	 	 	SPACE
dpc-5430	344	16	19998344	19998344	NUM
dpc-5430	344	17	.	.	PUNCT
dpc-5430	345	1	27	27	NUM
dpc-5430	345	2	.	.	PUNCT
dpc-5430	346	1	hwang	hwang	PROPN
dpc-5430	346	2	j	j	PROPN
dpc-5430	346	3	,	,	PUNCT
dpc-5430	346	4	lee	lee	PROPN
dpc-5430	346	5	yk	yk	PROPN
dpc-5430	346	6	,	,	PUNCT
dpc-5430	346	7	burm	burm	PROPN
dpc-5430	346	8	js	js	PROPN
dpc-5430	346	9	.	.	PUNCT
dpc-5430	347	1	treatment	treatment	NOUN
dpc-5430	347	2	of	of	ADP
dpc-5430	347	3	tongue	tongue	NOUN
dpc-5430	347	4	lymphangioma	lymphangioma	PROPN
dpc-5430	347	5	with	with	ADP
dpc-5430	347	6	intralesional	intralesional	ADJ
dpc-5430	347	7	combination	combination	NOUN
dpc-5430	347	8	injection	injection	NOUN
dpc-5430	347	9	of	of	ADP
dpc-5430	347	10	steroid	steroid	NOUN
dpc-5430	347	11	,	,	PUNCT
dpc-5430	347	12	bleomycin	bleomycin	PROPN
dpc-5430	347	13	and	and	CCONJ
dpc-5430	347	14	bevacizumab	bevacizumab	PROPN
dpc-5430	347	15	.	.	PUNCT
dpc-5430	348	1	arch	arch	ADJ
dpc-5430	348	2	craniofac	craniofac	NOUN
dpc-5430	348	3	surg	surg	NOUN
dpc-5430	348	4	.	.	PUNCT
dpc-5430	349	1	2017;18(1):54	2017;18(1):54	NUM
dpc-5430	349	2	-	-	SYM
dpc-5430	349	3	8	8	NUM
dpc-5430	349	4	.	.	PUNCT
dpc-5430	350	1	doi	doi	NOUN
dpc-5430	350	2	:	:	PUNCT
dpc-5430	350	3	 	 	SPACE
dpc-5430	350	4	10.7181	10.7181	NUM
dpc-5430	350	5	/	/	SYM
dpc-5430	350	6	acfs.2017.18.1.54	acfs.2017.18.1.54	NOUN
dpc-5430	350	7	.	.	PUNCT
dpc-5430	351	1	pmid	pmid	NOUN
dpc-5430	351	2	:	:	PUNCT
dpc-5430	351	3	 	 	SPACE
dpc-5430	351	4	28913305	28913305	NUM
dpc-5430	351	5	.	.	PUNCT
dpc-5430	351	6	  	  	SPACE
dpc-5430	352	1	28	28	NUM
dpc-5430	352	2	.	.	PUNCT
dpc-5430	353	1	kinzinger	kinzing	ADJ
dpc-5430	353	2	mr	mr	PROPN
dpc-5430	353	3	,	,	PUNCT
dpc-5430	353	4	strong	strong	PROPN
dpc-5430	353	5	eb	eb	PROPN
dpc-5430	353	6	,	,	PUNCT
dpc-5430	353	7	bernard	bernard	PROPN
dpc-5430	353	8	j	j	PROPN
dpc-5430	353	9	,	,	PUNCT
dpc-5430	353	10	steele	steele	PROPN
dpc-5430	353	11	to	to	PART
dpc-5430	353	12	.	.	PUNCT
dpc-5430	354	1	intralesional	intralesional	ADJ
dpc-5430	354	2	bevacizumab	bevacizumab	NOUN
dpc-5430	354	3	for	for	ADP
dpc-5430	354	4	the	the	DET
dpc-5430	354	5	treatment	treatment	NOUN
dpc-5430	354	6	of	of	ADP
dpc-5430	354	7	recurrent	recurrent	ADJ
dpc-5430	354	8	sinonasal	sinonasal	ADJ
dpc-5430	354	9	hemangioma	hemangioma	NOUN
dpc-5430	354	10	.	.	PUNCT
dpc-5430	355	1	ann	ann	PROPN
dpc-5430	355	2	otol	otol	PROPN
dpc-5430	355	3	rhinol	rhinol	NOUN
dpc-5430	355	4	laryngol	laryngol	NOUN
dpc-5430	355	5	.	.	PUNCT
dpc-5430	356	1	2018;127(12):969	2018;127(12):969	NUM
dpc-5430	356	2	-	-	SYM
dpc-5430	356	3	73	73	NUM
dpc-5430	356	4	.	.	PUNCT
dpc-5430	357	1	doi	doi	NOUN
dpc-5430	357	2	:	:	PUNCT
dpc-5430	357	3	 	 	SPACE
dpc-5430	357	4	10.1177/0003489418802288	10.1177/0003489418802288	NUM
dpc-5430	357	5	.	.	PUNCT
dpc-5430	358	1	pmid	pmid	NOUN
dpc-5430	358	2	:	:	PUNCT
dpc-5430	358	3	 	 	SPACE
dpc-5430	358	4	30246545	30246545	NUM
dpc-5430	358	5	.	.	PUNCT
dpc-5430	359	1	29	29	NUM
dpc-5430	359	2	.	.	PUNCT
dpc-5430	360	1	schlosser	schlosser	PROPN
dpc-5430	360	2	rj	rj	PROPN
dpc-5430	360	3	,	,	PUNCT
dpc-5430	360	4	woodworth	woodworth	PROPN
dpc-5430	360	5	ba	ba	PROPN
dpc-5430	360	6	,	,	PUNCT
dpc-5430	360	7	gillespie	gillespie	PROPN
dpc-5430	360	8	mb	mb	PROPN
dpc-5430	360	9	,	,	PUNCT
dpc-5430	360	10	day	day	NOUN
dpc-5430	360	11	ta	ta	PROPN
dpc-5430	360	12	.	.	PROPN
dpc-5430	360	13	endoscopic	endoscopic	ADJ
dpc-5430	360	14	resection	resection	NOUN
dpc-5430	360	15	of	of	ADP
dpc-5430	360	16	sinonasal	sinonasal	ADJ
dpc-5430	360	17	hemangiomas	hemangioma	NOUN
dpc-5430	360	18	and	and	CCONJ
dpc-5430	360	19	hemangiopericytomas	hemangiopericytoma	NOUN
dpc-5430	360	20	.	.	PUNCT
dpc-5430	361	1	orl	orl	PROPN
dpc-5430	361	2	j	j	PROPN
dpc-5430	361	3	otorhinolaryngol	otorhinolaryngol	PROPN
dpc-5430	361	4	relat	relat	PROPN
dpc-5430	361	5	spec	spec	PROPN
dpc-5430	361	6	.	.	PUNCT
dpc-5430	362	1	2006;68(2):69	2006;68(2):69	NUM
dpc-5430	362	2	-	-	SYM
dpc-5430	362	3	72	72	NUM
dpc-5430	362	4	.	.	PUNCT
dpc-5430	363	1	doi	doi	NOUN
dpc-5430	363	2	:	:	PUNCT
dpc-5430	363	3	 	 	SPACE
dpc-5430	363	4	10.1159/000091092	10.1159/000091092	NUM
dpc-5430	363	5	.	.	PUNCT
dpc-5430	364	1	pmid	pmid	NOUN
dpc-5430	364	2	:	:	PUNCT
dpc-5430	364	3	 	 	SPACE
dpc-5430	364	4	16428897	16428897	NUM
dpc-5430	364	5	.	.	PUNCT
dpc-5430	365	1	30	30	NUM
dpc-5430	365	2	.	.	PUNCT
dpc-5430	366	1	pourazizi	pourazizi	PROPN
dpc-5430	366	2	m	m	PROPN
dpc-5430	366	3	,	,	PUNCT
dpc-5430	366	4	kabiri	kabiri	PROPN
dpc-5430	366	5	s	s	PROPN
dpc-5430	366	6	,	,	PUNCT
dpc-5430	366	7	abtahi	abtahi	PROPN
dpc-5430	366	8	-	-	PUNCT
dpc-5430	366	9	naeini	naeini	PROPN
dpc-5430	366	10	b.	b.	PROPN
dpc-5430	366	11	intralesional	intralesional	PROPN
dpc-5430	366	12	bevacizumab	bevacizumab	PROPN
dpc-5430	366	13	(	(	PUNCT
dpc-5430	366	14	avastin	avastin	PROPN
dpc-5430	366	15	(	(	PUNCT
dpc-5430	366	16	®	®	NOUN
dpc-5430	366	17	)	)	PUNCT
dpc-5430	366	18	)	)	PUNCT
dpc-5430	367	1	as	as	ADP
dpc-5430	367	2	a	a	DET
dpc-5430	367	3	novel	novel	ADJ
dpc-5430	367	4	addition	addition	NOUN
dpc-5430	367	5	to	to	ADP
dpc-5430	367	6	infantile	infantile	ADJ
dpc-5430	367	7	hemangioma	hemangioma	NOUN
dpc-5430	367	8	management	management	NOUN
dpc-5430	367	9	:	:	PUNCT
dpc-5430	367	10	a	a	DET
dpc-5430	367	11	medical	medical	ADJ
dpc-5430	367	12	hypothesis	hypothesis	NOUN
dpc-5430	367	13	.	.	PUNCT
dpc-5430	368	1	j	j	PROPN
dpc-5430	368	2	res	res	PROPN
dpc-5430	368	3	pharm	pharm	PROPN
dpc-5430	368	4	pract	pract	PROPN
dpc-5430	368	5	.	.	PUNCT
dpc-5430	369	1	2017;6(3):190	2017;6(3):190	NUM
dpc-5430	369	2	-	-	SYM
dpc-5430	369	3	1	1	NUM
dpc-5430	369	4	.	.	PUNCT
dpc-5430	369	5	  	  	SPACE
dpc-5430	369	6	doi	doi	NOUN
dpc-5430	369	7	:	:	PUNCT
dpc-5430	369	8	  	  	SPACE
dpc-5430	369	9	10.4103	10.4103	NUM
dpc-5430	369	10	/	/	SYM
dpc-5430	369	11	jrpp.jrpp_17_38	jrpp.jrpp_17_38	PROPN
dpc-5430	369	12	.	.	PUNCT
dpc-5430	370	1	pmid	pmid	NOUN
dpc-5430	370	2	:	:	PUNCT
dpc-5430	370	3	  	  	SPACE
dpc-5430	370	4	29026847	29026847	NUM
dpc-5430	370	5	.	.	PUNCT
dpc-5430	371	1	31	31	NUM
dpc-5430	371	2	.	.	PUNCT
dpc-5430	372	1	steeples	steeple	NOUN
dpc-5430	372	2	lr	lr	PROPN
dpc-5430	372	3	,	,	PUNCT
dpc-5430	372	4	bonshek	bonshek	PROPN
dpc-5430	372	5	r	r	PROPN
dpc-5430	372	6	,	,	PUNCT
dpc-5430	372	7	morgan	morgan	PROPN
dpc-5430	372	8	l.	l.	PROPN
dpc-5430	372	9	intralesional	intralesional	PROPN
dpc-5430	372	10	bevacizumab	bevacizumab	NOUN
dpc-5430	372	11	for	for	ADP
dpc-5430	372	12	cutaneous	cutaneous	ADJ
dpc-5430	372	13	capillary	capillary	ADJ
dpc-5430	372	14	haemangioma	haemangioma	NOUN
dpc-5430	372	15	associated	associate	VERB
dpc-5430	372	16	with	with	ADP
dpc-5430	372	17	pregnancy	pregnancy	NOUN
dpc-5430	372	18	.	.	PUNCT
dpc-5430	373	1	clin	clin	PROPN
dpc-5430	373	2	exp	exp	PROPN
dpc-5430	373	3	ophthalmol	ophthalmol	PROPN
dpc-5430	373	4	.	.	PUNCT
dpc-5430	374	1	2013	2013	NUM
dpc-5430	374	2	may	may	AUX
dpc-5430	374	3	1;41(4	1;41(4	NUM
dpc-5430	374	4	)	)	PUNCT
dpc-5430	374	5	.	.	PUNCT
dpc-5430	375	1	doi	doi	NOUN
dpc-5430	375	2	:	:	PUNCT
dpc-5430	375	3	 	 	SPACE
dpc-5430	375	4	10.1111	10.1111	NUM
dpc-5430	375	5	/	/	SYM
dpc-5430	375	6	j.1442	j.1442	VERB
dpc-5430	375	7	-9071.2012.02881.x	-9071.2012.02881.x	NOUN
dpc-5430	375	8	.	.	PUNCT
dpc-5430	376	1	pmid	pmid	NOUN
dpc-5430	376	2	:	:	PUNCT
dpc-5430	376	3	 	 	SPACE
dpc-5430	376	4	22957786	22957786	NUM
dpc-5430	376	5	.	.	PUNCT
dpc-5430	377	1	32	32	NUM
dpc-5430	377	2	.	.	PUNCT
dpc-5430	378	1	mahmoud	mahmoud	PROPN
dpc-5430	378	2	mm	mm	PROPN
dpc-5430	378	3	,	,	PUNCT
dpc-5430	378	4	afifi	afifi	PROPN
dpc-5430	378	5	mm	mm	PROPN
dpc-5430	378	6	.	.	PUNCT
dpc-5430	379	1	anti	anti	ADJ
dpc-5430	379	2	-	-	ADJ
dpc-5430	379	3	angiogenic	angiogenic	ADJ
dpc-5430	379	4	therapy	therapy	NOUN
dpc-5430	379	5	(	(	PUNCT
dpc-5430	379	6	bevacizumab	bevacizumab	PROPN
dpc-5430	379	7	)	)	PUNCT
dpc-5430	379	8	in	in	ADP
dpc-5430	379	9	the	the	DET
dpc-5430	379	10	management	management	NOUN
dpc-5430	379	11	of	of	ADP
dpc-5430	379	12	oral	oral	ADJ
dpc-5430	379	13	lichen	lichen	NOUN
dpc-5430	379	14	planus	planus	NOUN
dpc-5430	379	15	.	.	PUNCT
dpc-5430	380	1	eur	eur	PROPN
dpc-5430	380	2	j	j	PROPN
dpc-5430	380	3	oral	oral	PROPN
dpc-5430	380	4	sci	sci	PROPN
dpc-5430	380	5	.	.	PUNCT
dpc-5430	381	1	2016;124(2):119	2016;124(2):119	NUM
dpc-5430	381	2	-	-	SYM
dpc-5430	381	3	26	26	NUM
dpc-5430	381	4	.	.	PUNCT
dpc-5430	382	1	doi	doi	NOUN
dpc-5430	382	2	:	:	PUNCT
dpc-5430	382	3	  	  	SPACE
dpc-5430	382	4	10.1111	10.1111	NUM
dpc-5430	382	5	/	/	SYM
dpc-5430	382	6	eos.12251	eos.12251	PROPN
dpc-5430	382	7	.	.	PUNCT
dpc-5430	383	1	pmid	pmid	NOUN
dpc-5430	383	2	:	:	PUNCT
dpc-5430	383	3	 	 	SPACE
dpc-5430	383	4	26892241	26892241	NUM
dpc-5430	383	5	.	.	PUNCT
dpc-5430	384	1	33	33	NUM
dpc-5430	384	2	.	.	PUNCT
dpc-5430	385	1	tanese	tanese	PROPN
dpc-5430	385	2	k.	k.	PROPN
dpc-5430	385	3	diagnosis	diagnosis	PROPN
dpc-5430	385	4	and	and	CCONJ
dpc-5430	385	5	management	management	NOUN
dpc-5430	385	6	of	of	ADP
dpc-5430	385	7	basal	basal	ADJ
dpc-5430	385	8	cell	cell	NOUN
dpc-5430	385	9	carcinoma	carcinoma	NOUN
dpc-5430	385	10	.	.	PUNCT
dpc-5430	386	1	curr	curr	PROPN
dpc-5430	386	2	treat	treat	PROPN
dpc-5430	386	3	options	option	NOUN
dpc-5430	386	4	oncol	oncol	ADJ
dpc-5430	386	5	.	.	PUNCT
dpc-5430	387	1	2019;20(2):13	2019;20(2):13	X
dpc-5430	387	2	.	.	PUNCT
dpc-5430	388	1	doi	doi	NOUN
dpc-5430	388	2	:	:	PUNCT
dpc-5430	388	3	 	 	SPACE
dpc-5430	388	4	10.1007	10.1007	NUM
dpc-5430	388	5	/s11864	/s11864	ADJ
dpc-5430	388	6	-	-	PUNCT
dpc-5430	388	7	019	019	NUM
dpc-5430	388	8	-	-	PUNCT
dpc-5430	388	9	0610	0610	NUM
dpc-5430	388	10	-	-	SYM
dpc-5430	388	11	0	0	NUM
dpc-5430	388	12	.	.	PUNCT
dpc-5430	389	1	pmid	pmid	NOUN
dpc-5430	389	2	:	:	PUNCT
dpc-5430	389	3	 	 	SPACE
dpc-5430	389	4	30741348	30741348	NUM
dpc-5430	389	5	.	.	PUNCT
dpc-5430	390	1	34	34	NUM
dpc-5430	390	2	.	.	PUNCT
dpc-5430	390	3	gaitanis	gaitanis	PROPN
dpc-5430	390	4	g	g	PROPN
dpc-5430	390	5	,	,	PUNCT
dpc-5430	390	6	bassukas	bassukas	PROPN
dpc-5430	390	7	i.	i.	PROPN
dpc-5430	390	8	intralesional	intralesional	PROPN
dpc-5430	390	9	bevacizumab	bevacizumab	PROPN
dpc-5430	390	10	as	as	ADP
dpc-5430	390	11	in	in	ADP
dpc-5430	390	12	-	-	PUNCT
dpc-5430	390	13	add	add	VERB
dpc-5430	390	14	adjuvant	adjuvant	ADJ
dpc-5430	390	15	to	to	ADP
dpc-5430	390	16	immunocryosurgery	immunocryosurgery	NOUN
dpc-5430	390	17	for	for	ADP
dpc-5430	390	18	locally	locally	ADV
dpc-5430	390	19	advanced	advance	VERB
dpc-5430	390	20	basal	basal	NOUN
dpc-5430	390	21	cell	cell	NOUN
dpc-5430	390	22	carcinoma	carcinoma	NOUN
dpc-5430	390	23	.	.	PUNCT
dpc-5430	391	1	j	j	PROPN
dpc-5430	391	2	eur	eur	PROPN
dpc-5430	391	3	acad	acad	PROPN
dpc-5430	391	4	dermatol	dermatol	NOUN
dpc-5430	391	5	venereol	venereol	NOUN
dpc-5430	391	6	.	.	PUNCT
dpc-5430	392	1	2014;28(8):1117	2014;28(8):1117	NUM
dpc-5430	392	2	-	-	SYM
dpc-5430	392	3	21	21	NUM
dpc-5430	392	4	.	.	PUNCT
dpc-5430	393	1	doi	doi	NOUN
dpc-5430	393	2	:	:	PUNCT
dpc-5430	393	3	 	 	SPACE
dpc-5430	393	4	10.1111	10.1111	NUM
dpc-5430	393	5	/	/	SYM
dpc-5430	393	6	jdv.12327	jdv.12327	NOUN
dpc-5430	393	7	.	.	PUNCT
dpc-5430	394	1	pmid	pmid	NOUN
dpc-5430	394	2	:	:	PUNCT
dpc-5430	394	3	 	 	SPACE
dpc-5430	394	4	25243268	25243268	NUM
dpc-5430	394	5	.	.	PUNCT
dpc-5430	395	1	35	35	NUM
dpc-5430	395	2	.	.	PUNCT
dpc-5430	395	3	gaitanis	gaitanis	PROPN
dpc-5430	395	4	g	g	PROPN
dpc-5430	395	5	,	,	PUNCT
dpc-5430	395	6	bassukas	bassukas	PROPN
dpc-5430	395	7	i.	i.	PROPN
dpc-5430	395	8	intralesional	intralesional	PROPN
dpc-5430	395	9	bevacizumab	bevacizumab	PROPN
dpc-5430	395	10	as	as	ADP
dpc-5430	395	11	in	in	ADP
dpc-5430	395	12	-	-	PUNCT
dpc-5430	395	13	add	add	VERB
dpc-5430	395	14	adjuvant	adjuvant	ADJ
dpc-5430	395	15	to	to	ADP
dpc-5430	395	16	immunocryosurgery	immunocryosurgery	NOUN
dpc-5430	395	17	for	for	ADP
dpc-5430	395	18	locally	locally	ADV
dpc-5430	395	19	advanced	advance	VERB
dpc-5430	395	20	basal	basal	NOUN
dpc-5430	395	21	cell	cell	NOUN
dpc-5430	395	22	carcinoma	carcinoma	NOUN
dpc-5430	395	23	.	.	PUNCT
dpc-5430	396	1	j	j	PROPN
dpc-5430	396	2	eur	eur	PROPN
dpc-5430	396	3	acad	acad	PROPN
dpc-5430	396	4	dermatol	dermatol	NOUN
dpc-5430	396	5	venereol	venereol	NOUN
dpc-5430	396	6	.	.	PUNCT
dpc-5430	397	1	2014;28(8):1117	2014;28(8):1117	NUM
dpc-5430	397	2	-	-	SYM
dpc-5430	397	3	21	21	NUM
dpc-5430	397	4	.	.	PUNCT
dpc-5430	398	1	doi	doi	NOUN
dpc-5430	398	2	:	:	PUNCT
dpc-5430	398	3	10.1111	10.1111	NUM
dpc-5430	398	4	/	/	SYM
dpc-5430	398	5	jdv.12327	jdv.12327	NOUN
dpc-5430	398	6	.	.	PUNCT
dpc-5430	399	1	pmid	pmid	NOUN
dpc-5430	399	2	:	:	PUNCT
dpc-5430	399	3	25243268	25243268	NUM
dpc-5430	399	4	.	.	PUNCT
dpc-5430	400	1	case	case	NOUN
dpc-5430	400	2	rep	rep	PROPN
dpc-5430	400	3	.	.	PROPN
dpc-5430	400	4	2020;13(11	2020;13(11	NUM
dpc-5430	400	5	)	)	PUNCT
dpc-5430	400	6	.	.	PUNCT
dpc-5430	401	1	doi	doi	NOUN
dpc-5430	401	2	:	:	PUNCT
dpc-5430	401	3	  	  	SPACE
dpc-5430	401	4	10.1136	10.1136	NUM
dpc-5430	401	5	/	/	SYM
dpc-5430	401	6	bcr-2020	bcr-2020	NOUN
dpc-5430	401	7	-	-	PUNCT
dpc-5430	401	8	238485	238485	NUM
dpc-5430	401	9	.	.	PUNCT
dpc-5430	402	1	pmid	pmid	NOUN
dpc-5430	402	2	:	:	PUNCT
dpc-5430	402	3	 	 	SPACE
dpc-5430	402	4	33139375	33139375	NUM
dpc-5430	402	5	.	.	PUNCT
dpc-5430	403	1	14	14	NUM
dpc-5430	403	2	.	.	PUNCT
dpc-5430	404	1	whitehead	whitehead	PROPN
dpc-5430	404	2	kj	kj	PROPN
dpc-5430	404	3	,	,	PUNCT
dpc-5430	404	4	sautter	sautter	PROPN
dpc-5430	404	5	nb	nb	PROPN
dpc-5430	404	6	,	,	PUNCT
dpc-5430	404	7	mcwilliams	mcwilliams	PROPN
dpc-5430	404	8	jp	jp	PROPN
dpc-5430	404	9	,	,	PUNCT
dpc-5430	404	10	chakinala	chakinala	PROPN
dpc-5430	404	11	mm	mm	PROPN
dpc-5430	404	12	,	,	PUNCT
dpc-5430	404	13	merlo	merlo	PROPN
dpc-5430	404	14	ca	ca	PROPN
dpc-5430	404	15	,	,	PUNCT
dpc-5430	404	16	johnson	johnson	PROPN
dpc-5430	404	17	mh	mh	PROPN
dpc-5430	404	18	,	,	PUNCT
dpc-5430	404	19	et	et	PROPN
dpc-5430	404	20	al	al	PROPN
dpc-5430	404	21	.	.	PROPN
dpc-5430	404	22	effect	effect	NOUN
dpc-5430	404	23	of	of	ADP
dpc-5430	404	24	topical	topical	ADJ
dpc-5430	404	25	intranasal	intranasal	NOUN
dpc-5430	404	26	therapy	therapy	NOUN
dpc-5430	404	27	on	on	ADP
dpc-5430	404	28	epistaxis	epistaxis	ADJ
dpc-5430	404	29	frequency	frequency	NOUN
dpc-5430	404	30	in	in	ADP
dpc-5430	404	31	patients	patient	NOUN
dpc-5430	404	32	with	with	ADP
dpc-5430	404	33	hereditary	hereditary	ADJ
dpc-5430	404	34	hemorrhagic	hemorrhagic	NOUN
dpc-5430	404	35	telangiectasia	telangiectasia	NOUN
dpc-5430	404	36	:	:	PUNCT
dpc-5430	404	37	a	a	DET
dpc-5430	404	38	randomized	randomized	ADJ
dpc-5430	404	39	clinical	clinical	ADJ
dpc-5430	404	40	trial	trial	NOUN
dpc-5430	404	41	.	.	PUNCT
dpc-5430	405	1	jama	jama	PROPN
dpc-5430	405	2	.	.	PUNCT
dpc-5430	406	1	2016;316(9):943	2016;316(9):943	NUM
dpc-5430	406	2	-	-	SYM
dpc-5430	406	3	51	51	NUM
dpc-5430	406	4	.	.	PUNCT
dpc-5430	406	5	doi	doi	NOUN
dpc-5430	406	6	:	:	PUNCT
dpc-5430	406	7	  	  	SPACE
dpc-5430	406	8	10.1001	10.1001	NUM
dpc-5430	406	9	/	/	SYM
dpc-5430	406	10	jama.2016.11724	jama.2016.11724	PROPN
dpc-5430	406	11	.	.	PUNCT
dpc-5430	407	1	pmid	pmid	NOUN
dpc-5430	407	2	:	:	PUNCT
dpc-5430	407	3	 	 	SPACE
dpc-5430	407	4	27599329	27599329	NUM
dpc-5430	407	5	.	.	PUNCT
dpc-5430	408	1	15	15	NUM
dpc-5430	408	2	.	.	PUNCT
dpc-5430	408	3	sabry	sabry	PROPN
dpc-5430	408	4	hh	hh	PROPN
dpc-5430	408	5	,	,	PUNCT
dpc-5430	408	6	sorour	sorour	PROPN
dpc-5430	408	7	ne	ne	PROPN
dpc-5430	408	8	,	,	PUNCT
dpc-5430	408	9	akl	akl	PROPN
dpc-5430	408	10	em	em	PRON
dpc-5430	408	11	.	.	PUNCT
dpc-5430	409	1	intralesional	intralesional	ADJ
dpc-5430	409	2	injection	injection	NOUN
dpc-5430	409	3	of	of	ADP
dpc-5430	409	4	bevacizumab	bevacizumab	NOUN
dpc-5430	409	5	versus	versus	ADP
dpc-5430	409	6	triamcinolone	triamcinolone	PROPN
dpc-5430	409	7	acetonide	acetonide	NOUN
dpc-5430	409	8	in	in	ADP
dpc-5430	409	9	infantile	infantile	ADJ
dpc-5430	409	10	hemangioma	hemangioma	NOUN
dpc-5430	409	11	.	.	PUNCT
dpc-5430	410	1	j	j	PROPN
dpc-5430	410	2	dermatolog	dermatolog	PROPN
dpc-5430	410	3	treat	treat	NOUN
dpc-5430	410	4	.	.	PUNCT
dpc-5430	411	1	2020;31(3):279	2020;31(3):279	NOUN
dpc-5430	411	2	-	-	SYM
dpc-5430	411	3	84	84	NUM
dpc-5430	411	4	.	.	PUNCT
dpc-5430	412	1	doi	doi	NOUN
dpc-5430	412	2	:	:	PUNCT
dpc-5430	412	3	  	  	SPACE
dpc-5430	412	4	10.1080/09546634	10.1080/09546634	NUM
dpc-5430	412	5	.2019.1590521	.2019.1590521	PROPN
dpc-5430	412	6	.	.	PUNCT
dpc-5430	413	1	pmid	pmid	NOUN
dpc-5430	413	2	:	:	PUNCT
dpc-5430	413	3	 	 	SPACE
dpc-5430	413	4	30835573	30835573	NUM
dpc-5430	413	5	.	.	PUNCT
dpc-5430	414	1	16	16	NUM
dpc-5430	414	2	.	.	PUNCT
dpc-5430	415	1	karnezis	karnezis	PROPN
dpc-5430	415	2	tt	tt	PROPN
dpc-5430	415	3	,	,	PUNCT
dpc-5430	415	4	davidson	davidson	PROPN
dpc-5430	415	5	tm	tm	PROPN
dpc-5430	415	6	.	.	PROPN
dpc-5430	415	7	treatment	treatment	NOUN
dpc-5430	415	8	of	of	ADP
dpc-5430	415	9	hereditary	hereditary	ADJ
dpc-5430	415	10	hemorrhagic	hemorrhagic	NOUN
dpc-5430	415	11	telangiectasia	telangiectasia	NOUN
dpc-5430	415	12	with	with	ADP
dpc-5430	415	13	submucosal	submucosal	NOUN
dpc-5430	415	14	and	and	CCONJ
dpc-5430	415	15	topical	topical	ADJ
dpc-5430	415	16	bevacizumab	bevacizumab	NOUN
dpc-5430	415	17	therapy	therapy	NOUN
dpc-5430	415	18	.	.	PUNCT
dpc-5430	416	1	laryngoscope	laryngoscope	NOUN
dpc-5430	416	2	.	.	PUNCT
dpc-5430	417	1	2012;122(3):495	2012;122(3):495	NUM
dpc-5430	417	2	-	-	SYM
dpc-5430	417	3	7	7	NUM
dpc-5430	417	4	.	.	PUNCT
dpc-5430	417	5	doi	doi	NOUN
dpc-5430	417	6	:	:	PUNCT
dpc-5430	417	7	  	  	SPACE
dpc-5430	417	8	10.1002	10.1002	NUM
dpc-5430	417	9	/lary.22501	/lary.22501	NOUN
dpc-5430	417	10	.	.	PUNCT
dpc-5430	418	1	pmid	pmid	NOUN
dpc-5430	418	2	:	:	PUNCT
dpc-5430	418	3	 	 	SPACE
dpc-5430	418	4	22147664	22147664	NUM
dpc-5430	418	5	.	.	PUNCT
dpc-5430	419	1	17	17	NUM
dpc-5430	419	2	.	.	PUNCT
dpc-5430	420	1	karnezis	karnezis	PROPN
dpc-5430	420	2	tt	tt	PROPN
dpc-5430	420	3	,	,	PUNCT
dpc-5430	420	4	davidson	davidson	PROPN
dpc-5430	420	5	tm	tm	PROPN
dpc-5430	420	6	.	.	PROPN
dpc-5430	420	7	efficacy	efficacy	NOUN
dpc-5430	420	8	of	of	ADP
dpc-5430	420	9	intranasal	intranasal	ADJ
dpc-5430	420	10	bevacizumab	bevacizumab	NOUN
dpc-5430	420	11	(	(	PUNCT
dpc-5430	420	12	avastin	avastin	NOUN
dpc-5430	420	13	)	)	PUNCT
dpc-5430	420	14	treatment	treatment	NOUN
dpc-5430	420	15	in	in	ADP
dpc-5430	420	16	patients	patient	NOUN
dpc-5430	420	17	with	with	ADP
dpc-5430	420	18	hereditary	hereditary	ADJ
dpc-5430	420	19	hemorrhagic	hemorrhagic	NOUN
dpc-5430	420	20	telangiectasia	telangiectasia	PROPN
dpc-5430	420	21	-	-	PUNCT
dpc-5430	420	22	associated	associated	ADJ
dpc-5430	420	23	epistaxis	epistaxis	NOUN
dpc-5430	420	24	.	.	PUNCT
dpc-5430	421	1	laryngoscope	laryngoscope	NOUN
dpc-5430	421	2	.	.	PUNCT
dpc-5430	422	1	2011	2011	NUM
dpc-5430	422	2	;	;	PUNCT
dpc-5430	422	3	121(3):636	121(3):636	NOUN
dpc-5430	422	4	-	-	SYM
dpc-5430	422	5	8	8	NUM
dpc-5430	422	6	.	.	PUNCT
dpc-5430	423	1	doi	doi	NOUN
dpc-5430	423	2	:	:	PUNCT
dpc-5430	423	3	 	 	SPACE
dpc-5430	423	4	10.1002	10.1002	NUM
dpc-5430	423	5	/	/	SYM
dpc-5430	423	6	lary.21415	lary.21415	PROPN
dpc-5430	423	7	.	.	PUNCT
dpc-5430	424	1	pmid	pmid	NOUN
dpc-5430	424	2	:	:	PUNCT
dpc-5430	424	3	 	 	SPACE
dpc-5430	424	4	21344445	21344445	NUM
dpc-5430	424	5	.	.	PUNCT
dpc-5430	425	1	18	18	NUM
dpc-5430	425	2	.	.	PUNCT
dpc-5430	425	3	guldmann	guldmann	PROPN
dpc-5430	425	4	r	r	PROPN
dpc-5430	425	5	,	,	PUNCT
dpc-5430	425	6	dupret	dupret	VERB
dpc-5430	425	7	a	a	PRON
dpc-5430	425	8	,	,	PUNCT
dpc-5430	425	9	nivoix	nivoix	PROPN
dpc-5430	425	10	y	y	PROPN
dpc-5430	425	11	,	,	PUNCT
dpc-5430	425	12	schultz	schultz	PROPN
dpc-5430	425	13	p	p	X
dpc-5430	425	14	,	,	PUNCT
dpc-5430	425	15	debry	debry	PROPN
dpc-5430	425	16	c.	c.	PROPN
dpc-5430	425	17	bevacizumab	bevacizumab	PROPN
dpc-5430	425	18	nasal	nasal	PROPN
dpc-5430	425	19	spray	spray	PROPN
dpc-5430	425	20	:	:	PUNCT
dpc-5430	425	21	noninvasive	noninvasive	ADJ
dpc-5430	425	22	treatment	treatment	NOUN
dpc-5430	425	23	of	of	ADP
dpc-5430	425	24	epistaxis	epistaxis	NOUN
dpc-5430	425	25	in	in	ADP
dpc-5430	425	26	patients	patient	NOUN
dpc-5430	425	27	with	with	ADP
dpc-5430	425	28	rendu	rendu	NOUN
dpc-5430	425	29	-	-	PUNCT
dpc-5430	425	30	osler	osler	NOUN
dpc-5430	425	31	disease	disease	NOUN
dpc-5430	425	32	.	.	PUNCT
dpc-5430	426	1	laryngoscope	laryngoscope	NOUN
dpc-5430	426	2	.	.	PUNCT
dpc-5430	427	1	2012;122(5):953	2012;122(5):953	NUM
dpc-5430	427	2	-	-	SYM
dpc-5430	427	3	5	5	NUM
dpc-5430	427	4	.	.	PUNCT
dpc-5430	427	5	doi	doi	NOUN
dpc-5430	427	6	:	:	PUNCT
dpc-5430	427	7	 	 	SPACE
dpc-5430	427	8	10.1002	10.1002	NUM
dpc-5430	427	9	/	/	SYM
dpc-5430	427	10	lary.23230	lary.23230	PROPN
dpc-5430	427	11	.	.	PUNCT
dpc-5430	428	1	pmid	pmid	NOUN
dpc-5430	428	2	:	:	PUNCT
dpc-5430	428	3	 	 	SPACE
dpc-5430	428	4	22447341	22447341	NUM
dpc-5430	428	5	.	.	PUNCT
dpc-5430	429	1	19	19	NUM
dpc-5430	429	2	.	.	PUNCT
dpc-5430	429	3	dupuis	dupuis	NOUN
dpc-5430	429	4	-	-	PUNCT
dpc-5430	429	5	girod	girod	PROPN
dpc-5430	429	6	s	s	NOUN
dpc-5430	429	7	,	,	PUNCT
dpc-5430	429	8	ambrun	ambrun	VERB
dpc-5430	429	9	a	a	DET
dpc-5430	429	10	,	,	PUNCT
dpc-5430	429	11	decullier	decullier	NOUN
dpc-5430	429	12	e	e	NOUN
dpc-5430	429	13	,	,	PUNCT
dpc-5430	429	14	samson	samson	PROPN
dpc-5430	429	15	g	g	NOUN
dpc-5430	429	16	,	,	PUNCT
dpc-5430	429	17	roux	roux	VERB
dpc-5430	429	18	a	a	DET
dpc-5430	429	19	,	,	PUNCT
dpc-5430	429	20	fargeton	fargeton	PROPN
dpc-5430	429	21	ae	ae	PROPN
dpc-5430	429	22	,	,	PUNCT
dpc-5430	429	23	et	et	PROPN
dpc-5430	429	24	al	al	PROPN
dpc-5430	429	25	.	.	PROPN
dpc-5430	429	26	ellipse	ellipse	PROPN
dpc-5430	429	27	study	study	NOUN
dpc-5430	429	28	:	:	PUNCT
dpc-5430	429	29	a	a	DET
dpc-5430	429	30	phase	phase	NOUN
dpc-5430	429	31	1	1	NUM
dpc-5430	429	32	study	study	NOUN
dpc-5430	429	33	evaluating	evaluate	VERB
dpc-5430	429	34	the	the	DET
dpc-5430	429	35	tolerance	tolerance	NOUN
dpc-5430	429	36	of	of	ADP
dpc-5430	429	37	bevacizumab	bevacizumab	PROPN
dpc-5430	429	38	nasal	nasal	PROPN
dpc-5430	429	39	spray	spray	VERB
dpc-5430	429	40	in	in	ADP
dpc-5430	429	41	the	the	DET
dpc-5430	429	42	treatment	treatment	NOUN
dpc-5430	429	43	of	of	ADP
dpc-5430	429	44	epistaxis	epistaxis	NOUN
dpc-5430	429	45	in	in	ADP
dpc-5430	429	46	hereditary	hereditary	ADJ
dpc-5430	429	47	hemorrhagic	hemorrhagic	NOUN
dpc-5430	429	48	telangiectasia	telangiectasia	NOUN
dpc-5430	429	49	.	.	PUNCT
dpc-5430	430	1	mabs	mab	NOUN
dpc-5430	430	2	.	.	PUNCT
dpc-5430	431	1	2014;6(3):794	2014;6(3):794	X
dpc-5430	431	2	-	-	SYM
dpc-5430	431	3	9	9	NUM
dpc-5430	431	4	.	.	PUNCT
dpc-5430	431	5	doi	doi	NOUN
dpc-5430	431	6	:	:	PUNCT
dpc-5430	431	7	  	  	SPACE
dpc-5430	431	8	10.4161	10.4161	NUM
dpc-5430	431	9	/	/	SYM
dpc-5430	431	10	mabs.28025	mabs.28025	PROPN
dpc-5430	431	11	.	.	PROPN
dpc-5430	432	1	pmid	pmid	PROPN
dpc-5430	432	2	:	:	PUNCT
dpc-5430	432	3	 	 	SPACE
dpc-5430	432	4	24481211	24481211	NUM
dpc-5430	432	5	.	.	PUNCT
dpc-5430	433	1	20	20	NUM
dpc-5430	433	2	.	.	PUNCT
dpc-5430	434	1	chen	chen	PROPN
dpc-5430	434	2	st	st	PROPN
dpc-5430	434	3	,	,	PUNCT
dpc-5430	434	4	karnezis	karnezis	PROPN
dpc-5430	434	5	t	t	PROPN
dpc-5430	434	6	,	,	PUNCT
dpc-5430	434	7	davidson	davidson	PROPN
dpc-5430	434	8	tm	tm	PROPN
dpc-5430	434	9	,	,	PUNCT
dpc-5430	434	10	chen	chen	PROPN
dpc-5430	434	11	iv	iv	PROPN
dpc-5430	434	12	s	s	PROPN
dpc-5430	434	13	,	,	PUNCT
dpc-5430	434	14	karnezis	karnezis	PROPN
dpc-5430	434	15	t	t	PROPN
dpc-5430	434	16	,	,	PUNCT
dpc-5430	434	17	davidson	davidson	PROPN
dpc-5430	434	18	tm	tm	PROPN
dpc-5430	434	19	.	.	PROPN
dpc-5430	434	20	safety	safety	NOUN
dpc-5430	434	21	of	of	ADP
dpc-5430	434	22	intranasal	intranasal	ADJ
dpc-5430	434	23	bevacizumab	bevacizumab	NOUN
dpc-5430	434	24	(	(	PUNCT
dpc-5430	434	25	avastin	avastin	NOUN
dpc-5430	434	26	)	)	PUNCT
dpc-5430	434	27	treatment	treatment	NOUN
dpc-5430	434	28	in	in	ADP
dpc-5430	434	29	patients	patient	NOUN
dpc-5430	434	30	with	with	ADP
dpc-5430	434	31	hereditary	hereditary	ADJ
dpc-5430	434	32	hemorrhagic	hemorrhagic	NOUN
dpc-5430	434	33	telangiectasia	telangiectasia	PROPN
dpc-5430	434	34	-	-	PUNCT
dpc-5430	434	35	associated	associated	ADJ
dpc-5430	434	36	epistaxis	epistaxis	NOUN
dpc-5430	434	37	.	.	PUNCT
dpc-5430	435	1	laryngoscope	laryngoscope	NOUN
dpc-5430	435	2	.	.	PUNCT
dpc-5430	436	1	2011	2011	NUM
dpc-5430	436	2	;	;	PUNCT
dpc-5430	436	3	121(3):644	121(3):644	NUM
dpc-5430	436	4	-	-	SYM
dpc-5430	436	5	6	6	NUM
dpc-5430	436	6	.	.	PUNCT
dpc-5430	436	7	doi	doi	NOUN
dpc-5430	436	8	:	:	PUNCT
dpc-5430	436	9	 	 	SPACE
dpc-5430	436	10	10.1002	10.1002	NUM
dpc-5430	436	11	/	/	SYM
dpc-5430	436	12	lary.21345	lary.21345	PROPN
dpc-5430	436	13	.	.	PUNCT
dpc-5430	437	1	pmid	pmid	NOUN
dpc-5430	437	2	:	:	PUNCT
dpc-5430	437	3	 	 	SPACE
dpc-5430	437	4	21344447	21344447	NUM
dpc-5430	437	5	.	.	PUNCT
dpc-5430	438	1	21	21	NUM
dpc-5430	438	2	.	.	PUNCT
dpc-5430	439	1	simonds	simonds	PROPN
dpc-5430	439	2	j	j	PROPN
dpc-5430	439	3	,	,	PUNCT
dpc-5430	439	4	miller	miller	PROPN
dpc-5430	439	5	f	f	PROPN
dpc-5430	439	6	,	,	PUNCT
dpc-5430	439	7	mandel	mandel	PROPN
dpc-5430	439	8	j	j	PROPN
dpc-5430	439	9	,	,	PUNCT
dpc-5430	439	10	davidson	davidson	PROPN
dpc-5430	439	11	tm	tm	PROPN
dpc-5430	439	12	.	.	PUNCT
dpc-5430	440	1	the	the	DET
dpc-5430	440	2	effect	effect	NOUN
dpc-5430	440	3	of	of	ADP
dpc-5430	440	4	bevacizumab	bevacizumab	NOUN
dpc-5430	440	5	(	(	PUNCT
dpc-5430	440	6	avastin	avastin	NOUN
dpc-5430	440	7	)	)	PUNCT
dpc-5430	440	8	treatment	treatment	NOUN
dpc-5430	440	9	on	on	ADP
dpc-5430	440	10	epistaxis	epistaxis	NOUN
dpc-5430	440	11	in	in	ADP
dpc-5430	440	12	hereditary	hereditary	ADJ
dpc-5430	440	13	hemorrhagic	hemorrhagic	NOUN
dpc-5430	440	14	telangiectasia	telangiectasia	NOUN
dpc-5430	440	15	.	.	PUNCT
dpc-5430	441	1	laryngoscope	laryngoscope	NOUN
dpc-5430	441	2	.	.	PUNCT
dpc-5430	442	1	2009;119(5):988	2009;119(5):988	NUM
dpc-5430	442	2	-	-	SYM
dpc-5430	442	3	92	92	NUM
dpc-5430	442	4	.	.	PUNCT
dpc-5430	443	1	doi	doi	NOUN
dpc-5430	443	2	:	:	PUNCT
dpc-5430	443	3	 	 	SPACE
dpc-5430	443	4	10.1002	10.1002	NUM
dpc-5430	443	5	/	/	SYM
dpc-5430	443	6	lary.20159	lary.20159	PROPN
dpc-5430	443	7	.	.	PUNCT
dpc-5430	444	1	pmid	pmid	NOUN
dpc-5430	444	2	:	:	PUNCT
dpc-5430	444	3	 	 	SPACE
dpc-5430	444	4	19194865	19194865	NUM
dpc-5430	444	5	.	.	PUNCT
dpc-5430	445	1	22	22	NUM
dpc-5430	445	2	.	.	PUNCT
dpc-5430	446	1	dheyauldeen	dheyauldeen	PROPN
dpc-5430	446	2	s	s	PROPN
dpc-5430	446	3	,	,	PUNCT
dpc-5430	446	4	østertun	østertun	PROPN
dpc-5430	446	5	geirdal	geirdal	PROPN
dpc-5430	446	6	a	a	PROPN
dpc-5430	446	7	,	,	PUNCT
dpc-5430	446	8	osnes	osne	NOUN
dpc-5430	446	9	t	t	PROPN
dpc-5430	446	10	,	,	PUNCT
dpc-5430	446	11	vartdal	vartdal	NOUN
dpc-5430	446	12	ls	ls	PROPN
dpc-5430	446	13	,	,	PUNCT
dpc-5430	446	14	dollner	dollner	PROPN
dpc-5430	446	15	r.	r.	PROPN
dpc-5430	446	16	bevacizumab	bevacizumab	PROPN
dpc-5430	446	17	in	in	ADP
dpc-5430	446	18	hereditary	hereditary	ADJ
dpc-5430	446	19	hemorrhagic	hemorrhagic	NOUN
dpc-5430	446	20	telangiectasia	telangiectasia	PROPN
dpc-5430	446	21	-	-	PUNCT
dpc-5430	446	22	associated	associated	ADJ
dpc-5430	446	23	epistaxis	epistaxis	NOUN
dpc-5430	446	24	:	:	PUNCT
dpc-5430	446	25	effectiveness	effectiveness	NOUN
dpc-5430	446	26	of	of	ADP
dpc-5430	446	27	an	an	DET
dpc-5430	446	28	injection	injection	NOUN
dpc-5430	446	29	protocol	protocol	NOUN
dpc-5430	446	30	based	base	VERB
dpc-5430	446	31	on	on	ADP
dpc-5430	446	32	the	the	DET
dpc-5430	446	33	vascular	vascular	ADJ
dpc-5430	446	34	anatomy	anatomy	NOUN
dpc-5430	446	35	of	of	ADP
dpc-5430	446	36	the	the	DET
dpc-5430	446	37	nose	nose	NOUN
dpc-5430	446	38	.	.	PUNCT
dpc-5430	447	1	laryngoscope	laryngoscope	NOUN
dpc-5430	447	2	.	.	PUNCT
dpc-5430	448	1	2012;122(6):1210	2012;122(6):1210	NUM
dpc-5430	448	2	-	-	SYM
dpc-5430	448	3	4	4	NUM
dpc-5430	448	4	.	.	PUNCT
dpc-5430	448	5	doi	doi	NOUN
dpc-5430	448	6	:	:	PUNCT
dpc-5430	448	7	 	 	SPACE
dpc-5430	448	8	10.1002	10.1002	NUM
dpc-5430	448	9	/	/	SYM
dpc-5430	448	10	lary.23303	lary.23303	PROPN
dpc-5430	448	11	.	.	PUNCT
dpc-5430	449	1	pmid	pmid	NOUN
dpc-5430	449	2	:	:	PUNCT
dpc-5430	449	3	 	 	SPACE
dpc-5430	449	4	22565282	22565282	NUM
dpc-5430	449	5	.	.	PUNCT
dpc-5430	450	1	23	23	NUM
dpc-5430	450	2	.	.	X
dpc-5430	451	1	riss	riss	PROPN
dpc-5430	451	2	d	d	PROPN
dpc-5430	451	3	,	,	PUNCT
dpc-5430	451	4	burian	burian	PROPN
dpc-5430	451	5	m	m	PROPN
dpc-5430	451	6	,	,	PUNCT
dpc-5430	451	7	wolf	wolf	PROPN
dpc-5430	451	8	a	a	PRON
dpc-5430	451	9	,	,	PUNCT
dpc-5430	451	10	kranebitter	kranebitter	PROPN
dpc-5430	451	11	v	v	PROPN
dpc-5430	451	12	,	,	PUNCT
dpc-5430	451	13	kaider	kaider	NOUN
dpc-5430	451	14	a	a	NOUN
dpc-5430	451	15	,	,	PUNCT
dpc-5430	451	16	arnoldner	arnoldner	NOUN
dpc-5430	451	17	c.	c.	PROPN
dpc-5430	451	18	intranasal	intranasal	PROPN
dpc-5430	451	19	submucosal	submucosal	PROPN
dpc-5430	451	20	bevacizumab	bevacizumab	NOUN
dpc-5430	451	21	for	for	ADP
dpc-5430	451	22	epistaxis	epistaxis	NOUN
dpc-5430	451	23	in	in	ADP
dpc-5430	451	24	hereditary	hereditary	ADJ
dpc-5430	451	25	hemorrhagic	hemorrhagic	NOUN
dpc-5430	451	26	telangiectasia	telangiectasia	NOUN
dpc-5430	451	27	:	:	PUNCT
dpc-5430	451	28	a	a	DET
dpc-5430	451	29	double	double	ADJ
dpc-5430	451	30	-	-	PUNCT
dpc-5430	451	31	blind	blind	ADJ
dpc-5430	451	32	,	,	PUNCT
dpc-5430	451	33	randomized	randomize	VERB
dpc-5430	451	34	,	,	PUNCT
dpc-5430	451	35	placebo	placebo	NOUN
dpc-5430	451	36	-	-	PUNCT
dpc-5430	451	37	controlled	control	VERB
dpc-5430	451	38	trial	trial	NOUN
dpc-5430	451	39	.	.	PUNCT
dpc-5430	452	1	head	head	NOUN
dpc-5430	452	2	neck	neck	NOUN
dpc-5430	452	3	.	.	PUNCT
dpc-5430	453	1	2015;37(6):783	2015;37(6):783	NUM
dpc-5430	453	2	-	-	SYM
dpc-5430	453	3	7	7	NUM
dpc-5430	453	4	.	.	PUNCT
dpc-5430	453	5	doi	doi	NOUN
dpc-5430	453	6	:	:	PUNCT
dpc-5430	453	7	 	 	SPACE
dpc-5430	453	8	10.1002	10.1002	NUM
dpc-5430	453	9	/	/	SYM
dpc-5430	453	10	hed.23655	hed.23655	NOUN
dpc-5430	453	11	.	.	PUNCT
dpc-5430	454	1	pmid	pmid	NOUN
dpc-5430	454	2	:	:	PUNCT
dpc-5430	454	3	 	 	SPACE
dpc-5430	454	4	24595923	24595923	NUM
dpc-5430	454	5	.	.	PUNCT